clopidogrel has been researched along with Coronary Artery Disease in 986 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (0.20) | 18.2507 |
| 2000's | 279 (28.30) | 29.6817 |
| 2010's | 602 (61.05) | 24.3611 |
| 2020's | 103 (10.45) | 2.80 |
| Authors | Studies |
|---|---|
| Benit, E; Diletti, R; Ferrario, M; Hamm, C; Heg, D; Huber, K; Janssens, L; Jüni, P; Mc Fadden, EP; Odutayo, A; Onuma, Y; Räber, L; Serruys, PW; Steg, PG; Valgimigli, M; Vranckx, P; Windecker, S | 1 |
| Bressi, E; Capuano, M; Cavallari, I; Colaiori, I; Di Sciascio, G; Grigioni, F; Mangiacapra, F; Ricottini, E; Spoto, S; Sticchi, A; Ussia, GP; Viscusi, MM | 1 |
| Amano, T; Ikari, Y; Inohara, T; Ishii, H; Kohsaka, S; Nishida, H; Noma, S; Shimoji, K; Tanaka, N; Ueno, K; Yamaji, K; Yashima, F | 1 |
| Chen, XP; Du, YX; Hu, XL; Li, H; Li, MP; Li, MY; Liu, YL; Ma, QL; Peng, LM; Song, MY; Song, PY | 1 |
| Contreras Bravo, NC; Corredor-Orlandelli, D; Fonseca Mendoza, DJ; Leal, MF; León-Torres, J; Mantilla-García, S; Mendoza-Ayús, SD; Ortega-Recalde, O; Pardo-Oviedo, JM; Parra Abaunza, K; Peña, LC; Rodríguez-Carrillo, J; Sambracos-Parrado, S; Tovar-Tirado, J; Vega-Ramírez, V | 1 |
| Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A | 1 |
| De Luca, L; Ferraro, PM; Gabrielli, D; Grigioni, F; Mangiacapra, F; Mangiacapra, R; Melfi, R; Nusca, A; Paolucci, L; Ussia, GP; Viscusi, MM | 1 |
| Barry, HC | 1 |
| Akimaru, K; Arima, H; Higa, N; Ikemiyagi, H; Ishida, A; Iwabuchi, M; Kakazu, M; Maeda, T; Miyagi, A; Ohya, Y; Shiohira, S; Shiohira, T; Tokashiki, S; Toma, Y; Uehara, H; Wake, M; Wakugawa, H; Zaima, S | 1 |
| Alraies, MC; Cuisset, T; Faisaluddin, M; Fischman, DL; Khalil, F; Pasha, AK; Rao, SV; Sabouret, P; Sandhyavenu, H; Savage, MP; Ullah, W; Zahid, S | 1 |
| Gong, Y; Han, Y; Jiang, H; Kang, Y; Lai, X; Li, J; Li, Y; Liu, B; Liu, Y; Ma, S; Qi, Z; Ren, L; Sun, H; Tang, C; Tang, Y; Zhao, X; Zheng, M | 1 |
| Circhetta, S; De Luca, R; Grigioni, F; Mangiacapra, F; Melfi, R; Nusca, A; Paolucci, L; Ricottini, E; Ussia, GP; Viscusi, MM | 1 |
| Ben-Yehuda, O; Brodie, BR; Kirtane, AJ; Liu, M; Mehran, R; Metzger, DC; Musikantow, DR; Redfors, B; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B | 1 |
| Ahn, CM; Cho, JY; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, YJ; Yun, KH | 1 |
| Ahn, SG; Chang, K; Cho, JR; Her, AY; Jeong, YH; Joo, HJ; Kim, BK; Kim, HS; Kim, MH; Lee, SY; Lim, DS; Park, Y; Shin, ES; Song, YB; Suh, JW | 1 |
| Agewall, S; Hasegawa, K; Komiyama, M | 1 |
| Dou, KF; Gao, R; Guan, C; Huang, Y; Qiao, S; Wang, HY; Wu, Y; Xie, L; Xu, B; Yang, W; Yang, Y; Zhang, R | 1 |
| Agewall, S; Barton, JC; Drexel, H; Hasegawa, K; Kaski, JC; Kimura, T; Komiyama, M; Lewis, BS; Tamargo, J; Yamamoto, K | 1 |
| Al-Sayaghi, KM; Albadrani, MS; Alotaibi, YA; Elhusein, AM; Fadlalmola, HA; Hussein, MK; Mamanao, DM; Masada, HK; Mohamedsalih, WE | 1 |
| Chen, Y; Gao, H; Han, P; Li, C; Lian, K; Liang, Y; Liu, Y; Tan, Z; Tao, F; Wang, Q; Wang, Z; Xu, S; Yang, L; Zhang, A; Zhang, Y; Zhao, S; Zhu, B | 1 |
| Angiolillo, DJ; Been, L; Franchi, F; Galli, M; Rollini, F; Zenni, MM | 1 |
| Dookeeram, D; Giddings, S; Gomes, C; Grimaldos, G; Grimaldos, K; Ishmael, A; Kampradi, L; Peram, L; Ramlackhansingh, A; Raza, S; Richard, S; Sandy, S; Schneider, D; Seecheran, NA; Seecheran, R; Seecheran, V; Sukha, D; Tello-Montoliu, A; Umaharan, P | 1 |
| Han, K; Huang, X; Ma, M; Sun, T; Yang, S; Zhao, Z; Zhou, Y | 1 |
| Ben-Yehuda, O; Brodie, BR; Cox, DA; Duffy, PL; Henry, TD; Kirtane, AJ; Liu, M; Madhavan, MV; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Redfors, B; Rinaldi, MJ; Shahim, B; Srdanovic, I; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Zhou, Z | 1 |
| Banach, M; Biondi-Zoccai, G; Costabel, JP; De Rosa, S; Fischman, D; Galli, M; Gulati, M; Sabouret, P; Savage, MP; Spadafora, L; Ullah, W; Zeitouni, M | 1 |
| Aboyans, V; Angiolillo, D; Atar, D; Capodanno, D; Fox, KAA; Halvorsen, S; James, S; Jüni, P; Kunadian, V; Landi, A; Leonardi, S; Mehran, R; Montalescot, G; Navarese, EP; Niebauer, J; Oliva, A; Piccolo, R; Price, S; Storey, RF; Valgimigli, M; Völler, H; Vranckx, P; Windecker, S | 1 |
| Baruś, P; Filipiak, KJ; Grabowski, M; Gumiężna, K; Klimczak-Tomaniak, D; Kochman, J; Kuca-Warnawin, E; Ochijewicz, D; Opolski, G; Pasierb, K; Sygitowicz, G; Tomaniak, M; Wiśniewska, A | 1 |
| Gong, Y; Li, J; Wang, X; Wang, Y; Zhou, T | 1 |
| Bae, JH; Bailey, K; Baudhuin, LM; Bell, MR; Farkouh, ME; Fu, YP; Geller, N; Goodman, SG; Hasan, A; Ingraham, BS; Iturriaga, E; Jeong, MH; Lennon, RJ; Lerman, A; Mathew, V; Pereira, NL; Rihal, C; Rosenberg, Y; So, D; Tanguay, JF; Welsh, RC | 1 |
| Chen, X; Hu, X; Li, H; Li, M; Ma, Q; Peng, L; Song, P; Tang, J; Zhang, Y; Zhou, G | 1 |
| Ahn, SG; Chang, K; Cho, JR; Her, AY; Jeong, YH; Joo, HJ; Kim, BK; Kim, HS; Kim, MH; Kim, SJ; Lee, SY; Lim, DS; Park, Y; Shin, ES; Song, YB; Suh, JW | 1 |
| Esposito, G; Piccolo, R; Simonetti, F; Spaccarotella, C | 1 |
| Wang, B; Wang, M; Xu, Y; Yan, M; Yu, S | 1 |
| Farley, JF; Kumar, A; Lutsey, PL; Rajpurohit, A; Schommer, JC; St Peter, WL; Van't Hof, JR | 1 |
| Berdibekov, BS; Bulaeva, NI; Golukhova, EZ; Kubova, MC; Ruzina, EV | 1 |
| Cai, Y; Chen, Z; He, Y; Li, C; Zhang, J | 1 |
| Agarwal, M; Angiolillo, DJ; Bass, TA; Been, L; Briceno, M; Franchi, F; Garcia, E; Kairouz, V; Kureti, M; Moon, JY; Nagaraju, D; Rivas Rios, J; Rivas, A; Rollini, F; Soffer, D; Suryadevara, S; Wali, M; Yaranov, D; Zenni, MM | 1 |
| Gorog, DA | 1 |
| Alexopoulos, D; Altman, RB; Aradi, D; Backman, JD; Bergmeijer, TO; Bliden, KP; Campo, G; Chang, K; Cleator, JH; Déry, JP; Dridi, NP; Fernandez-Cadenas, I; Fontana, P; Gawaz, M; Geisler, T; Gensini, GF; Giusti, B; Gong, L; Gurbel, PA; Hochholzer, W; Holmvang, L; Kim, EY; Kim, HS; Klein, TE; Kubo, M; Lee, MTM; Lewis, JP; Marcucci, R; Mitchell, BD; Montaner, J; Pakyz, RE; Reny, JL; Ritchie, MD; Roden, DM; Ryan, K; Schaeffeler, E; Schwab, M; Shin, JG; Shuldiner, AR; Siller-Matula, JM; Ten Berg, JM; Trenk, D; Valgimigli, M; Wen, MS; Whaley, RM; Winter, S | 1 |
| Ajisaka, H; Fukumoto, Y; Harada, A; Hirakawa, Y; Ishimatsu, T; Ishizaki, Y; Kagiyama, K; Kakuma, T; Katsuki, Y; Kawasaki, T; Murasato, Y; Sasaki, KI; Shimamatsu, J; Tashiro, H; Ueno, T; Yokoi, H | 1 |
| Wang, P; Wang, XZ; Yao, Y; Zhang, L; Zhao, W; Zhao, X; Zhou, TN | 1 |
| Doukas, D; Schimmer, H; Zehtabchi, S | 1 |
| Ceriello, A; Di Sciascio, G; Grigioni, F; Manfrini, S; Melfi, R; Nicolucci, A; Nusca, A; Pozzilli, P; Proscia, C; Tuccinardi, D; Ussia, GP | 1 |
| Ali, ZA; Baber, U; Ben-Yehuda, O; Brodie, BR; Chen, S; Cox, DA; Duffy, PL; Henry, TD; Kirtane, AJ; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Redfors, B; Rinaldi, MJ; Rubin, GA; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Zhang, Y | 1 |
| Barbato, E; Bressi, E; Capuano, M; Cavallari, I; Colaiori, I; Di Sciascio, G; Mangiacapra, F; Ricottini, E; Spoto, S; Viscusi, MM | 1 |
| Ahn, CM; Cho, S; Choi, D; Choi, SH; Gwon, HC; Hahn, JY; Hong, MK; Hong, SJ; Jang, Y; Kang, TS; Kim, BK; Kim, JS; Ko, YG; Shin, DH; Song, YB | 1 |
| Ayari, A; Barra, N; Billé, J; Joly, P; Maillard, L; Peycher, P; Sévilla, J; Silvestri, M; Tavildari, A; Vochelet, F | 1 |
| Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Jansky, P; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Seung, KB; Steg, PG; Ten Berg, JM; Zateyshchikov, DA | 1 |
| Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Maeng, M; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Brophy, DF; Guzman, LA; Martin, E; Puckett, L; Siddiqui, MS; Stravitz, T; Trankle, CR; Vo, C | 1 |
| Chen, M; Zhang, L; Zhang, Z; Zhao, Q | 1 |
| Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Colombo, A; Gallo, F; Giannini, F; Khokhar, AA; Laricchia, A; Mangieri, A; Sticchi, A | 1 |
| Bliden, K; Gurbel, PA; Rout, A; Tantry, US; Timilsina, S | 1 |
| Alexopoulos, D; Andreadou, I; Dimitriadis, G; Ikonomidis, I; Katogiannis, K; Katsimaglis, G; Kousathana, F; Kyriakou, E; Lambadiari, V; Maratou, E; Papadopoulou, A; Parissis, J; Plotas, P; Stamatelopoulos, K; Taichert, M; Tsantes, AE; Tsoumani, M; Varlamos, C | 1 |
| Aurigemma, C; Borovac, JA; Buffon, A; Burzotta, F; Canonico, F; Ceccarelli, I; Crea, F; D'Amario, D; Flex, A; Franceschi, F; Francese, F; Galli, M; Leone, AM; Limbruno, U; Migliaro, S; Montone, RA; Niccoli, G; Porto, I; Restivo, A; Tinelli, G; Trani, C; Vergallo, R | 1 |
| Álvarez-Antón, S; Carballeira, D; Concepción, R; Dejuán-Bitriá, C; Del Castillo, H; Delgado-Calva, FA; López-Soberón, E; Marschall, A; Martí, D; Morales, MJ; Palazuelos, J; Pérez-Guzmán, J | 1 |
| Cang, H; He, M; Li, J; Li, Y; Liu, G; Mu, H; Shi, J; Sun, D; Wang, J; Wang, W; Xu, M; Zhang, C; Zhang, H; Zhang, Z; Zhao, C; Zhao, S | 1 |
| Chai, M; Liang, J; Liu, W; Liu, X; Xi, Z; Yu, Y; Zhao, Y; Zhou, Y | 1 |
| Berry, NC; Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Mauri, L; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Cao, J; Deng, XL; Fan, L; Huang, X; Li, JH; Liu, L; Wang, YM; Zou, X | 1 |
| Ben-Dor, I; Chen, Y; Gajanana, D; Iantorno, M; Khalid, N; Khan, JM; Kolm, P; Musallam, A; Rogers, T; Satler, LF; Shlofmitz, E; Torguson, R; Waksman, R; Weintraub, WS; Zhang, C | 1 |
| Katkat, F; Kum, G; Okuyan, E; Şahin, İ; Varol, S | 1 |
| Gwak, HS; Lee, N; Seong, JM; Yoon, HY | 1 |
| Amorim, MJ; Barros, AS; Cerqueira, RJ; Ferreira, AF; Leite-Moreira, AF; Lourenço, AP; Moreira, R; Pinho, P; Rocha-Gomes, JN; Saraiva, FA | 1 |
| Alexopoulos, D; Altman, RB; Aradi, D; Backman, JD; Bergmeijer, TO; Bliden, K; Bradford, Y; Campo, G; Chang, K; Cleator, JH; Déry, JP; Dridi, NP; Fernandez-Cadenas, I; Fontana, P; Gawaz, M; Geisler, T; Gensini, GF; Giusti, B; Gong, L; Gurbel, PA; Hochholzer, W; Holmvang, L; Kim, EY; Kim, HS; Klein, TE; Kubo, M; Lee, MTM; Lewis, JP; Marcucci, R; Mitchell, BD; Montaner, J; Pakyz, RE; Reny, JL; Ritchie, MD; Roden, DM; Schaeffeler, E; Schwab, M; Shin, JG; Shuldiner, AR; Siller-Matula, JM; Ten Berg, JM; Trenk, D; Valgimigli, M; Verma, SS; Wallace, J; Wen, MS; Whaley, R; Winter, S | 1 |
| Ahuja, N; Baker, MC; Robinson, WH; Rohatgi, N; Weng, Y | 1 |
| Choi, WG; Kim, DW; Kim, GC; Kim, HY; Lee, CH | 1 |
| Feng, W; Song, Y; Tiemuerniyazi, X; Xu, F; Yan, H | 1 |
| Bao, S; Feng, J; Guo, X; Jia, L; Li, H; Sun, L; Wang, T; Yu, A; Yu, L; Zhao, T | 1 |
| Bao, D; Han, X; Han, Y; Li, J; Li, Y; Li, Z; Liao, Z; Stone, GW; Wang, H; Wang, X; Xu, K | 1 |
| Endo, H; Goto, I; Ishida, M; Itoh, T; Kimura, T; Koeda, Y; Kojima, T; Maegawa, Y; Morino, Y; Niiyama, M; Nishiyama, O; Osaki, T; Saitoh, H; Sakamoto, R; Sakamoto, T; Takahashi, F | 1 |
| Abbott, JD; Bae, JH; Bailey, K; Baudhuin, L; Bell, M; Cagin, C; Chavez, I; Farkouh, ME; Fu, YP; Geller, N; Goodman, SG; Gordon, P; Hasan, A; Iturriaga, E; Jeong, MH; Lennon, R; Lerman, A; Mathew, V; Pereira, NL; Rihal, C; Rosenberg, Y; Sidhu, M; So, D; Tanguay, JF; Wang, L; Weinshilboum, R; Welsh, R | 1 |
| Alsanjari, O; Hildick-Smith, D; Parker, J; Thomson, C; Trivedi, U | 1 |
| Li, J; Ma, L; Yu, C; Yuan, Y; Zhao, J | 1 |
| Angiolillo, DJ; Beitelshees, AL; Cavallari, LH; Chen, Y; Cook, KJ; Coons, JC; Dillon, C; Duarte, JD; Empey, PE; Franchi, F; Giri, J; Gong, Y; Johnson, JA; Kreutz, RP; Lee, CR; Lee, JC; Limdi, NA; McDonough, CW; Skaar, TC; Stevenson, JM; Stouffer, GA; Thomas, CD; Tuteja, S; Weck, KE | 1 |
| Gao, R; Guo, T; Li, J; Li, Y; Qiao, S; Qiu, H; Tang, Y; Wang, Y; Xu, B; Yan, L; Yang, Y; Zheng, J | 2 |
| Abdus, S; Gong, X; Gu, Q; Li, C; Shi, L; Tan, C; Wang, G; Wang, J; Yang, M | 1 |
| Besteiro, A; Cequier, Á; Comin-Colet, J; Ferreiro, JL; Fuentes, L; Gómez-Hospital, JA; Gomez-Lara, J; Gracida, M; Lugo, LM; Marcano, AL; Romaguera, R; Roura, G; Sosa, SG; Teruel, L | 1 |
| Adamson, PD; Loganath, K; Moss, AJ | 1 |
| Bonaca, MP; De Luca, L; Magnani, G | 1 |
| Camaj, A; Giustino, G; Halperin, JL; Miller, MS | 1 |
| Biswas, M; Biswas, TK; Ibrahim, B; Rahaman, S | 2 |
| Chen, XP; Du, YX; Li, MP; Ma, QL; Peng, LM; Song, PY; Zhu, KX | 1 |
| Bhatt, DL; Cannon, CP; Costa, F; Hohnloser, SH; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM; Valgimigli, M | 1 |
| Cai, ZX; Dou, KF; Song, WH; Wang, HY; Yang, YJ; Yin, D | 1 |
| Bae, JW; Cho, BR; Cho, DK; Cho, JH; Choi, JH; Choi, JW; Choi, SH; Choi, WG; Chun, WJ; Gwon, HC; Hahn, JY; Im, ES; Jang, WJ; Jeong, JO; Koh, YY; Lee, JM; Lee, JY; Lee, SH; Lee, SU; Lee, SY; Lee, WS; Oh, JH; Oh, SK; Park, TK; Park, YH; Rha, SW; Song, YB; Yang, JH; Yoon, HJ; Yun, KH | 1 |
| Jamali, HK; Khan, S; Kheiri, B; Osman, M; Saleem, M; Waqar, F | 1 |
| Biswas, M; Kali, SK | 1 |
| Chelidze, K; Mamatsashvili, I; Sikharulidze, I | 1 |
| Deng, B; He, W; Lin, Y; Nie, R; Shu, X; Wang, J; Wu, X; Zhou, Z; Zhu, E | 1 |
| Akao, M; Ako, J; Hagiwara, N; Hirayama, A; Kaikita, K; Kimura, K; Matoba, T; Matsui, K; Miyauchi, K; Nakamura, M; Ogawa, H; Yasuda, S | 1 |
| Chen, R; Chen, X; Cheng, J; Hu, H; Hu, Y; Lin, S; Xu, X | 1 |
| Fu, W; Hu, X; Jiang, H; Ma, R; Yang, J; Zhang, J | 1 |
| Che, J; Chen, K; Dou, S; Liu, H; Liu, X; Wang, W; Wang, X; Zhang, X; Zhou, X | 1 |
| Ahn, JH; Cho, SW; Choi, JH; Choi, KH; Choi, SH; Gwon, HC; Hahn, JY; Jang, YH; Kim, DY; Lee, JM; Lee, SH; Park, KT; Park, TK; Song, YB; Yang, JH | 1 |
| Chen, S; Feng, W; Hu, S; Liu, S; Qu, J; Rao, C; Song, Y; Sun, H; Wang, L; Wang, S; Zhang, H; Zhao, Y; Zheng, Z | 1 |
| Bae, JW; Cho, YH; Han, JK; Hur, SH; Jeon, DW; Kang, J; Kim, BS; Kim, HS; Kim, SH; Koo, BK; Lee, NH; Lim, SW; Park, KW; Park, TH; Rha, SW; Rhee, TM; Shin, ES; Won, KB; Yang, HM; Yoon, J | 1 |
| Aziz, MA; Islam, MS; Jafrin, S; Naznin, NE; Reza, MS | 1 |
| Abou Jaoude, P; Angiolillo, DJ; Bass, TA; Been, L; Briceno, M; Franchi, F; Jia, S; Lee, CH; Maaliki, N; Pineda, AM; Rivas, A; Rollini, F; Soffer, D; Suryadevara, S; Zenni, MM; Zhou, X | 1 |
| Chen, X; Ji, L; Li, J; Su, J; Yang, J; Yu, Q; Zheng, N; Zhong, J | 1 |
| Su, J; Xu, H; Xu, Z; Yang, J; Yu, Q; Zheng, N; Zhou, H | 1 |
| Ariyoshi, N; Kitahara, H; Kobayashi, Y; Nishi, T; Ohno, Y; Saito, Y; Wakabayashi, S | 1 |
| Aquila, G; Balla, C; Biscaglia, S; Campo, G; Cimaglia, P; Contoli, M; Del Franco, A; Ferrari, R; Fortini, F; Gallo, F; Pavasini, R; Pecoraro, A; Pestelli, G; Rizzo, P; Tonet, E; Vieceli Dalla Sega, F | 1 |
| Bacchi-Reggiani, ML; Bordoni, B; Calabrò, P; Dallago, M; Di Pasquale, G; Franco, N; Leone, AM; Maggiolini, S; Magnavacchi, P; Mameli, S; Nicolino, A; Palmieri, C; Piccalò, G; Piovaccari, G; Rubboli, A; Saia, F; Sciahbasi, A; Steffanon, L; Vignali, L | 1 |
| Dong, Y; He, H; Lu, J; Ma, X; Meng, T; Xie, J; Zhai, Y | 1 |
| Amann, M; Bömicke, T; Hochholzer, W; Neumann, FJ; Stratz, C; Valina, CM | 1 |
| Altman, DG; Benedetto, U; Flather, M; Gerry, S; Gray, A; Lees, B; Taggart, DP | 1 |
| Bellomo, G; Carriero, A; Daffara, V; De Luca, G; Marino, P; Pergolini, P; Rolla, R; Verdoia, M | 1 |
| Arima, Y; Hokimoto, S; Ishii, M; Ito, M; Iwashita, S; Kaikita, K; Kojima, S; Mitsuse, T; Oimatsu, Y; Sueta, D; Takahashi, A; Tsujita, K; Yamamoto, E | 1 |
| Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW | 1 |
| Bhatt, DL; Grove, EL; Kristensen, SD; Pareek, M; Ten Berg, JM | 1 |
| Aldazabal, A; Cerrato, E; Echavarría-Pinto, M; Escaned, J; Fernández-Ortiz, A; Gonzalo, N; Jimenez-Quevedo, P; Macaya, C; Mejia-Renteria, H; Nombela-Franco, L; Núñez-Gil, IJ; Quirós, A; Rumoroso, JR; Ryan, N; Salinas, P | 1 |
| Ahn, JM; Choi, HI; Kang, SH; Kang, SJ; Kim, YH; Lee, CW; Lee, PH; Lee, SW; Park, DW; Park, SJ; Park, SW | 1 |
| Bil, J; Bojko, K; Gil, RJ; Górny, J; Januszko-Giergielewicz, B; Kern, A; Sienkiewicz, E | 1 |
| Gao, Y; He, J; Li, M; Li, Q; Luo, Y; Ren, X; Wu, C; Yu, X; Zhang, X; Zhang, Y | 1 |
| Abnousi, F; Bhatt, DL; Deliargyris, EN; Desai, M; Ding, VY; Généreux, P; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; Sundaram, V; White, HD; Yang, L; Yong, CM | 1 |
| Gawrońska-Szklarz, B; Gorący, J; Jastrzębska, M; Kiedrowicz, R; Kornacewicz-Jach, Z; Olędzki, S; Safranow, K | 1 |
| Ariotti, S; Baldo, A; Franzone, A; Gargiulo, G; Moschovitis, A; Piccolo, R; Santucci, A; Tumscitz, C; Valgimigli, M; Windecker, S | 1 |
| Ako, J; Ando, K; Anzai, H; Hamasaki, T; Iijima, R; Inoue, K; Ishiwata, S; Ito, Y; Kadotani, M; Kawaguchi, K; Morita, T; Nakamura, M; Niinuma, H; Nishida, Y; Ochiai, M; Ohira, H; Okada, H; Omiya, K; Shinke, T; Takiuchi, S; Tanaka, H; Ueda, Y; Yasaka, Y; Yokoi, H; Zen, K | 1 |
| Armengaud, J; Barragan, P; Ben Amer, H; Berlan, J; Blanchard, D; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Didier, R; Druelles, P; Dupouy, P; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J | 1 |
| Chow, B; Erthal, F; Farkouh, M; Fortier, J; Glineur, D; Hage, A; Ko, G; Kulik, A; Larose, É; LeMay, M; Mesana, TG; Ruel, M; Tremblay, H; Une, D; Voisine, P | 1 |
| Ayele, GM; Ben-Yehuda, O; Cox, DA; Duffy, PL; Furer, A; Généreux, P; Giustino, G; Henry, TD; Kirtane, AJ; Lin, SH; Maehara, A; Mazzaferri, EL; Mehran, R; Metzger, DC; Mintz, GS; Neumann, FJ; Redfors, B; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B | 1 |
| Emami Zeydi, A; Habibi, V; Sharifi, H | 1 |
| Aquino, M; Ariti, C; Baber, U; Bhasin, A; Chandrasekhar, J; Chieffo, A; Cohen, D; Colombo, A; Dangas, G; Farhan, S; Gibson, CM; Henry, TD; Iakovou, I; Kini, A; Kruckoff, M; Mehran, R; Moliterno, D; Pocock, S; Sartori, S; Schoos, M; Sorrentino, S; Steg, PG; Stuckey, T; Vogel, B; Weisz, G; Witzenbichler, B | 1 |
| Abdul Kader, MASK; Amin, AM; Ibrahim, B; Kah Hay, Y; Mohamed Noor, DA; Mostafa, H; Sheau Chin, L | 1 |
| Amin, AM; Ibrahim, B; Kah Hay, Y; Mohamed Noor, DA; Mostafa, H; Sheau Chin, L; Sk Abdul Kader, MA; Teh, CH | 1 |
| Lim, GB | 1 |
| Barlow, C; Salhiyyah, K | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Cho, DK; Choi, S; Hong, BK; Hong, MK; Jang, Y; Jeon, DW; Kang, TS; Kang, WC; Kim, BK; Kim, BO; Kim, JS; Kim, S; Kim, YH; Kwon, HM; Lee, BK; Lee, OH; Min, PK; Shin, DH; Woo, SI; Yoon, YW | 1 |
| de Man, FHAF; Doggen, CJM; Hartmann, M; Knottnerus, IL; Kok, MM; Linssen, GCM; Louwerenburg, JW; Löwik, MM; Stoel, MG; van der Heijden, LC; van Houwelingen, KG; von Birgelen, C; Zocca, P | 1 |
| AlHelal, J; Fang, F; Liu, W; Wang, J; Xi, Z; Zhou, Y | 1 |
| Ahn, JM; Cho, JH; Choi, SW; Choi, YJ; Her, SH; Kang, SJ; Kim, HS; Kim, YH; Lee, CH; Lee, CW; Lee, JH; Lee, JY; Lee, PH; Lee, SW; Min, PK; Nam, CW; Park, DW; Park, GM; Park, SJ; Park, SW; Seo, JB; Shin, WY | 1 |
| Ferenc, M; Hochholzer, W; Löffelhardt, N; Mashayekhi, K; Neumann, FJ; Nührenberg, T; Stratz, C; Trenk, D; Valina, CM | 1 |
| Chen, J; Fu, Y; Li, JL; Liang, GK; Liu, J; Lu, Y; Nie, XY; Qin, SB; Shao, H; Shi, LW | 1 |
| Abdul Kader, MASK; Amin, AM; Ibrahim, B; Kah Hay, Y; Mohamed Noor, DA; Mostafa, H; Sheau Chin, L; Teh, CH | 1 |
| Agarwal, M; Angiolillo, DJ; Bass, TA; Been, L; Briceno, M; Franchi, F; Kureti, M; Moon, JY; Nagaraju, D; Nawaz, A; Rivas Rios, J; Rivas, A; Rollini, F; Shaikh, Z; Soffer, D; Suryadevara, S; Wali, M; Zenni, MM | 1 |
| Al-Allawi, NAS; Mohammad, AM | 1 |
| Campbell, H; Chen, VM; Connor, D; Hogg, PJ; Kritharides, L; Lau, E; Lau, JK; Liang, HP; Muller, D; Pasalic, L; Pennings, GJ; Wing-Lun, E | 1 |
| Bella, J; Krim, N; Zeb, I | 1 |
| Baumann, A; Berghold, A; Bornemann-Cimenti, H; Goeroeg, C; Gurbel, PA; Mahla, E; Metzler, H; Pregartner, G; Prueller, F; Raggam, RB | 1 |
| Agarwal, SK; Garg, N; Goel, P; Kapoor, A; Khanna, R; Kumar, S; Pande, S; Pereira, P; Sinha, A; Srivastava, N; Tewari, S | 1 |
| Bundhun, PK; Huang, F | 1 |
| Al-Jarallah, M; Al-Lawati, JA; Al-Mahmeed, W; Al-Motarreb, A; Al-Zakwani, I; AlFaleh, H; AlHabib, KF; Alnobani, O; Alsheikh-Ali, AA; Amin, H; Asaad, N; Bazargani, N; Bulbanat, B; Panduranga, P; Ridha, M; Sulaiman, K; Suwaidi, JA | 1 |
| Gibler, WB | 1 |
| Chen, S; Li, S; Xie, W; Yin, Q; Zhang, M | 1 |
| Chai, DY; Chen, SL; Gao, XF; Ge, Z; Kong, XQ; Lu, S; Wang, F; Wang, ZM; Zhang, JJ; Zuo, GF | 1 |
| Chen, JY; Deng, CY; Fu, YH; Han, YL; Lei, HP; Li, XH; Lin, YB; Sheng, WS; Tang, QJ; Wu, H; Zhong, SL | 1 |
| Brunner, S; Hamm, W; Lackermair, K; Mehr, M; Rizas, K | 1 |
| Ben-Yehuda, O; Brodie, BR; Cox, DA; Dangas, GD; Duffy, PL; Farhan, S; Généreux, P; Giustino, G; Gurbel, P; Henry, TD; Kirtane, AJ; Maehara, A; Mazzaferri, EL; McAndrew, T; Mehran, R; Metzger, DC; Neumann, FJ; Redfors, B; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B | 1 |
| Gao, Y; Hu, C; Liu, Y; Luo, Y; Wang, X; Zhang, X; Zhao, X; Zhou, H | 1 |
| Alves, RC; Cantarelli, FL; de Barros, IML; de Oliveira, FRA; Falcão, FJA; Nascimento Silva, JS; Pedrosa, RP; Silva, JMDS | 1 |
| Akasaka, T; Hariki, H; Hiranuma, N; Hirata, KI; Inoue, T; Iwasaki, M; Kinutani, H; Konishi, A; Kuroda, M; Nakagawa, M; Nakamura, M; Nishio, R; Osue, T; Otake, H; Saito, S; Shinke, T; Shite, J; Taniguchi, Y | 1 |
| Abramson, BL; Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FGR; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Lopes, RD; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C; Rockhold, FW | 1 |
| Alper, AT; Barutca, H; Bora Şişman, S; Bozbeyoğlu, E; Çakıllı, Y; Çinier, G; Güzelburç, Ö; Şahin, S; Tekkeşin, Aİ; Velibey, Y; Yıldırımtürk, Ö | 1 |
| Ariyoshi, N; Fujii, K; Fujimoto, Y; Kitahara, H; Kobayashi, Y; Kohno, Y; Nishi, T; Ohno, Y | 1 |
| Ahn, J; Ahn, JH; Carriere, KC; Cho, SW; Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Kim, J; Lee, JM; Lee, SH; Lee, SY; Park, K; Park, TK; Song, YB; Yang, JH | 1 |
| Abderrazak, F; Abroug, H; Ben Hamda, K; Chouchene, S; Dabboubi, R; Gaaloul, M; Hadj Fredj, S; Hassine, M; Hellara, I; Khefacha, L; Maatouk, F; Messaoud, T; Najjar, MF; Neffeti, F; Nouira, S; Raddaoui, H; Rezek, M; Sassi, M; Sriha, A | 1 |
| Chen, XP; Hu, XL; Li, H; Li, MP; Ma, QL; Peng, LM; Song, PY; Wang, JY; Zhang, YJ | 1 |
| Benit, E; Chichareon, P; Dominici, M; Ferrario, M; Hamm, C; Heg, D; Huber, K; Janssens, L; Jüni, P; McFadden, EP; Möllmann, H; Moschovitis, A; Onuma, Y; Serruys, PW; Slagboom, T; Steg, PG; Valgimigli, M; van Es, GA; Van Geuns, RJ; van Meijeren, C; Vranckx, P; Windecker, S; Zurakowski, A | 1 |
| Niu, P; Ouyang, S; Xiao, M; Zhuo, B; Zhuo, X | 1 |
| Brodie, BR; Chung, CJ; Cox, DA; Duffy, PL; Henry, TD; Kirtane, AJ; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Zhang, Y | 1 |
| Allocco, DJ; Christen, T; Dauerman, HL; Kereiakes, DJ; Kirtane, AJ; Mauri, L; Meredith, IT; Price, MJ; Windecker, S; Yeh, RW | 1 |
| Berger, JS; Gislason, GH; Lamberts, M; Lock Hansen, M; Nissen Bonde, A; Olesen, JB; Pallisgaard, JL; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C | 1 |
| Baccar, H; Boughalleb, M; Charfi, R; Gorgi, Y; Hammami, N; Hosni, H; Kharrat, M; Klouz, A; Kouidhi, S; Limam, M; Mrabet, A; Mzoughi, K; Sfar, I; Trabelsi, S; Zaïri, I; Zedini, C | 1 |
| Franchi, F; Rollini, F | 1 |
| Brener, SJ; Brodie, BR; Cox, DA; Duffy, PL; Gurbel, PA; Henry, TD; Kirtane, AJ; Mazzaferri, EL; McAndrew, T; Mehran, R; Metzger, DC; Neumann, FJ; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B | 1 |
| Apostolovic, S; Konstantinovic, SS; Lilic, J; Marinkovic, V; Nikolic, VN; Pavlovic, M; Stokanovic, D; Zvezdanovic, JB | 1 |
| Abellán-Huerta, J; Jurado-Román, A; López-Lluva, MT; Lozano-Ruiz Poveda, F; Piqueras-Flores, J; Sánchez-Pérez, I | 1 |
| Abdalla, A; Ahmed, S; Bachuwa, G; Bhatt, DL; Chahine, A; Hassan, M; Haykal, T; Kheiri, B; Osman, K; Osman, M; Pandrangi, PV | 1 |
| Briguori, C; Condorelli, G; D'Alessio, F; D'Amore, C; De Caterina, R; Del Vecchio, L; Donahue, M; Quintavalle, C; Signoriello, G | 1 |
| Farag, M; Gorog, DA; Gue, YX; Spinthakis, N; Srinivasan, M; Wellsted, DM | 1 |
| Chelstowski, K; Clark, JS; Jastrzebska, M; Klysz, M; Marcinowska, Z; Oledzki, S; Siennicka, A | 1 |
| Michaud, G; Zouk, AN | 1 |
| Banerjee, S; Baskar, A; Chauhan, S; Cui, Z; Dargham, BB; Sum-Ping, J; Tejani, I; Weideman, RA | 1 |
| Ali, BR; Bartsakoulia, M; Chalikiopoulou, K; Dávila-Fajardo, CL; Díaz-Villamarín, X; Fragoulakis, V; Gkotsi, M; John, A; Katrali, E; Katsila, T; Kehagia, K; Martínez-González, LJ; Mitropoulou, C; Patrinos, GP; Ramos, JGS; Skoufas, E; Vozikis, A; Wordsworth, S | 1 |
| Baruś, P; Filipiak, KJ; Huczek, Z; Jonik, S; Kochman, J; Kołtowski, Ł; Ochijewicz, D; Opolski, G; Pędzich-Placha, E; Pietrasik, A; Rdzanek, A; Tomaniak, M | 1 |
| Åkerblom, A; Asselbergs, FW; Becker, RC; Bernlochner, I; Bopp, R; Byrne, RA; Erdmann, J; Eriksson, N; James, S; Kastrati, A; Katus, HA; Kessler, T; Koenig, W; Kofink, D; Laugwitz, KL; Mahmoodi, BK; Mayer, K; Munz, M; Nordio, F; O'Donoghue, ML; Rai, H; Sager, HB; Schunkert, H; Sibbing, D; Solakov, L; Storey, RF; Ten Berg, JM; Tragante, V; Wallentin, L; Wobst, J; Wolf, B | 1 |
| Chang, CC; Chen, SM; Chen, YC; Cheng, SM; Chuang, CL; Lin, FY; Lin, RH; Lin, YW; Sheu, JS; Tsai, CS | 1 |
| Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Chen, S; Huang, B; Xie, W; Yin, Q | 1 |
| Li, L; Long, M; Ye, Z | 1 |
| Deng, BQ; Feng, ZM; Ke, X; Lin, YQ; Nie, RQ; Shu, XR | 1 |
| Chen, X; Li, J; Li, X; Su, J; Wang, J; Xu, X; Yang, J; Yu, Q | 1 |
| Bianco, M; Biscaglia, S; Campo, G; Cerrato, E; Corleto, A; Destefanis, P; Giolitto, S; Gravinese, C; Lo Savio, L; Luciano, A; Nuñez-Gil, I; Pozzi, R; Quadri, G; Tizzani, E; Varbella, F | 1 |
| Chen, GZ; Huang, LA; Ma, Q; Zhang, L; Zhang, YH | 1 |
| Coons, JC; Huang, L; Iasella, CJ; Kreider, MS; Stevenson, JM | 1 |
| Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kreuzer, J; Lip, GYH; Mauri, L; Miede, C; Montalescot, G; Nordaby, M; Oldgren, J; Ozkor, M; Steg, PG; Ten Berg, JM; Vardas, P | 1 |
| Fujimoto, Y; Fukushima, KI; Himi, T; Kitahara, H; Kobayashi, Y; Nakayama, T; Nameki, M; Shiba, T; Shikama, N; Tokimasa, S | 1 |
| Batista, DV; Feitosa, MPM; Lima, EG; Linhares Filho, JPP; Lobo Filho, HG; Serrano Júnior, CV; Soffiatti, CD | 1 |
| Chan, NC; Chen, J; Fan, Y; Hu, X; Kong, D; Li, C; Li, J; Wang, F; Xu, K; Xu, L; Yang, L; Yang, M; Ye, S; Ying, L; Zhang, J; Zhang, S; Zhang, X; Zhu, H; Zhu, T | 1 |
| Fox, KAA; Gurbel, PA; Tantry, US; Ten Cate, H; Weitz, JI | 1 |
| Gleason, TG; Kilic, A; Navid, F; Seese, L; Sultan, I; Wang, Y | 1 |
| Hirayama, A; Isomura, N; Isshiki, T; Kato, M; Kimura, K; Nanasato, M; Nishikawa, H; Nishikawa, M; Nishimura, Y; Takayama, T; Takeda, Y; Tanigawa, T; Tsukahara, K; Yokoi, H | 1 |
| Andreev, DA; Grishina, EA; Mirzaev, KB; Potapov, PP; Ryzhikova, KA; Samsonova, KI; Sychev, DA | 1 |
| Calogiuri, G; Di Leo, E; Foti, C; Kounis, NG; Macchia, L; Mandurino-Mirizzi, A; Nettis, E; Vacca, A | 1 |
| Brust, K; Garncarek, M; Jagas, J; Roleder, T; Witkiewicz, W | 1 |
| Ding, J; Xu, GM; Yuan, J | 1 |
| Aznaouridis, K; Georgakopoulos, C; Ioakeimidis, N; Koutouzis, M; Latsios, G; Pietri, P; Rigatou, A; Terentes-Printzios, D; Tousoulis, D; Toutouzas, K; Vaina, S; Vlachopoulos, C | 1 |
| Andric, T; Haller, PM; Huber, K; Jäger, B; Kahl, BS; Piackova, E; Stojkovic, S; Vargas, KG; Wojta, J | 1 |
| Levy, MS; Price, DJ | 1 |
| Bruno, V; Egger, F; Farhan, S; Freynhofer, MK; Geppert, A; Huber, K; Hübl, W; Rohla, M; Tscharre, M; Weiss, TW; Willheim, M; Wojta, J | 1 |
| Fu, S; Luo, L; Ping, P; Ye, P | 1 |
| Chelstowski, K; Clark, JS; Jastrzebska, M; Lisman, D; Oledzki, S; Siennicka, A; Szelepajlo, A | 1 |
| Fan, B; Ge, J; Shen, L; Wu, H; Xu, H; Zhao, X | 1 |
| Andric, T; Haller, PM; Huber, K; Jäger, B; Piackova, E; Spittler, A; Stojkovic, S; Wisgrill, L; Wojta, J | 1 |
| Kioufis, S; Kokkou, E; Maniatis, K; Oikonomou, E; Papavassiliou, AG; Siasos, G; Stefanadis, C; Tousoulis, D; Zaromitidou, M | 1 |
| Han, JK; Jeon, KH; Kang, HJ; Kang, J; Kang, SH; Kim, HS; Koo, BK; Lee, HY; Lee, SE; Oh, BH; Park, JJ; Park, KW; Park, YB; Yang, HM | 1 |
| Chen, F; Gao, Y; He, J; Luo, Y; Lv, S; Ren, X; Wu, C; Yu, X; Zhang, X; Zhang, Y | 1 |
| Bonello, L; Laine, M; Paganelli, F | 1 |
| Abbate, R; Angiolillo, DJ; Bellandi, F; Giusti, B; Leoncini, M; Maioli, M; Marcucci, R; Toso, A | 1 |
| Sellke, FW | 1 |
| Akturk, IF; Caglar, FN; Caglar, IM; Erturk, M; Surgit, O; Tuncer, N; Uzun, F; Yalcın, AA | 1 |
| Fleck, E; Graf, K; Hauptmann, T; Kappert, K; Kaufmann, J; Meixner, M; Meyborg, H; Müller, A; Stawowy, P; Urban, D; Wellnhofer, E | 1 |
| Gurbel, PA; Jeong, YH; Kubica, J; Navarese, EP; Tantry, US | 1 |
| Geisler, T; Karathanos, A | 1 |
| Angiolillo, DJ; Bailey, WL; Baker, BA; Bliden, KP; Gurbel, PA; Jakubowski, JA; Jeong, YH; Kereiakes, DJ; Lasseter, KC; Logan, DK; Maa, JF; Nolin, TD; Ojeh, CK; Tantry, US; White, A | 1 |
| Chen, JY; Kang, YH; Lai, WH; Lao, HY; Li, XX; Wu, H; Yu, XY; Zhong, SL | 1 |
| Franken, CC; Kaiser, AF; Krüger, JC; Mügge, A; Neubauer, H; Overbeck, K | 1 |
| Ardati, AK; Aronow, HD; Chetcuti, S; Grossman, PM; Gurm, HS; Moscucci, M; Pitt, B; Share, D; Smith, DE | 1 |
| Chan, HL; Chan, KK; Chau, CH; Cheung, CY; Cheung, GS; Choi, MC; Lee, JK; Li, SK; Tsui, KL; Wu, KL | 1 |
| McDermott, MW; Rouine-Rapp, K | 1 |
| Angiolillo, DJ; Brown, PB; Erlinge, D; Foley, DP; Gurbel, PA; Jakubowski, JA; James, S; Lindahl, TL; Luo, J; Moser, BA; Small, DS; Svensson, P; Ten Berg, JM; Wagner, H; Winters, KJ; Zhou, C | 1 |
| Bonello, L; Frère, C; Laine, M; Paganelli, F | 1 |
| Bliden, KP; Gurbel, PA; Hwang, JY; Hwang, SJ; Jang, JS; Jeong, YH; Kim, IS; Kim, S; Koh, EH; Koh, JS; Kwak, CH; Lee, DH; Park, JR; Park, Y; Tantry, US | 1 |
| Bonovas, S; Douramani, P; Gialeraki, A; Ikonomidis, I; Kapsimali, V; Karakitsos, P; Kokori, S; Kopterides, P; Kottaridi, C; Kyriakou, E; Lekakis, J; Papadakis, I; Tsantes, AE | 1 |
| Bastos, G; Bravo, M; Brión, M; Carracedo, A; Cavichioli, D; Hirata, MH; Hirata, RD; Iñiguez, A; Lima-Neto, LG; Luchessi, AD; Silbiger, VN; Sousa, AG | 1 |
| Baituola, G; Chen, BD; Chen, Y; Fu, ZY; Huang, Y; Li, XM; Li, Y; Liu, C; Liu, F; Ma, X; Ma, YT; Xie, X; Yang, YN; Yu, ZX; Zheng, YY | 1 |
| Gao, W; Han, JL; Li, HY; Li, L; Qiao, R; Yu, HY; Zhang, J | 1 |
| McCormack, T | 1 |
| Albalbissi, K; Coffey, B; Khosla, S; Molnar, J; Panchal, HB; Patel, P; Ramu, V; Shah, T | 1 |
| Choi, DJ; Kang, HJ; Kim, HS; Kim, MA; Koo, BK; Lee, HY; Lee, S; Oh, BH; Park, KW | 1 |
| Akgün, T; Can, MM; Kaymaz, C; Koca, F; Kurt, M; Ozkan, A; Tanboğa, IH; Tokgöz, HC | 1 |
| Akiyama, E; Fujisue, K; Hokimoto, S; Iwashita, S; Kaikita, K; Kurokawa, H; Matsubara, J; Matsui, K; Matsuzawa, Y; Nakagawa, K; Ogawa, H; Oniki, K; Ono, T; Sugamura, K; Sugiyama, S; Sumida, H | 1 |
| Darvish-Kazem, S; Douketis, JD; Gandhi, M; Marcucci, M | 1 |
| Bsharat, RS; Catela Ivković, T; Galić, E; Kapitanović, S; Milicević, Z; Mirat, J; Petro, D; Vcev, A; Vrbanić, L; Vuković, I | 1 |
| Angiolillo, DJ; Bender, N; Darlington, A; Desai, B; Franchi, F; Muñiz-Lozano, A; Patel, R; Rollini, F; Sakariassen, KS; Tello-Montoliu, A; Wilson, RE | 1 |
| Ahn, T; Choi, H; Choi, IS; Han, SH; Kang, WC; Lee, K; Moon, CI; Oh, PC; Shin, EK; Suh, SY | 1 |
| Angiolillo, DJ; Braun, OÖ; Costigan, TM; Duvvuru, S; Effron, MB; Ferreiro, JL; Jakubowski, JA; Kleiman, NS; Saucedo, JF; Sundseth, S; Varenhorst, C; Walker, JR; Winters, KJ | 1 |
| Baber, U; Bander, J; Desnick, RJ; Hulot, JS; Kornreich, R; Martis, S; Scott, SA; Tan, Q; Yang, Y | 1 |
| Chua, D; Nishi, C | 1 |
| Cha, KS; Chae, IH; Hwang, KK; Jeon, HK; Jeong, MH; Kang, HJ; Kang, SH; Kim, HS; Kim, S; Koo, BK; Kwon, HM; Lee, SY; Moon, KW; Oh, JH; Park, BE; Park, JJ; Park, KW; Park, TH; Rhew, JY; Shin, ES; Yang, HM; Yoon, JH | 1 |
| DiNicolantonio, JJ; Lavie, CJ | 1 |
| Abbate, R; Antoniucci, D; Carrabba, N; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R | 1 |
| Ahn, JM; Cho, YR; Han, S; Jang, JY; Kang, SJ; Kim, JJ; Kim, WJ; Kim, YH; Kwon, CH; Lee, CW; Lee, JY; Lee, SW; Lee, WS; Park, DW; Park, GM; Park, SJ; Park, SW; Park, YK | 1 |
| Bauters, A; Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Landel, JB; Lemesle, G; Sudre, A; Susen, S | 1 |
| Ahn, JM; Chae, JK; Cheong, SS; Choi, YS; Han, S; Hur, SH; Jang, JS; Jeon, DS; Jeong, MH; Kang, SJ; Kim, HS; Kim, KS; Kim, YH; Lee, BK; Lee, CW; Lee, K; Lee, NH; Lee, SG; Lee, SU; Lee, SW; Lim, DS; Nah, DY; Park, DW; Park, HS; Park, SJ; Park, SW; Rha, SW; Seong, IW; Seung, KB; Suh, IW; Yang, JY; Yoon, JH | 1 |
| Bigalke, B; Gawaz, M; Geisler, T; Karathanos, A; Meissner, M; Müller, II; Müller, KA; Schaeffeler, E; Schwab, M; Stellos, K; Stimpfle, F; Tavlaki, E | 1 |
| Acharji, S; Kaluski, E; Lakshmanadoss, U; Rudzinski, W; Stapleton, DD | 1 |
| Åsenblad, N; Becker, RC; Cannon, CP; Held, C; Husted, SE; James, SK; Siegbahn, A; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L; Ycas, J | 1 |
| Ha, SJ; Hwang, SJ; Kim, KS; Kim, MK; Kim, SJ; Kim, W; Kim, WS; Woo, JS | 1 |
| Anderson, RA; Bundhoo, S; James, PE; Sagan, E | 1 |
| Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M | 1 |
| Abizaid, A; Abizaid, AS; Bhatt, DL; Botelho, RV; Castello, HJ; Costa, JR; Costa, RA; de Castro, JP; de Paula, JE; Devito, FS; Feres, F; Gusmão, M; King, SB; Labrunie, A; Leon, MB; Liu, M; Mangione, JA; Marin-Neto, JA; Meireles, GX; Negoita, M; Nicolela, EL; Perin, MA; Salvadori, D; Staico, R | 1 |
| Alessi, MC; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Dutour, A; Gaborit, B; Lambert, M; Loundou, AD; Morange, PE; Pankert, M; Quilici, J; Valéro, R; Verdier, V | 1 |
| Clemmensen, P; Dridi, NP; Engstrøm, T; Helqvist, S; Holmvang, L; Johansson, PI; Jørgensen, E; Kelbæk, H; Pedersen, F; Qayyum, A; Radu, MD; Saunamäki, K; Stissing, T | 1 |
| Briguori, C; Condorelli, G; De Micco, F; Focaccio, A; Latronico, MV; Pagnotta, P; Papa, L; Roncarati, R; Visconti, G; Viviani Anselmi, C | 1 |
| Bevan, P; Bunton, R; Menon, A | 1 |
| Binongo, JN; Dhawan, SS; Ghazzal, ZB; Pohlel, FK; Quyyumi, AA; Ramadan, R; Syed, H | 1 |
| Bocksch, W; Fateh-Moghadam, S; Gawaz, M; Geisler, T; Htun, P; Kan, T; Mueller, E; Pohle, C; Schindler, R | 1 |
| Angiolillo, DJ; Bass, TA; Cho, JR; Desai, B; Ferrante, E; Franchi, F; Guzman, LA; Haas, MJ; Muñiz-Lozano, A; Rollini, F; Tello-Montoliu, A | 1 |
| Araki, T; Enomoto, Y; Hara, H; Hori, M; Iijima, R; Itaya, H; Ito, N; Nagashima, Y; Nakamura, M; Shiba, M; Sugi, K; Tokue, M; Utsunomiya, M; Yamazaki, K | 1 |
| Franzoni, F; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Polacco, M; Rosano, G; Speziale, G; Spoletini, I; Vitale, C | 1 |
| de Groot, PG; Hillaert, MA; Pasterkamp, G; Pijls, NH; Roest, M; Rutten, B; Sels, JW; van Holten, TC; Waltenberger, J | 1 |
| Gremmel, T; Kopp, CW; Koppensteiner, R; Panzer, S; Steiner, S; Xhelili, E | 1 |
| Brown, PB; Duvvuru, S; Erlinge, D; Gurbel, PA; Jakubowski, JA; James, S; Moser, BA; Small, D; Sundseth, SS; Tantry, US; Varenhorst, C; Wagner, H; Walker, JR; Winters, KJ | 1 |
| Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Price, MJ | 1 |
| Ay, C; Badr Eslam, R; Eichelberger, B; Gremmel, T; Lang, IM; Panzer, S; Posch, F | 1 |
| Ahn, SG; Choi, H; Hong, MK; Hong, YJ; Jang, Y; Kwon, HM; Lee, JW; Lee, SH; Yoon, J; Youn, YJ; Yu, CW | 1 |
| Gislason, GH; Hansen, ML; Køber, L; Lamberts, M; Lassen, JF; Lip, GY; Mikkelsen, AP; Olesen, JB; Sørensen, R; Torp-Pedersen, C | 1 |
| Grajek, S; Komosa, A; Kowal, J; Lesiak, M; Mączyński, M; Michalak, M; Mularek-Kubzdela, T; Siller-Matula, JM; Siniawski, A | 1 |
| Barbato, E; Cavallari, I; D'Ambrosio, A; De Bruyne, B; Di Sciascio, G; Mangiacapra, F; Patti, G; Ricottini, E; Vizzi, V; Wijns, W | 1 |
| Bitar, A; Breall, JA; Desta, Z; Flockhart, DA; Jin, Y; Kreutz, RP; Nystrom, P; Owens, J; Sinha, A; Vatta, M; von der Lohe, E | 1 |
| Cameron, JD; Luu, LJ; Nelson, AJ; Schultz, CD; Willoughby, SR; Worthley, MI; Worthley, SG | 1 |
| Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ | 1 |
| Bailey, WL; Baker, BA; Bliden, KP; Gurbel, PA; Tantry, US | 1 |
| Best, LG; Dobesh, PP; Oestreich, JH | 1 |
| Alpert, JS; Asencio, LA; Huang, JJ | 1 |
| Asselbergs, FW; de Borst, GJ; de Groot, PG; Moll, FL; Roest, M; van der Graaf, Y; Wisman, PP | 1 |
| de Boer, A; Deneer, VH; Klungel, OH; Yasmina, A | 1 |
| Byrne, RA; Fiedler, KA; Ibrahim, T; Kastrati, A; Laugwitz, KL; Maeng, M; Mehilli, J; Sarafoff, N; Schulz, S; Sibbing, D | 1 |
| Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Comito, V; De Luca, G; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Ramazzotti, RN; Valenti, R | 1 |
| Biocina, B; Djuric, Z; Gasparovic, H; Kopjar, T; Petricevic, M; Svetina, L | 1 |
| Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Jang, Y; Kim, HS; Lee, SH; Oh, JH; Seung, KB; Song, PS; Song, YB; Yang, JH | 1 |
| Byrne, RA; Kastrati, A; Laugwitz, KL; Ndrepepa, G; Neumann, FJ; Pache, J; Pöhler, A; Richardt, G; Schulz, S | 1 |
| Asher, E; Beigel, R; Fefer, P; Hod, H; Matetzky, S; Savion, N; Shechter, M; Shenkman, B; Varon, D | 1 |
| Bovier, P; Harr, T; Seebach, JD | 1 |
| Chen, X; Cui, H; Du, W; Fei, X; Li, X; Lin, S; Liu, J; Liu, Y; Song, H; Su, J; Tong, M; Wang, J; Wang, Y; Xu, J; Yu, Q; Zhang, L; Zheng, W; Zhong, J | 1 |
| Fujikawa, T; Tanaka, A | 1 |
| Akasaka, T; Arima, Y; Chitose, T; Hokimoto, S; Iwashita, S; Kaikita, K; Matsui, K; Miyazaki, H; Mizobe, M; Morita, K; Nakagawa, K; Ogawa, H; Oniki, K | 1 |
| Akasaka, T; Arima, Y; Hokimoto, S; Kaikita, K; Miyazaki, H; Mizobe, M; Morita, K; Nakagawa, K; Ogawa, H; Oniki, K | 1 |
| Desta, Z; Flockhart, DA; Jin, Y; Kreutz, RP; Kreutz, Y; Lu, D; Nystrom, P; Owens, J | 1 |
| Barnard, J; Bhatt, DL; Kottke-Marchant, K; Murugesan, G; Timur, AA; Zhang, L | 1 |
| Joo, HC; Lee, S; Yi, G; Yoo, KJ; Youn, YN | 1 |
| Han, H; Li, Y; Liang, J; Liu, W; Liu, Y; Shi, D; Wang, Z; Yang, L; Zhang, L; Zhao, Y; Zhou, Y | 1 |
| Emanuelsson, H; Hiasa, Y; Teng, R | 1 |
| Head, SJ; Hunink, MG; Janssens, AC; Kappetein, AP; Osnabrugge, RL; ten Berg, JM; Zijlstra, F | 1 |
| Barbato, E; Boland, J; Chenu, P; Claeys, MJ; Cuisset, T; Dens, J; Gach, O; Legrand, V; Magne, J; Martinez, C; Vrolix, M; Wijns, W | 1 |
| Hou, X; Shi, J; Sun, H | 1 |
| Chen, XM; Li, XJ | 1 |
| Angiolillo, DJ; Bergmeijer, TO; Brown, PB; Duvvuru, S; Erlinge, D; Gurbel, PA; Jakubowski, JA; James, S; Lindahl, TL; Moser, BA; Small, D; Sundseth, S; Svensson, P; Tantry, US; ten Berg, JM; Walker, JR; Winters, KJ | 1 |
| Abtan, J; Anzaha, G; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Charland, SL; Collet, JP; Galier, S; Gallois, V; Hulot, JS; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J; Stanek, EJ | 1 |
| Angiolillo, DJ; Brown, PB; Erlinge, D; Jakubowski, JA; James, S; Moser, BA; Small, DS; Ten Berg, JM; Winters, KJ; Zhou, C | 1 |
| Han, L; Li, Y; Liu, H; Tian, L; Wang, D; Yan, L; Zhang, X | 1 |
| Angiolillo, DJ; Berg, DD; Cyr, JF; Frelinger, AL; Hochholzer, W; Lei, L; Mattimore, JF; Mega, JL; Mesa, RA; Michelson, AD; O'Donoghue, ML; Ruff, CT; Sabatine, MS | 1 |
| Ben-Yehuda, O | 1 |
| Adithan, C; Dkhar, SA; Narayan, SK; Priyadharsini, R; Ravindra, BK; Satheesh, S; Shewade, DG; Sridhar, MG; Subraja, K; Umamaheswaran, G | 1 |
| Christ, G; Dechant, C; Delle-Karth, G; Francesconi, M; Grohs, K; Gruber, C; Jilma, B; Podczeck-Schweighofer, A; Siller-Matula, JM | 1 |
| Diodati, JG; Lordkipanidzé, M; Palisaitis, DA; Pharand, C; Schampaert, E | 4 |
| Ahn, DG; Kim, BJ; Kim, JG; Kim, JW | 1 |
| Price, MJ | 1 |
| Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Franchi, F; Guzman, LA; Jakubowski, JA; Moser, BA; Rollini, F; Sugidachi, A; Tello-Montoliu, A; Ueno, M | 1 |
| Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P | 1 |
| Thompson, PL; Verheugt, FW | 1 |
| Alexander, JH; Califf, RM; Englum, BR; Gibson, CM; Hager, R; Hess, CN; Kouchoukos, NT; Lopes, RD; Mack, MJ; Peterson, ED; Wojdyla, DM | 1 |
| Angiolillo, DJ; Caplan, R; Carlson, G; Clavijo, L; Maya, J; Price, MJ; Teng, R | 1 |
| Duru, OK; Edgington, S; Ettner, S; Kimbro, L; Mangione, C; Tseng, CH; Turk, N | 1 |
| Kim, JJ; Kim, N | 1 |
| Hunnangkul, S; Kamkaew, R; Likidlilid, A; Poldee, S; Suktitipat, B; Tassaneetrithep, B; Tresukosol, D | 1 |
| Bliden, KP; Franzese, C; Gurbel, PA; Jeong, YH; Kang, K; Lev, EI; Pandya, S; Tantry, US | 1 |
| Chyrchel, B; Chyrchel, M; Kołton-Wróż, M; Kruszelnicka, O; Mielecki, W; Surdacki, A; Totoń-Żurańska, J; Wołkow, P | 1 |
| Christ, G; Dechant, C; Francesconi, M; Grohs, K; Podczeck-Schweighofer, A; Siller-Matula, JM | 1 |
| Dohi, Y; Fukuda, Y; Higaki, T; Ikenaga, H; Ishibashi, K; Iwasaki, T; Kihara, Y; Kurisu, S; Mitsuba, N; Shimonaga, T; Watanabe, N | 1 |
| Kioufis, S; Maniatis, K; Mourouzis, K; Oikonomou, E; Papageorgiou, N; Papaioannou, S; Papavassiliou, AG; Siasos, G; Stefanadis, C; Tousoulis, D; Tsalamandris, S; Vavuranakis, M; Zaromitidou, M | 1 |
| Abergel, H; Ajzenberg, N; Ducrocq, G; Esposito-Farèse, M; Feldman, L; Himbert, D; Huisse, MG; Juliard, JM; Kerner, A; Roussel, R; Sorbets, E; Steg, PG; Triantafyllou, K; Tubach, F | 1 |
| Armengaud, J; Barragan, P; Benamer, H; Berland, J; Blanchard, D; Boschat, J; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Druelles, P; Dupouy, P; Endresen, K; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J | 1 |
| Kioufis, S; Kokkou, E; Maniatis, K; Oikonomou, E; Papageorgiou, N; Papaioannou, S; Papavassiliou, AG; Siasos, G; Stefanadis, C; Tourikis, P; Tousoulis, D; Vavuranakis, M; Zaromitidou, M | 1 |
| Cho, DK; Kim, SH; Lee, HJ; Lee, HS; Lim, SW; Shin, J; Sung, JH | 1 |
| Abdel-Wahab, M; Adriaenssens, T; Angiolillo, DJ; Bernlochner, I; Byrne, RA; Desmet, W; Feuchtenberger, A; Fischer, M; Han, Y; Hengstenberg, C; Ibrahim, T; Jacobshagen, C; Janssen, PW; Kastrati, A; Kufner, S; Laugwitz, KL; Li, Y; Maeng, M; Mehilli, J; Morath, T; Mudra, H; Neumann, FJ; Rifatov, N; Schömig, A; Schulz-Schüpke, S; Schunkert, H; Seyfarth, M; Ten Berg, JM; Tiroch, K; Tölg, R; Valina, C; von Hodenberg, E; von Merzljak, B; Wöhrle, J; Zrenner, B | 1 |
| Angiolillo, DJ; Fujita, K; Ikeda, T; Ikuta, S; Iwanaga, Y; Kobuke, K; Miyazaki, S; Suga, T; Ueno, M; Yamaji, K; Yamamoto, H | 1 |
| Chlouverakis, G; Hamilos, M; Igoumenidis, N; Kambouris, M; Kochiadakis, G; Loggakis, I; Saloustros, I; Skalidis, E; Vardas, PE; Vougia, D | 1 |
| Bauters, C; Bonello, L; Delhaye, C; Hurt, C; Lemesle, G; Manchuelle, A; Puymirat, E; Schurtz, G; Sudre, A | 1 |
| Bhatt, DL; Cortese, B; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD; Wilensky, M | 1 |
| Ando, G; Calabro, P; Costa, F; Leonardi, S; Moscarella, E; Oreto, G; Valgimigli, M; Vranckx, P; Zijlstra, F | 1 |
| Kereiakes, DJ; Mauri, L; Yeh, RW | 1 |
| Airoldi, F; Briguori, C; Campo, G; Colangelo, S; de Cesare, N; Dellavalle, A; Ferlini, M; Gabriel, HM; Garbo, R; Liistro, F; McFadden, E; Meliga, E; Menozzi, A; Patialiakas, A; Roffi, M; Tebaldi, M; Testa, L; Thury, A; Tondi, S; Ungi, I; Valgimigli, M; Vranckx, P | 1 |
| Kandzari, DE | 1 |
| Baker, N; Bliden, KP; Chen, F; Escarcega, RO; Gurbel, PA; Lhermusier, T; Lipinski, MJ; Magalhaes, MA; Minha, S; Ota, H; Pendyala, L; Tantry, US; Tian, W; Torguson, R; Waksman, R | 1 |
| Lee, CW | 1 |
| Hvas, AM; Kristensen, SD; Modrau, IS; Würtz, M | 1 |
| Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo-Silberman, S; Sideris, G; Voicu, S | 1 |
| Amann, M; Bömicke, T; Hochholzer, W; Neumann, FJ; Nührenberg, T; Stratz, C; Trenk, D; Valina, CM | 1 |
| Andjelkovic, N; Davidovic, G; Djurdjevic, P; Ignjatovic, V; Ignjatovic, VD; Iric-Cupic, V; Jovanovic, D; Miloradovic, V; Nesic, J; Pavlovic, S; Petrovic, N; Simic, I; Simovic, S; Smiljanic, Z; Stolic, R; Zdravkovic, V | 1 |
| Gao, F; Liu, XL; Shen, H; Wang, ZJ; Yang, SW; Zhou, YJ | 1 |
| Calcagno, S; Cavallo, E; Di Roma, A; Fedele, F; Guadagni, F; Lucisano, L; Mancone, M; Palmirotta, R; Pennacchi, M; Placentino, F; Sardella, G; Stio, RE | 1 |
| Chen, HB; Huang, BY; Liang, HB; Liu, XW; Xiu, J; Zhang, XL; Zhang, XY | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M | 4 |
| Cayla, G; Collet, JP; Finzi, J; Hulot, JS; Montalescot, G; Simon, N | 1 |
| Angiolillo, DJ; Caplan, RJ; Carlson, GF; Ferdinand, KC; Maya, J; Teng, R; Waksman, R | 1 |
| Cho, K; Dufour, AB; Faxon, DP; Gagnon, DR; Gaziano, JM; Kinlay, S; Ly, S; Siddiqi, OK; Smoot, KJ; Temiyasathit, S; Young, M | 1 |
| Brand, A; Bruggemans, EF; Eikenboom, J; Gielen, CL; Klautz, RJ; Stijnen, T; Tavilla, G | 1 |
| Arya, V; Bhargava, M; Mahajan, P; Mohanty, A; Saraf, A; Sawhney, JP | 1 |
| Gick, M; Hochholzer, W; Kirtane, AJ; Leggewie, S; Neumann, FJ; Nührenberg, TG; Stone, GW; Stratz, C; Trenk, D; Valina, CM | 1 |
| Ariyoshi, N; Fujimoto, Y; Hanaoka, H; Kobayashi, Y; Koshizaka, M; Nakayama, T; Nishi, T; Sugimoto, K; Takahara, M; Wakabayashi, S | 1 |
| Antonopoulos, A; Dimitropoulos, S; Kioufis, S; Kokkou, E; Mourouzis, K; Oikonomou, E; Papavassiliou, AG; Siasos, G; Stefanadis, C; Tousoulis, D; Tsalamandris, S; Vavuranakis, M; Zaromitidou, M; Zografos, T | 1 |
| Dohi, K; Fujimoto, N; Fukuoka, S; Ito, M; Izumi, D; Miyahara, M; Sakai, M | 1 |
| Agrawal, K; Cho, K; Dufour, AB; Faxon, DP; Gagnon, DR; Gaziano, JM; Kinlay, S; Ly, S; Prince, L; Smoot, KJ; Sokolovskaya, G; Temiyasathit, S; Thukkani, AK | 1 |
| Berman, E; Boccara, F; Carrie, D; Cattan, S; Cayla, G; Diallo, A; Douard, H; Dreyfus, X; Eltchaninoff, H; Falquier, JF; Furber, A; Georges, JL; Hammoudi, N; Helft, G; Henry, P; Komajda, M; Le Feuvre, C; Leclercq, F; Metzger, JP; Michel, PL; Sebagh, L; Steg, PG; Tuambilangana, A; Vicaut, E | 1 |
| Gierlotka, M; Kaczmarski, J; Kim, MH; Kuliczkowski, W; Serebruany, V; Sliwka, J; Steter, D; Zembala, M; Zysko, D | 1 |
| Akram, MM; Barn, K; Berger, PB; Boga, G; Henry, YM; Ismail-Sayed, I; Mizrahi, E; Suryadevara, RS; Troup, MA | 1 |
| Agarwal, Z; Gogo, P; Schneider, DJ; Seecheran, N | 1 |
| Abbate, R; Antoniucci, D; Cantini, G; Comito, V; Gensini, GF; Marcucci, R; Marrani, M; Migliorini, A; Parodi, G; Valenti, R | 1 |
| Ahn, T; Bae, JH; Cha, KS; Cha, TJ; Cho, DK; Choi, CU; Choi, WG; Chun, KJ; Hong, BK; Jeon, DW; Jung, KT; Kim, BS; Kim, DI; Kim, DS; Kim, DW; Kim, TI; Kim, YD; Kwan, J; Oh, PC; Pyun, WB; Yang, YM | 1 |
| Angiolillo, DJ; Caplan, R; Carlson, G; Clavijo, LC; Maya, J; Price, MJ; Teng, R | 1 |
| Bundhun, PK; Chen, MH; Qin, T | 1 |
| Kim, YS; Lee, SR | 1 |
| Baek, C; Chang, K; Chung, WS; Kim, HY; Kim, PJ; Kim, TH; Koh, YS; Lim, S; Park, HJ; Seung, KB | 1 |
| Dolor, RJ; Hasselblad, V; Jones, WS; Melloni, C; Sherwood, MW; Washam, JB | 1 |
| Cho, YR; De Jin, C; Guo, LZ; Kim, MH; Lee, DH; Park, JS; Park, K; Park, TH; Serebruany, V | 1 |
| Ajjan, RA; Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Franchi, F; Guzman, LA; King, R; Phoenix, F; Rollini, F; Tello-Montoliu, A; Zenni, MM | 1 |
| Ayers, C; Berry, JD; Cooper, M; Das, SR; de Lemos, JA; Edwards, A; Khalili, H; Moss, E; Singh, R; Vongpatanasin, W; Wood, M | 1 |
| Bai, J; Han, Q; Huang, XH; Liu, C; Shen, DL; Wang, B; Zhang, JY | 1 |
| Arima, Y; Hokimoto, S; Ishii, M; Ito, M; Kaikita, K; Kojima, S; Nakagawa, K; Ogawa, H; Oimatsu, Y; Sakamoto, K; Sueta, D; Tsujita, K | 1 |
| Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O | 1 |
| Ansell, J; Chang, P; Fonarow, GC; Gersh, BJ; Go, AS; Hylek, EM; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Rao, M; Simon, DN; Singer, DE; Thomas, L | 1 |
| Grajek, S; Komosa, A; Kowal, J; Lesiak, M; Mączyński, M; Michalak, M; Mularek-Kubzdela, T; Siller-Matula, JM; Siniawski, A; Wiśniewski, S | 1 |
| Alamri, HS; Alkhudair, AA; AlMasood, AS; Almoghairi, AM; Sakr, HI | 1 |
| Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Dunn, EC; Ferrante, E; Franchi, F; Guzman, LA; Muniz-Lozano, A; Rollini, F; Singh, K; Wilson, RE; Zenni, MM | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M | 1 |
| Brodie, BR; Duffy, PL; Inaba, S; Kirtane, AJ; Maehara, A; Mazzaferri, EL; Metzger, DC; Mintz, GS; Rinaldi, MJ; Shimizu, T; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Yun, KH | 1 |
| Angiolillo, DJ; Berger, PB; Cannon, CP; Price, MJ; Reed, GW; Tanguay, JF; Teirstein, PS; Waalen, J | 1 |
| Kioufis, S; Kokkou, E; Maniatis, K; Oikonomou, E; Siasos, G; Tousoulis, D; Vavuranakis, M; Zaromitidou, M | 1 |
| Angiolillo, DJ; Capodanno, D | 1 |
| Arbel, Y; Lev, EI; Mosseri, M; Musallam, A; Orvin, K; Perl, L; Roguin, A | 1 |
| Hellkamp, AS; Hess, CN; Peng, SA; Peterson, ED; Roe, MT; Scirica, BM; Thomas, L; Wang, TY | 1 |
| Bianchi, M; Di Nardo, V; Fioranelli, M; Roccia, MG | 1 |
| Deliargyris, EN; Fan, W; Plent, S; Prats, J | 1 |
| Cai, W; Han, Y; Liu, D; Liu, T; Yan, C; Zhang, D; Zhang, X | 1 |
| Angiolillo, DJ; Carreras, ET; Frelinger, AL; Hochholzer, W; Mega, JL; Michelson, AD; Nordio, F; O'Donoghue, ML; Sabatine, MS; Wiviott, SD | 1 |
| Ahn, YK; Chae, IH; Choi, DJ; Choi, SW; Doh, JH; Han, KR; Hwang, KK; Hyon, MS; Kim, HS; Kim, KS; Kim, MA; Kim, SH; Kim, SW; Kim, YK; Lee, BK; Lee, HC; Lee, SH; Lim, SW; Lim, WH; Park, WJ; Seol, SH; Shin, ES; Yoon, CH; Yoon, JH | 1 |
| Fu, ZH; Han, BS; Li, DY; Ren, YH; Song, YQ; Xue, Q; Yi, J; Zhou, CF | 1 |
| Fabiszak, T; Kubica, A; Kubica, J; Obońska, K | 1 |
| Arteaga, M; Etxeberria-Lekuona, D; Jarne, V; Méndez-López, I; Mercado, MR; Oteiza, J | 1 |
| Dong, X; Han, Y; He, M; Li, M; Li, Y; Liu, B; Lu, S; Pan, Y; Shi, J; Sun, D; Zhao, S; Zheng, W | 1 |
| Bekbossynova, M; Cattaneo, M; Golukhova, E; Kim, MH; Marciniak, TA; Pya, Y; Serebruany, VL | 1 |
| Baber, U; Brodie, BR; Cox, DA; Dangas, GD; Duffy, PL; Francese, DP; Généreux, P; Giustino, G; Gurbel, PA; Henry, TD; Kirtane, AJ; Maehara, A; Mazzaferri, EL; Mehran, R; Metzger, C; Neumann, FJ; Ozan, O; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B | 1 |
| Gillette, M; Hoang, V; Jneid, H; Morneau, K; Virani, S | 1 |
| Bhatt, DL; Grunwald, GK; Ho, PM; Maddox, TM; O'Donnell, CI; Rumsfeld, JS; Tsai, TT; Vigen, R | 1 |
| Borna, C; Brown, P; Erlinge, D; Gidlöf, O; Jakubowski, JA; Lood, C; Truedsson, L; Wagner, H; Winters, K; Zhou, C | 1 |
| Hou, FL; Li, X; Liu, YH; Tian, YJ; Wang, SH; Zheng, SL | 1 |
| Arora, V; Kapoor, D; Omar, A; Pillai, A; Poommipanit, P; Shah, RR; Zhao, J | 1 |
| Baber, U; Collet, JP; Desnick, RJ; Fuster, V; Hajjar, RJ; Hulot, JS; Kini, AS; Linderman, M; Montalescot, G; Peter, I; Qiao, W; Scott, SA; Sharma, SK; Sload, J; Yang, Y | 1 |
| Agarwal, S; Barakat, AF; Chaudhury, P; Ellis, SG; Faza, NN; Kapadia, SR; Mentias, A; Murat Tuzcu, E; Parashar, A; Wayangankar, S | 1 |
| Sha, WH; Tan, GY; Wang, QY; Zhang, ZF | 1 |
| Alper, AT; Borklu, EB; Bozbeyoğlu, E; Çakıllı, Y; Gümüşdağ, A; Hayıroğlu, Mİ; Kalenderoğlu, K; Kaya, A; Tatlısu, MA; Tekkeşin, Aİ; Türkkan, C; Yıldırımtürk, Ö | 1 |
| Bernlochner, I; Gross, L; Jaitner, J; Kastrati, A; Laugwitz, KL; Mayer, K; Morath, T; Orban, M; Rössner, L; Sibbing, D | 1 |
| D'Amico, EA; Filho, CC; Filho, RK; Freire, BT; Furtado, RHM; Giugliano, RP; Neto, PAL; Nicolau, JC; Pereira, AC; Ramires, JAF; Rocha, TR; Strunz, CMC | 1 |
| Brener, SJ; Brodie, BR; Cox, DA; Duffy, PL; Henry, TD; Kirtane, AJ; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Parvataneni, R; Rinaldi, MJ; Stone, GW; Stuckey, TD; Witzenbichler, B | 1 |
| Fischman, DL; Kaliyadan, A; Nardone, E; Poll, D; Savage, MP; Siu, H | 1 |
| Barbieri, L; Brouwer, MA; Camaro, C; Damen, SA; de Boer, MJ; De Luca, G; Kedhi, E; Lee, SW; Ligtenberg, E; Rognoni, A; Suryapranata, H; van T Hof, AW; Verdoia, M | 1 |
| Fahed, E; Ghauche, J; Maarrawi, J; Menassa-Moussa, L; Moussa, R; Nohra, G; Okais, N; Rahme, R; Rizk, T; Samaha, E | 1 |
| Gwon, HC; Han, KR; Hur, SH; Jeong, MH; Kim, HS; Koo, BK; Park, JS; Park, KW; Park, SJ; Rha, SW; Seo, JB; Seong, IW; Shin, DH; Tahk, SJ; Yang, JY; Yoon, JH | 1 |
| Chiżynski, K; Golański, J; Kassasir, H; Kuliczkowski, W; Sakowicz, A; Syska, K; Watała, C | 1 |
| Barbieri, L; Bellomo, G; Daffara, V; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Ariotti, S; Baldo, A; Esposito, G; Franzone, A; Gargiulo, G; Magnani, G; Marino, M; Piccolo, R; Santucci, A; Valgimigli, M; Windecker, S | 1 |
| García Rodríguez, LA; González-Pérez, A; Himmelmann, A; Johansson, S; Sáez, ME | 1 |
| Ferneini, EM; Ghantous, AE | 1 |
| Bouman, HJ; Henskens, YM; Olie, RH; Ten Cate, H; Ten Cate-Hoek, AJ; van der Meijden, PE; Veenstra, LF; Verhezen, PW; Vries, MJ; Zwaveling, S | 1 |
| Barbato, E; Colaiori, I; Di Sciascio, G; Lauria Pantano, A; Mangiacapra, F; Panaioli, E; Pozzilli, P; Ricottini, E | 1 |
| Choi, D; Hong, MK; Jang, Y; Kim, BK; Kim, HS; Kim, JS; Ko, YG; Lee, SY; Palmerini, T; Shin, DH; Stone, GW; Valgimigli, M | 1 |
| Serebruany, VL | 2 |
| Barbieri, L; De Luca, G; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Bovio, E; Nardi, P; Pellegrino, A; Russo, M; Ruvolo, G; Saitto, G; Scafuri, A | 1 |
| Chen, SL; Gao, XF; Ge, Z; Lin, S; Liu, ZZ; Tian, NL; Ye, F; Zhang, JJ | 1 |
| Cha, KS; Choi, JH; Hong, TJ; Kim, HS; Lee, HC; Lee, HW; Oh, JH; Park, JS | 1 |
| Jamil, K; Kumar, YS; Reddy, KP; Tantray, JA | 1 |
| Chae, HJ; Cho, HJ; Chun, S; Ji, M; Kim, IS; Kim, S; Lee, SY; Lee, W; Song, SH; Wee, KA; Woo, HI; Yun, YM | 1 |
| Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD | 1 |
| Antloga, CM; Badran, AV; Figueiredo, GL; Lago, IM; Lemos, DC; Lima-Filho, MO; Lorenzi, JC; Marchini, JF; Marin-Neto, JA; Novaes, GC; Oliveira, L; Pavão, RB; Pinto, MR; Tonani, M | 1 |
| Fan, Y; Hong, LF; Li, JJ; Lu, ZH; Luo, SH; Wu, Q; Yan, XN; Yang, B; Ye, F | 1 |
| Abizaid, A; Angelini, GD; Bacchi Reggiani, L; Benedetto, U; Bhatt, DL; Biondi-Zoccai, G; Chieffo, A; Colombo, A; Della Riva, D; Feres, F; Généreux, P; Gilard, M; Hong, MK; Jang, Y; Kim, BK; Kim, HS; Morice, MC; Palmerini, T; Park, KW; Pufulete, M; Sangiorgi, D; Stone, GW; Valgimigli, M; White, J | 1 |
| Ata, N; Birdane, A; Çolak, E; Değirmenci, İ; Güneş, HV; Özbayer, C; Özdemir, M; Saydam, F; Ulus, T | 1 |
| Barbato, E; Bartunek, J; De Biase, C; Delrue, L; Di Gioia, G; Izzo, R; Mangiacapra, F; Pellicano, M; Strisciuglio, T; Trimarco, B; Vanderheyden, M; Wijns, W | 1 |
| Chao, PW; Chen, HT; Chen, YT; Hsu, CY; Kuo, SC; Ou, SM; Shih, CJ | 1 |
| Baber, U; Ben-Yehuda, O; Brodie, BR; Cox, DA; Duffy, PL; Henry, TD; Kirtane, AJ; Maehara, A; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Ooi, SY; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Xu, K; Yu, J | 1 |
| Abizaid, A; Costa, JR; Costa, R; Feres, F; Mangione, JA; Piva E Mattos, LA; Siqueira, D; Sousa, A; Staico, R; Zuliani Mauro, MF | 1 |
| Blankenberg, S; Brieger, D; Chen, JY; Goodman, SG; Granger, CB; Grieve, R; Maguire, A; Nicolau, JC; Pocock, SJ; Requena, G; Simon, T; Vega, AM; Yasuda, S | 1 |
| Aradi, D; Balsam, P; Filipiak, KJ; Gajda, S; Huczek, Z; Kochman, J; Koltowski, L; Opolski, G; Tomaniak, M | 1 |
| Ben-Yehuda, O; Brodie, BR; Gupta, R; Kirtane, AJ; Mehran, R; Metzger, DC; Ozan, MO; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B | 1 |
| Filonenko, IV; Grinshtein, IY; Grinshtein, YI; Kosinova, AA; Savchenko, AA | 1 |
| Bhatt, DL; Colombo, A; Costa, F; Feres, F; Heg, D; Hong, MK; James, S; Kim, HS; Palmerini, T; Pilgrim, T; Räber, L; Steg, PG; Steyerberg, EW; Stone, GW; Valgimigli, M; van Klaveren, D; Wallentin, L; Windecker, S; Zanchin, T | 1 |
| Aharonian, V; Brar, SK; Brar, SS; Hyett, R; Kim, J; Liu, IL; Mansukhani, P; Ree, M; Shen, AY; Zadegan, R | 1 |
| Choi, SH; Prasad, A; Tsimikas, S | 1 |
| Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM | 1 |
| Becker, RC; Berger, PB; Ezekowitz, M; Guyatt, GH; Harrington, RA; Mark, DB; Meade, TW; O'Connor, CM; Vorchheimer, DA | 1 |
| Abderazek, F; Addad, F; Asma, A; Chakroune, T; Elalamy, I; Gamra, H; Ghrissi, I; Hassine, M; Zohra, D | 1 |
| Badimon, J; Chesebro, J; Kuliczkowski, W; Pokov, I; Serebruany, V | 1 |
| Fukushima, K; Iwata, Y; Kitahara, H; Kobayashi, Y; Komuro, I; Kuroda, N; Nakayama, T; Nomura, F; Ooyama, M | 1 |
| Abuzahra, M; Bobek, J; Caldera, A; Dokainish, H; Gonzalez, R; Hartley, WB; Lakkis, N; Pillai, M | 1 |
| Aygul, N; Duzenli, MA; Ozdemir, K; Soylu, A; Tokac, M | 1 |
| Badimón, JJ; De Miguel, A; Ibanez, B | 1 |
| Cohn, WE; Cooley, DA; de la Cruz, KI; Tsai, PI | 1 |
| Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Gori, AM; Marcucci, R; Migliorini, A; Moschi, G; Paniccia, R; Valenti, R; Vergara, R | 1 |
| Neumann, FJ; Trenk, D | 1 |
| Alviar, CL; Arikan, M; DeLao, T; Dong, JF; Granada, JF; Guthikonda, S; Kleiman, NS; Lev, EI; Tellez, A; Vaduganathan, M | 1 |
| Bischofs, C; Buse, V; Dippon, J; Gawaz, M; Geisler, T; Moerike, K; Schaeffeler, E; Schwab, M; Winter, S; Zuern, C | 1 |
| Berndt, MC; Dicker, P; Foley, DP; Kenny, D; Peace, AJ; Tedesco, AF | 1 |
| Diodati, JG; Lordkipanidzé, M; Nguyen, TA; Palisaitis, DA; Pharand, C; Schampaert, E | 1 |
| Asakura, Y; Ehara, M; Katoh, O; Kimura, M; Kinoshita, Y; Matsubara, T; Nasu, K; Suzuki, T; Tanaka, N; Terashima, M; Tsuchikane, E | 1 |
| Adhikari, S; Bystron, M; Cervinka, P; Jakabcin, J; Kvasnak, M; Spacek, R | 1 |
| Chirkov, YY; Horowitz, JD | 1 |
| Bauersachs, J; Eigenthaler, M; Ertl, G; Flierl, U; Schäfer, A; Störk, S; Walter, U; Weinberger, S | 1 |
| Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Johnell, M; Siegbahn, A; Varenhorst, C; Wallentin, L; Winters, KJ | 1 |
| Giannitsis, E; Ivandic, BT; Katus, HA; Keck, F; Kurz, K; Lehrke, S; Staritz, P | 1 |
| Rokkas, CK; Tourmousoglou, CE | 1 |
| Dokainish, H; Ferguson, AD; Lakkis, N | 1 |
| Xiang, YZ | 1 |
| Béres, BJ; Kerecsen, G; Kiss, RG; László, A; Masszi, T; Préda, I; Tóth-Zsámboki, E; Vargová, K | 1 |
| Fujioka, D; Hirano, M; Kawabata, K; Kitta, Y; Kobayashi, T; Kodama, Y; Kugiyama, K; Mende, A; Nakamura, T; Obata, JE; Ozaki, Y; Saitoh, Y; Sano, K; Satoh, K; Yano, T | 1 |
| Cha, KS; Goh, RY; Han, JY; Kim, KE; Kim, MH; Quan, ML; Woo, KS | 1 |
| Fu, W; Guo, H; Huang, J; Huang, L; Jian, Z; Li, A; Li, J; Qian, D; Song, Y | 1 |
| Ernest, CS; Rohatagi, S; Salazar, DE; Small, DS; Wallentin, L; Winters, KJ; Wrishko, RE | 1 |
| Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ | 1 |
| Cairns, JA; Eikelboom, J | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Ozdemir, M; Ozturk, B; Sahin, G; Tacoy, G; Topal, S; Yaman, E; Yildiz, R | 1 |
| Bonello, L; de Labriolle, A; Kaneshige, K; Kent, KM; Lemesle, G; Lindsay, J; Pichard, AD; Roy, P; Satler, LF; Slottow, TL; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R; Xue, Z | 1 |
| Acikel, S; Akdemir, R; Cagirci, G; Dogan, M; Kilic, H; Yesilay, AB | 1 |
| Haberl, K; Jilma, B; Lang, I; Panzer, S; Prillinger, K; Siller-Matula, JM | 1 |
| Bhatt, DL | 2 |
| Aronow, HD; Berger, PB; Brennan, DM; Steinhubl, SR; Topol, EJ | 1 |
| Bauters, C; Broucqsault, D; Delhaye, C; Lablanche, JM; Lemesle, G; Rosey, G; Sudre, A | 1 |
| Bilkova, D; Kala, P; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P | 1 |
| Stone, GW | 1 |
| Jennings, LK | 1 |
| Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Sibbing, D; Vogt, W; von Beckerath, N | 1 |
| Antonino, MJ; Gurbel, PA; Mahla, E; Tantry, US | 1 |
| Kala, P; Motovska, Z | 1 |
| Banerjee, S; Berger, P; Bissett, JK; Brilakis, ES; de Lemos, JA; Fasseas, P; Gadiparthi, C; Haagen, D; Kar, B; Karyofillis, P; Lichtenwalter, C; Obel, O; Roesle, M; Rossen, J; Sachdeva, R; Saeed, B; Voudris, VV | 1 |
| Colombo, A; Merlini, P | 1 |
| Dean, J; Wanjun, C; Yingxin, Z; Yonghe, G; Yujie, Z; Yuyang, L; Zheng, C | 1 |
| Byun, KH; Cho, JR; Choi, S; Jung, JH; Lee, N; Lee, SH; Min, PK; Sung, CW | 1 |
| Akers, WS; Campbell, CL; Charnigo, R; Dunn, SP; Holt, J; Oestreich, JH; Smyth, SS; Steinhubl, SR | 1 |
| Augoustides, JG; Ramakrishna, H | 1 |
| Lozano, ML; Marín, F; Pastor-Pérez, FJ; Rivera, J | 1 |
| Capodanno, D; Capranzano, P; Di Salvo, ME; Francaviglia, B; Galassi, AR; Mirabella, F; Tamburino, C; Ussia, GP | 1 |
| Caraccciolo, EA; Chrissoheris, M; Ionescu, CN | 1 |
| Goto, S; Serebruany, V | 1 |
| Braun, S; Hadamitzky, M; Kastrati, A; Morath, T; Schömig, A; Sibbing, D; Stegherr, J; Vogt, W; von Beckerath, N | 1 |
| Spinler, SA | 1 |
| Ebina, T; Hashiba, K; Hibi, K; Kimura, K; Kiyokuni, M; Komura, N; Kosuge, M; Morita, S; Nakayama, N; Umemura, S | 1 |
| Morton, J; Nelluri, S | 1 |
| Dai, X; Jauhar, R; Makaryus, AN; Makaryus, JN | 1 |
| Hartenthaler, B; Hofmann, R; Hönig, S; Kammler, J; Kerschner, K; Kypta, A; Lambert, T; Leisch, F; Steinwender, C | 1 |
| Butt, M; Lip, GY; Shantsila, E; Siddique, A | 1 |
| Gama, V; Guerra, M; Mota, JC; Veloso, M; Vouga, L | 1 |
| Bruskina, O; Byrne, RA; Dirschinger, J; Iijima, R; Kastrati, A; Laugwitz, KL; Massberg, S; Mehilli, J; Pache, J; Schömig, A; Schulz, S; Seyfarth, M | 1 |
| Diodati, JG; Lordkipanidzé, M; Pharand, C | 1 |
| Gurbel, PA; Kereiakes, DJ | 1 |
| Cheong, SS; Hong, MK; Kim, JJ; Kim, YH; Lee, CW; Lee, SW; Park, DW; Park, SJ; Park, SW; Yun, SC | 1 |
| Abizaid, A; Bonan, R; Costa, JR; Costa, R; Feres, F; Mattos, LA; Siqueira, D; Sousa, AG; Sousa, JE; Staico, R; Tanajura, LF | 1 |
| Kleiman, NS | 1 |
| Aleil, B; Cazenave, JP; Collet, JP; De Poli, F; Dickele, MC; Gachet, C; Jacquemin, L; Monassier, JP; Montalescot, G; Zaehringer, M | 1 |
| Armstrong, G; Dahl, ML; El-Jack, S; Farrell, H; Gladding, P; Gunes, A; Kay, P; Ormiston, J; Ruygrok, P; Scott, D; Stewart, J; Webster, M; Zeng, I | 1 |
| Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G | 1 |
| Alessi, MC; Bali, L; Bonnet, JL; Cuisset, T; Frere, C; Lambert, M; Morange, PE; Moro, PJ; Mouret, JP; Quilici, J | 1 |
| Margolis, JR | 1 |
| Chen, X; Gao, R; Han, Y; Jiang, T; Jing, Q; Li, H; Li, Y; Li, Z; Liu, H; Liu, Y; Qiu, J; Shang, X; Xu, B; Yang, L; Zhang, H | 1 |
| Albiero, R; Bertoldo, F; Chiariello, L; Del Giudice, C; Gandini, R; Giacomin, A; Pellegrino, A; Reimers, B; Saccà, S; Schofer, J; Simonetti, G; Versaci, F | 1 |
| Abizaid, A; Bonan, R; Costa, JR; Costa, R; Feres, F; Maldonado, G; Siqueira, D; Sousa, AG; Sousa, JE; Staico, R; Tanajura, LF | 1 |
| Gawaz, M; Geisler, T | 2 |
| Asanin, M; Lasica, R; Marinkovic, J; Mrdovic, I; Ostojic, M; Perunicic, J; Savic, L; Vasiljevic, Z | 1 |
| Kao, J; Kumar, A | 1 |
| Angiolillo, DJ; Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Furgieri, A; Hamon, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Valgimigli, M; Vranckx, P | 1 |
| Bilkova, D; Hajkova, J; Kala, P; Kvasnicka, J; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P | 1 |
| Hjemdahl, P; Jørgensen, L; Malmström, RE; Ostergren, J | 1 |
| Bhatt, DL; Dastros-Pitei, D; Flather, M; Kogushi, M; Serebruany, VL | 1 |
| Chang, CW; Choi, D; Jang, Y; Kim, JS; Ko, YG; Lee, JE; Lee, JM; Park, S; Shim, CY; Shin, DJ; Shin, ES | 1 |
| Ben-Dor, I; Kleiman, NS; Lev, E | 1 |
| Branicka, A; Stepień, E; Tracz, W; Undas, A; Wołkow, P; Zmudka, K | 1 |
| Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Li, YG; Ni, L; Payne, CD; Rohatagi, S; Small, DS; Winters, KJ | 1 |
| Cuellas, C; de Miguel, A; Diego, A; Fernandez-Vazquez, F; Perez de Prado, A | 1 |
| Han, K; Jeon, HK; Kim, H; Lee, HK | 1 |
| Kerchner, K; Sangüeza, OP; Walsh, SN | 1 |
| Diodati, JG; Lordkipanidzé, M; Nguyen, TA; Palisaitis, DA; Pharand, C; Schampaert, E; Turgeon, J | 1 |
| Doganov, A; Formuszewicz, R; Gil, RJ; Rusicka-Piekarz, T; Vassilev, D | 1 |
| Bliden, KP; Damcott, CM; Faraday, N; Gandhi, A; Gibson, Q; Gurbel, PA; Herzog, W; Horenstein, RB; Mitchell, BD; O'Connell, JR; Pakyz, R; Parsa, A; Pollin, TI; Post, W; Ryan, K; Shuldiner, AR; Tantry, US | 1 |
| Alberts, P; Bounameaux, H; Fontana, P; Mann, J; Sakariassen, KS; Sorensen, AS | 1 |
| Bongard, V; Boudou, N; Carrié, D; Dumonteil, N; Ghenim, R; Léobon, B; Marcheix, B; Roncalli, J; Tidjane, AM; Ziani, A | 1 |
| Heldman, AW; Hennebry, TA; Latif, F | 1 |
| Cahoon, WD; Ensor, CR | 1 |
| Almaroof, B; Castillo-Sang, M; Cireddu, J; Engoren, M; Kasper, G; Sferra, J; Tsang, AW; Zelenock, GB | 1 |
| Bagur, R; Bertrand, OF; Costerousse, O; Larochellière, RD; Larose, E; Nguyen, CM; Noel, B; Poirier, P; Rinfret, S; Rodés-Cabau, J; Roy, L | 1 |
| Gawaz, M; Geisler, T; Lutilsky, N; Schwab, M; Winter, S; Zuern, CS | 1 |
| Motovska, Z; Widimsky, P | 1 |
| Bigalke, B; Gawaz, M; Geisler, T; Herdeg, C; Kilias, A; Kraibooj, H; May, AE; Rapin, M; Schwab, M; Simonenko, R; Stellos, K; Zürn, C | 1 |
| Antonino, MJ; Bliden, KP; Conley, PB; Gretler, DD; Gurbel, PA; Jurek, MM; Pakyz, RE; Shuldiner, AR; Stephens, G; Tantry, US | 1 |
| Bagur, R; Bertrand, OF; Costerousse, O; De Larochellière, R; Gleeton, O; Larose, E; Proulx, G; Rinfret, S; Rodés-Cabau, J; Roy, L | 1 |
| Kuliczkowski, W | 1 |
| Berg, JT; Dewilde, W | 1 |
| Atar, D; Donovan, JL; Goto, S; Kannan, AO; Makarov, L; Rao, SV; Serebruany, V; Silva, MA | 1 |
| Chapman, N; Schachter, M | 1 |
| Bigalke, B; Gawaz, M; Henkelmann, N; Stakos, D; Stellos, K | 1 |
| Menon, V; Raymond, C | 1 |
| Armero, S; Arques, S; Bonello, C; Bonello, L; Bonello-Palot, N; Camoin-Jau, L; Dignat-George, F; Mokhtar, OA; Paganelli, F | 1 |
| Abbate, R; Antoniucci, D; Buonamici, P; Carrabba, N; Cerisano, G; Gensini, GF; Giuliani, G; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R | 1 |
| Antonino, MJ; Bliden, KP; Butler, K; Gesheff, T; Gurbel, PA; Karunakaran, A; Kereiakes, DJ; Ledley, GS; Parris, C; Patil, SB; Purdy, D; Storey, RF; Tantry, US; Teng, R; Wei, C; Wilson, V | 1 |
| Armero, S; Barragan, P; Bonello, C; Bonello, L; Bonello-Palot, N; Camoin-Jau, L; De Labriolle, A; Dignat-George, F; Lévy, N; Maillard, L; Mancini, J; Paganelli, F | 1 |
| Bode, C; Diehl, P; Halscheid, C; Helbing, T; Moser, M; Olivier, C | 1 |
| Christ, G; Delle-Karth, G; Huber, K; Jilma, B; Lang, IM; Siller-Matula, JM | 1 |
| Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Schulz, S; Sibbing, D; Stegherr, J; von Beckerath, N | 1 |
| Gilchrist, IC | 1 |
| Atar, D; Booze, C; Cherala, G; Kuliczkowski, W; Serebruany, V; Surigin, S; Williams, C | 1 |
| Dedaj, R; Levy, W | 1 |
| Chae, IH; Chang, HJ; Cho, SI; Cho, YS; Choi, DJ; Choi, YJ; Chung, WY; Gwon, HC; Han, KR; Kwon, DA; Shin, DH; Suh, JW; Youn, TJ | 1 |
| Bhatt, G; Reddy, HK; Sharma, R; Sharma, RK; Singh, VN; Voelker, DJ | 1 |
| Bouman, HJ; de Maat, MP; Hackeng, CM; Kruit, A; Leebeek, FW; Rudez, G; Ruven, HJ; ten Berg, JM; van Werkum, JW | 1 |
| Bouman, HJ; Breet, NJ; Hackeng, CM; Parlak, E; Taubert, D; ten Berg, JM; ten Cate, H; van Werkum, JW | 1 |
| Braun, S; Gebhard, D; Kastrati, A; Koch, W; Morath, T; Schömig, A; Schuster, T; Sibbing, D; Stegherr, J; von Beckerath, N | 1 |
| Fukushima, K; Iwata, Y; Kitahara, H; Kobayashi, Y; Komuro, I; Kuroda, N; Kuwabara, Y; Nomura, F; Ooyama, M | 1 |
| Resnic, FS; Sparling, JM | 1 |
| Akhter, M; Baber, U; Kini, A; Kothari, S; Sharma, SK | 1 |
| Luo, N; Nie, R; Wang, J | 1 |
| Barbato, E; Bartunek, J; De Bruyne, B; Di Sciascio, G; Heyndrickx, G; Mangiacapra, F; Muller, O; Ntalianis, A; Trana, C; Wijns, W | 1 |
| Abbate, R; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Sofi, F | 2 |
| Bolliger, D; Levy, JH; Rumph, B; Szlam, F; Tanaka, KA | 1 |
| Breet, N; Dewilde, W; Ten Berg, J | 2 |
| Di Sciascio, G; Irini, D; Pasceri, V; Patti, G; Pelliccia, F; Pristipino, C; Roncella, A; Speciale, G; Varveri, A | 1 |
| Braun, S; Kastrati, A; Mehilli, J; Morath, T; Sarafoff, N; Schömig, A; Schulz, S; Sibbing, D; Stegherr, J; von Beckerath, N | 1 |
| Abe, M; Doi, O; Hayashi, Y; Hiasa, Y; Hinohara, T; Kato, K; Kimura, T; Mitsudo, K; Morimoto, T; Morino, Y; Muramatsu, T; Noguchi, Y; Ochiai, M; Shibata, Y; Yamashita, T | 1 |
| Ebina, T; Hashiba, K; Hibi, K; Iwahashi, N; Kimura, K; Kosuge, M; Maejima, N; Morita, S; Nakachi, T; Ohtsuka, F; Okuda, J; Sugano, T; Tahara, Y; Tsukahara, K; Umemura, S | 1 |
| Bal, ET; Bouman, HJ; Breet, NJ; Deneer, VH; Hackeng, CM; Harmsze, AM; Kelder, JC; Rensing, BJ; Ruven, HJ; Suttorp, MJ; ten Berg, JM; van der Heyden, JA; van Werkum, JW | 1 |
| Antonino, MJ; Bliden, KP; Butler, K; Eikelboom, JW; Gurbel, PA; Henderson, D; Husted, S; Kereiakes, DJ; Nielsen, T; Patel, DV; Rasmussen, L; Sabe-Affaki, G; Storey, RF; Tantry, US; Teng, R; Wei, C | 1 |
| Lip, GY; Shantsila, E; Tapp, L | 1 |
| Gao, P; Gao, R; Hu, SS; Li, L; Xiong, H; Zheng, Z | 1 |
| Gao, F; Jia, de A; Liu, XL; Nie, B; Shen, H; Wang, ZJ; Yan, ZX; Yang, SW; Yu, M; Zhou, YJ | 1 |
| Alfonso, F; Angiolillo, DJ; Bass, TA; Bernardo, E; Capodanno, D; Fernandez-Ortiz, A; Ferreiro, JL; Jimenez-Quevedo, P; Macaya, C; Sabaté, M; Ueno, M; Vivas, D | 1 |
| Dorsch, MP; Momary, KM | 1 |
| Tricoci, P; Vergara-Jimenez, J | 1 |
| Barbato, E; D'Ambrosio, A; Di Sciascio, G; Gatto, L; Mangiacapra, F; Patti, G; Ricottini, E; Vizzi, V; Wijns, W | 1 |
| Favaloro, EJ; Franchini, M; Lippi, G | 1 |
| Aylward, PE; Behan, MW; Chew, DP | 1 |
| Jakubowski, JA; Li, YG; Luo, J; Payne, CD; Small, DS; Tomlin, ME; Winters, KJ | 1 |
| Gajos, G; Piwowarska, W; Rostoff, P; Undas, A | 1 |
| Börgel, J; Endres, HG; Engelhardt, A; Krüger, JC; Lask, S; Mügge, A; Neubauer, H | 1 |
| Chew, DP; Prakash, R; Wong, YW | 1 |
| Adams, HP | 1 |
| Schill, DM | 1 |
| Angiolillo, DJ | 1 |
| Ben-Dor, I; Collins, SD; Delhaye, C; Gaglia, MA; Gonzalez, MA; Kaneshige, K; Kent, KM; Li, Y; Maluenda, G; Pichard, AD; Satler, LF; Scheinowitz, M; Suddath, WO; Syed, AI; Torguson, R; Wakabayashi, K; Waksman, R; Xue, Z | 1 |
| Billinger, M; Cook, S; Eshtehardi, P; Garachemani, A; Hess, OM; Meier, B; Togni, M; Wenaweser, P; Windecker, S | 1 |
| Dardas, P; Mezilis, N; Ninios, V; Tsikaderis, D | 1 |
| Buckland, RJ; Jakubowski, JA; Judge, HM; Patil, SB; Storey, RF | 1 |
| Antypa, E; Bolos, K; Megaloikonomos, P; Moutiris, JA; Nikas, D; Palatianos, G; Polydorou, A; Polydorou, AD; Polydorou, V; Testembasi, E; Tziakouri, CH | 1 |
| Fukushima, K; Iwata, Y; Kitahara, H; Kobayashi, Y; Komuro, I; Kuroda, N; Nomura, F; Ooyama, M | 1 |
| Ahn, YJ; Hwang, JY; Hwang, SJ; Jeong, YH; Kang, MK; Kim, IS; Koh, JS; Kwak, CH; Park, Y | 1 |
| Aichele, S; Bigalke, B; Fateh-Moghadam, S; Gawaz, M; Geisler, T; Htun, P; May, AE; Mueller, K; Ninci, E; Stellos, K | 1 |
| Alhan, C; Karabulut, H; Senay, S; Toraman, F | 1 |
| Chan, WL; Chen, JW; Chen, TJ; Chen, YC; Huang, CC; Leu, HB; Lin, SJ | 1 |
| Bauersachs, J; Flierl, U; Micka, J; Pförtsch, S; Schäfer, A; Seydelmann, N | 1 |
| Bhatt, DL; Gibson, CM; Gretler, DD; Harrington, RA; Huber, K; Kochman, J; Leonardi, S; Madan, M; McClure, MW; Paynter, GE; Rao, SV; Roe, MT; Thompson, V; Welsh, RC; Zeymer, U | 1 |
| Munzel, T; Nick, E; Ostad, MA; Paixao-Gatinho, V; Schiewe, R; Schnorbus, B; Tschentscher, P; Warnholtz, A | 1 |
| Angiolillo, DJ; Vivas, D | 1 |
| Gratsianskiĭ, NA | 1 |
| Abrecht, L; Eshtehardi, P; Haeberli, A; Hess, OM; Meier, B; Schmidlin, K; Wenaweser, P; Windecker, S; Zwahlen, M | 1 |
| Caglayan, E; Er, F; Erdmann, E; Gassanov, N; Nia, AM | 1 |
| Arméro, S; Arques, S; Bonello, L; Burignat-Bonello, C; Camoin Jau, L; Dignat-George, F; Mancini, J; Omar Aït Mokhtar, O; Paganelli, F; Tahirou, I | 1 |
| Stankovic, G; Zivkovic, M | 1 |
| Aichele, S; Bigalke, B; Fateh-Moghadam, S; Flather, M; Gawaz, M; Geisler, T; Herkommer, M; Htun, P; May, AE; Müller, K; Stellos, K | 1 |
| Alfonso, F; Baz, JA; Brugaletta, S; Capote, ML; Cárdenas, M; Casanova, J; Cascant, P; De La Torre, JM; Ferreira-González, I; García-Del Blanco, B; García-Dorado, D; González-Béjar, O; Iñiguez, A; Marsal, JR; Martí, G; Martín-Yuste, V; Permanyer-Miralda, G; Pujol, B; Ribera, A; Ruíz-Lera, M; Sabaté, M; Sánchez-Gila, J; Sanmiguel, D; Trillo, R | 1 |
| Nathisuwan, S; Panomvana, D; Sansanayudh, N; Siriswangvat, S | 1 |
| Ben-Dor, I; Collins, SD; Gaglia, MA; Kaneshige, K; Kent, KM; Lemesle, G; Li, Y; Maluenda, G; Pichard, AD; Satler, LF; Suddath, WO; Syed, AI; Torguson, R; Waksman, R; Xue, Z | 1 |
| Aradi, D; Horváth, IG; Komócsi, A; Magyarlaki, T; Rideg, O; Serebruany, VL; Tokés-Füzesi, M; Vorobcsuk, A | 1 |
| Angiolillo, DJ; Becker, R; Bhatt, DL; Blindt, R; Bonello, L; Cattaneo, M; Collet, JP; Cuisset, T; Gachet, C; Gurbel, PA; Jennings, LK; Kereiakes, D; Marcucci, R; Montalescot, G; Paganelli, F; Price, MJ; Sibbing, D; Tantry, US; Trenk, D; Van Werkum, JW; Waksman, R | 1 |
| Jin, B; Li, J; Li, Y; Ni, HC; Shen, W; Shi, HM | 1 |
| Bauersachs, J; Flierl, U; Kobsar, AL; Koessler, J; Pfoertsch, S; Rajkovic, MS; Rechner, AR; Schafer, A; Steigerwald, U; Walter, U | 1 |
| Freedman, JE; Iafrati, HF | 1 |
| Behnia, M; Brieger, D; Chang, M; Chung, T; Hamzah, A; Krilis, SA; Kritharides, L; Lowe, HC; Ng, MK; Pennings, GJ; Qi, M; Yong, AS | 1 |
| Goh, RY; Han, JY; Kim, BR; Kim, JE; Kim, MH; Woo, KS; Yu, LH | 1 |
| Bhatt, DL; Cannon, CP; Cohen, M; Contant, CF; Cryer, BL; Goldsmith, MA; Laine, L; Lanas, A; Lapuerta, P; Murphy, SA; Schnitzer, TJ; Scirica, BM; Shook, TL | 1 |
| Barriales, V; Fernández-Cimadevilla, OC; Lozano, I | 1 |
| Barker, CM; Kandzari, DE; Murray, SS; Price, MJ; Teirstein, PS; Topol, EJ | 1 |
| Gurbel, PA; Tantry, US | 2 |
| Kandulski, A; Malfertheiner, P; Venerito, M | 1 |
| Gao, G; Hu, S; Lu, B; Lu, J; Pi, Y; Zheng, Z | 1 |
| Southworth, MR; Temple, R | 1 |
| Hwang, JY; Hwang, SJ; Jeong, YH; Kang, MK; Kim, IS; Koh, JS; Kwak, CH; Park, Y | 1 |
| Armstrong, M; Bliden, KP; Butler, K; Gurbel, PA; Storey, RF; Tantry, US; Wei, C | 1 |
| Danikiewicz, A; Hudzik, B; Lekston, A; Polonski, L; Romanowski, W; Szkodzinski, J; Wilczek, K; Zubelewicz-Szkodzinska, B | 1 |
| Chello, M; Colonna, D; Colonna, G; Covino, E; Di Sciascio, G; Montinaro, A; Pasceri, V; Patti, G; Pepe, LL | 1 |
| Bauters, C; Delhaye, C; Fayad, G; Koussa, M; Lablanche, JM; Lemesle, G; Modine, T; Sudre, A; Vanesson, L | 1 |
| Delarochelliere, R; Kulik, A; Le May, MR; Mesana, TG; Naidoo, S; Ruel, M; Tardif, JC; Voisine, P; Wells, GA | 1 |
| Jilma, B; Siller-Matula, JM | 1 |
| Gao, F; Ge, HL; Liu, XL; Liu, YY; Shi, DM; Wang, ZJ; Yang, Q; Zhao, YX; Zhou, YJ | 1 |
| Escudero, D; Monreal, M; Muñoz-Torrero, JF; Pascual, MT; Sanclemente, C; Suárez, C; Trujillo-Santos, J; Zamorano, J | 1 |
| Ando, H; Asai, T; Fujimura, A; Hosohata, K; Ishiguro, H; Kobayashi, T; Maeda, A; Morishima, M; Ohta, M; Sumida, A; Umemoto, N; Ushijima, K | 1 |
| Abu-Fara, M; Awidi, A; Bener, A; Dweik, M; Kailani, B; Nabulsi, R; Saleh, A | 1 |
| Ebina, T; Endo, M; Hibi, K; Ishikawa, T; Iwahashi, N; Kimura, K; Kosuge, M; Maejima, N; Morita, S; Okada, K; Umemura, S | 1 |
| Akazawa, Y; Hirata, A; Kashiwase, K; Kashiyama, T; Kodama, K; Masumura, Y; Matsuo, K; Muller, JE; Nemoto, T; Nishio, M; Ueda, Y; Wada, M | 1 |
| Abbate, R; Antonucci, E; Gori, AM; Maggini, N; Marcucci, R; Miranda, M; Paniccia, R; Prisco, D; Romano, E | 1 |
| Alissa, R; Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M | 1 |
| Caixeta, A; Gordon, P; Hermiller, JB; Jonnavithula, L; Lansky, AJ; Miquel-Hebert, K; Onuma, Y; Ruygrok, P; Serruys, PW; Sood, P; Stone, GW; Su, X; Sudhir, K; Veldhof, S; Yaqub, M | 1 |
| Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B | 1 |
| Bonatti, J; Zimrin, D | 1 |
| Baker, BA; Effron, MB; Jakubowski, JA; Kulkarni, MP; Li, YG; Luo, J; Miller, DL; Small, DS; Winters, KJ; Zhu, B | 1 |
| Banya, W; Bigalke, B; Bischofs, C; Fateh-Moghadam, S; Flather, M; Gawaz, M; Geisler, T; Htun, P; May, AE; Müller, K; Stellos, K | 1 |
| Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N | 1 |
| Barbato, E; Bartunek, J; Cuisset, T; De Bruyne, B; Dierickx, K; Hamilos, M; Mangiacapra, F; Meeus, P; Muller, O; Ntalianis, A; Sarno, G; Trana, C; Wijns, W | 1 |
| Chen, H; Wu, XY; Yan, W | 1 |
| Juurlink, DN | 1 |
| Ford, AC; Sadek, A | 1 |
| Capodanno, D; Cicorella, N; Gavazzi, A; Guagliumi, G; Lettieri, C; Lortkipanidze, N; Musumeci, G; Nijaradze, T; Romano, M; Rosiello, R; Rossini, R; Sirbu, V; Tarantini, G; Valsecchi, O | 1 |
| Bobrov, VS; Demakova, NL; Faĭl', IL; Gubenko, AV; Loenko, VB; Sorokina, EA | 1 |
| White, HD | 1 |
| Bliden, KP; Gurbel, PA; Pakyz, RE; Ryan, K; Shuldiner, AR; Tantry, US | 1 |
| Bernlochner, I; Kastrati, A; Mehilli, J; Morath, T; Neumann, L; Sarafoff, N; Schömig, A; Sibbing, D | 1 |
| Bang, DW; Cho, YH; Choi, SW; Choi, YJ; Hyon, MS; Kang, SJ; Kim, HS; Kim, MK; Kim, YH; Lee, BK; Lee, CW; Lee, JH; Lee, K; Lee, NH; Lee, SG; Lee, SJ; Lee, SW; Park, CB; Park, DW; Park, HK; Park, KH; Park, SJ; Park, SW; Park, WJ; Seong, IW; Shin, WY; Yun, SC | 1 |
| Chai, H; Chen, M; Huang, DJ; Li, Q; Liu, XJ; Peng, Y; Wei, JF; Wu, WC; Xu, YN; Yan, SD | 1 |
| Cattaneo, M; Chassot, PG; Eichinger, S; Hofmann, N; Huber, K; Korte, W; Rickli, H; Spannagl, M; Verheugt, F; von Heymann, C; Ziegler, B | 1 |
| Arima, M; Matsuda, A; Nitta, M; Shimizu, M; Yoshida, K | 1 |
| Freynhofer, MK; Huber, K; Schrör, K; Siller-Matula, J; Yukhanyan, L | 1 |
| Ahn, SG; Kim, JY; Lee, SH; Sung, JK; Yoon, J | 1 |
| Farhan, S; Huber, K; Jarai, R; Siller-Matula, J; Tentzeris, I; Wojta, J | 1 |
| Burstein, S; Perez, E; Yang, EH; Zhiroff, KA | 1 |
| Crimizade, U; El Adraa, E; El Ghannudi, S; Gachet, C; Jesel, L; Morel, O; Ohlmann, P; Radulescu, B; Wiesel, ML | 1 |
| Alexopoulos, D; Damelou, A; Davlouros, P; Karantalis, V; Mitropoulou, G; Xanthopoulou, I | 1 |
| Egred, M | 1 |
| French, JK; Juergens, CP; Parikh, D; Rajendran, S; Shugman, I | 1 |
| Bonello, L; Camilleri, E; Jacquin, L; Paganelli, F | 1 |
| Gajos, G; Nessler, J; Piwowarska, W; Rostoff, P; Undas, A; Zalewski, J | 1 |
| Angiolillo, DJ; Tello-Montoliu, A; Ueno, M | 1 |
| Bergmeijer, TO; Bouman, HJ; Breet, NJ; Deneer, VH; Hackeng, CM; Harmsze, AM; Ten Berg, JM; Ten Cate, H; van Werkum, JW | 1 |
| Brugada, R; Elosua, R; Lluis-Ganella, C; Lucas, G; Marrugat, J; Masiá, R; Sala, J; Subirana, I; Tomás, M; Zabalza, M | 1 |
| El-Omar, M; Imola, F; Mamas, MA; Manzoli, A; Pappalardo, A; Prati, F; Ramazzotti, V | 1 |
| Cook, S; Garachemani, A; Jüni, P; Khattab, AA; Limacher, A; Löffel, L; Meier, B; Moschovitis, A; Pilgrim, T; Räber, L; Seiler, C; Stauffer, JC; Togni, M; Vogel, R; Wenaweser, P; Windecker, S | 1 |
| Airaksinen, KE; Biancari, F; Lip, GY | 1 |
| Cosentino, N; Crea, F; Minelli, S; Niccoli, G | 1 |
| Bliden, KP; Butler, K; Ecob, R; Gurbel, PA; Karunakaran, A; Storey, RF; Tantry, U; Wei, C | 1 |
| Flaherty, MP; Johnston, PV; Rade, JJ | 1 |
| Alfieri, A; Bellone, P; Berti, S; Cassese, S; De Luca, G; Marraccini, P; Montinaro, A; Piscione, F; Quaranta, G; Villari, B | 1 |
| Bliden, KP; Gesheff, M; Gurbel, PA; Jeong, YH; Storey, RF; Tantry, US; Wei, C | 1 |
| Banerjee, A; Bhala, N; Rajasekhar, P; Taggar, JS | 1 |
| Calver, A; Corbett, S; Curzen, N; Dent, H; Englyst, N; Gray, H; Leadbeater, P; Morgan, J; Roderick, P; Sambu, N; Simpson, I; Warner, TD | 1 |
| Fritsma, GA; McGlasson, DL; Shah, AD | 1 |
| Bonello, L; de Labriolle, A; Doazan, JP; Lemesle, G | 1 |
| Biocina, B; Gasparovic, H; Petricevic, M | 1 |
| Bisdas, T; Haverich, A; Teebken, OE | 1 |
| Höchtl, T; Huber, K; Schrör, K; Tentzeris, I | 1 |
| Alexopoulos, D; Athanassiadou, A; Davlouros, P; Kassimis, G; Stavrou, EF; Xanthopoulou, I | 1 |
| Arai, T; Fukuda, K; Ikeda, Y; Kawamura, A; Matsubara, Y; Murata, M; Yokoyama, K | 1 |
| Angiolillo, DJ; Bass, TA; Capodanno, D; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M | 1 |
| Barone-Rochette, G; Danchin, N; Foote, A; Machecourt, J; Motreff, P; Quesada, JL; Vanzetto, G | 1 |
| Abe, T; Deguchi, M; Hokimoto, S; Horio, E; Iwashita, S; Kaikita, K; Miyazaki, Y; Nakagawa, K; Nakamura, S; Ogawa, H; Ono, T; Sato, K; Sugiyama, S; Sumida, H; Tayama, S; Tsujita, K; Yamabe, H; Yamamoto, K | 1 |
| Antonino, MJ; Bliden, KP; Cummings, CC; Dubois, BV; Gesheff, T; Gurbel, PA; Herzog, WR; Tantry, US | 1 |
| Kafian, S; Kalani, M; Mobarrez, F; Samad, BA; Wallén, H | 1 |
| Avdeeva, LV; Mosina, VA; Shtegman, OA | 1 |
| Bernlochner, I; Contant, CF; Guo, J; Hochholzer, W; Kastrati, A; Mega, JL; Morath, T; Neumann, FJ; O'Donoghue, ML; Sabatine, MS; Schömig, A; Sibbing, D; Stratz, C; Trenk, D; Valina, CM; Wiviott, SD | 1 |
| Alfonso, F; Fernandez-Ortiz, A; Zakhem, B | 1 |
| Angiolillo, DJ; Bass, TA; Capodanno, D; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Pham, JP; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M | 1 |
| Borsiczky, B; Gaszner, B; Konyi, A; Sarszegi, Z; Szabados, S | 1 |
| Banerjee, S; Hall, HM; McGuire, DK | 1 |
| Babin, J; Bonnefoy, A; Bryckaert, M; Labarthe, B; Théroux, P | 1 |
| Alexopoulos, D; Davlouros, P; Hahalis, G; Mavronasiou, E; Panagiotou, A; Plakomyti, TE; Xanthopoulou, I | 1 |
| Bonaventura, K; Kleber, FX; Sonntag, S | 1 |
| Allanic, F; Barthélémy, O; Beygui, F; Cayla, G; Collet, JP; de la Briolle, A; Gruel, Y; Huerre, Y; Hulot, JS; Montalescot, G; O'Connor, SA; Pathak, A; Scott, SA; Silvain, J; Vignalou, JB | 1 |
| Bastos, G; Bravo, M; Brion, M; Carracedo, A; Cerda, A; Hirata, MH; Hirata, RD; Iñiguez, A; Luchessi, AD; Silbiger, VN; Sousa, AG | 1 |
| Eskind, L; Gulati, S; Montegudo, A; Narang, T; Pierson, J; Russo, MW | 1 |
| Antonijevic, N; Asanin, M; Kocev, N; Krljanac, G; Lasica, R; Marinkovic, J; Mrdovic, I; Ostojic, M; Perunicic, J; Savic, L; Vasiljevic, Z | 1 |
| Angiolillo, DJ; Capodanno, D; Gavazzi, A; Guagliumi, G; Lettieri, C; Musumeci, G; Romano, M; Rosiello, R; Rossini, R; Valsecchi, O | 1 |
| Hu, B; Luo, Y; Qi, WG; Verdo, A; Zhang, DF; Zhao, YT | 1 |
| Jung, KH; Kim, W; Kim, WS; Lee, SR; Lee, TW; Lew, JH; Lim, CK; Woo, JS | 1 |
| Malenka, DJ; Morden, NE; Roth, GA; Skinner, J; Zhou, W | 1 |
| Fischerova, M; Maly, M; Morawska, P; Motovska, Z; Odvodyova, D; Stepankova, S; Widimsky, P | 1 |
| Ikeda, Y; Isshiki, T; Kimura, T; Ogawa, H; Yokoi, H | 1 |
| Barbosa, SP; Bianco, HT; Brunialti, MK; de Nucci, G; Fonseca, FA; França, CN; Izar, MC; Kasmas, SH; Pinheiro, LF; Salomão, R | 1 |
| Aihara, H; Akiyama, D; Aonuma, K; Hoshi, T; Kakefuda, Y; Nishina, H; Sato, A; Takeyasu, N; Watabe, H | 1 |
| Delle-Karth, G; Grzybowski, T; Huber, K; Jilma, B; Kozinski, M; Kubica, J; Lang, IM; Linkowska, K; Maurer, G; Neunteufl, T; Siller-Matula, JM | 1 |
| Ho, PM; Magid, D; Powers, D; Raebel, MA; Shetterly, S; Tsai, TT; Xu, S | 1 |
| Bruno, V; Freynhofer, MK; Huber, K; Hübl, W; Willheim, M; Wojta, J | 1 |
| Mutnick, JL | 1 |
| Baccouche, H; Bandi, A; Chaari, M; Elalamy, I; Galea, V; Gerotziafas, GT; Mossialos, L; Sassi, M; Tsinopoulos, G; Zarifis, J | 1 |
| Baker, BA; Bernlochner, I; Brown, PB; Gupta, N; Jakubowski, JA; Kastrati, A; Morath, T; Schömig, A; Sibbing, D; Winters, KJ; Zhou, C | 1 |
| Carbonell-Porras, A; Fernández-Ruiz, M; García-Reyne, A; López-Medrano, F | 1 |
| Ahrens, I; Bode, C; Brandt, C; Duerschmied, D; Mauler, M; Moser, M; Weidner, S | 1 |
| Angiolillo, DJ; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Rollini, F; Tello-Montoliu, A; Ueno, M | 1 |
| Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M | 1 |
| Airaksinen, KE; Biancari, F; Karjalainen, P; Kiviniemi, T; Niemelä, M; Pietilä, M; Puurunen, M; Vikman, S; Ylitalo, A | 1 |
| Horiuchi, H; Ikeda, T; Imai, M; Jinnai, T; Kato, Y; Kimura, T; Makiyama, T; Shirakawa, R; Tada, T; Tazaki, J; Yamane, K | 1 |
| Jia, KY; Peng, JJ; Ren, LH; Xu, XL; Ye, HM | 1 |
| Ahn, JH; Bliden, KP; Gho, EH; Gurbel, PA; Hwang, JY; Hwang, SJ; Jeong, YH; Kim, S; Kwak, CH; Kwon, TJ; Park, JR; Park, Y; Tantry, US | 1 |
| Bliden, K; Butler, K; Gurbel, PA; Husted, SE; Høimark, L; Storey, RF; Tantry, US; Teng, R; Wei, C | 1 |
| Angiolillo, DJ; Gawaz, M; Jakubowski, JA; Kastrati, A; Müller, U; Neumann, FJ; Richardt, G; Stone, GW; Trenk, D | 1 |
| Cao, J; Fan, L; Gao, Y; Liu, X; Lu, X; Ma, C | 1 |
| Huang, B; Huang, H; Huang, Y; Jing, X; Li, J; Li, Y; Yao, H | 1 |
| He, J; He, Y; Liu, G; Ma, C; Tang, P; Wang, P; Yang, J; Zhou, R; Zhou, S | 1 |
| Cho, KI; Jang, JS; Je, HG; Jeong, YH; Jin, HY; Kim, BH; Kim, DI; Kim, DK; Kim, DS; Lee, SW; Park, YH; Seo, JS; Seol, SH; Yang, TH | 1 |
| Baber, U; Chirumamilla, AP; Dangas, GD; Fahy, M; Guo, N; Hakim, D; Hassanin, A; Kanwal, S; Kovacic, JC; Maehara, A; Mehran, R; Mintz, GS; Moses, JW; Pyo, R; Weisz, G | 1 |
| Bhatt, DL; Dietrich, M; Gallup, D; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Liu, T; Mahaffey, KW; Price, MJ; Skerjanec, S; Steg, GW; Stone, GW; Todd, M; White, HD | 1 |
| Hulot, JS; Montalescot, G | 1 |
| Cao, J; Fan, L; Gao, Y; Liu, XF; Lu, XC; Ma, C | 1 |
| Abe, M; Araki, M; Byrne, RA; Ehara, N; Eizawa, H; Fujiwara, H; Furukawa, Y; Inada, T; Iwabuchi, M; Kaburagi, S; Kadota, K; Kastrati, A; Kimura, T; Kita, T; Mitsudo, K; Mitsuoka, H; Mizoguchi, T; Morimoto, T; Nakagawa, Y; Nakano, A; Natsuaki, M; Nobuyoshi, M; Nohara, R; Shiomi, H; Shizuta, S; Suwa, S; Tada, T; Takizawa, A; Taniguchi, R; Tazaki, J | 1 |
| Gajos, G; Nessler, J; Piwowarska, W; Undas, A; Zalewski, J; Zmudka, K | 1 |
| Huczek, Z | 1 |
| Chan, MY; Cornel, JH; Erlinge, D; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Ohman, EM; Roe, MT; Shah, S; Tantry, US | 1 |
| Bauersachs, J; Flierl, U; Fraccarollo, D; Lausenmeyer, E; Massberg, S; Rosenstock, T; Schäfer, A; Schulz, C | 1 |
| Gupta, A; Hirst, J; McKay, RG; Rai, M; Ruaño, G; Seip, RL; Thompson, PD | 1 |
| Chen, H; Dai, ZL; Wu, XY | 1 |
| Kar, R; Kar, SS; Meena, A; Saxena, R; Yadav, BK; Yadav, R | 1 |
| Angiolillo, DJ; Ferreiro, JL | 1 |
| Baber, U; Karajgikar, R; Kini, AS; Kovacic, JC; Lee, P; Moreno, PR; Narechania, B; Sharma, SK; Suleman, J | 1 |
| Barn, K; Steinhubl, SR | 1 |
| Eikelboom, JW; Hirsh, J; Johnston, M; Li, C; Liang, Y; Mehta, S; Pare, G; Sloane, D; Teo, KK; Yi, Q; Zhu, J | 1 |
| Angiolillo, DJ; Rollini, F; Tello-Montoliu, A | 2 |
| Devlin, G; Hyde, L; Liang, M; Liew, TV; Puri, A | 1 |
| Dong, L; Feng, Y; Hu, XY; Jiang, J; Liu, XB; Sun, Y; Wang, JA; Xiang, MX | 1 |
| Aburadani, I; Inomata, J; Kinoshita, M; Kurokawa, K; Maruyama, M; Nagata, Y; Usuda, K | 1 |
| Huber, K | 1 |
| El Mallah, W; Moliterno, DJ | 1 |
| Brilakis, ES; Klein, AJ | 1 |
| Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G | 1 |
| Ji, H; Li, L; Lv, H; Shi, J; Wang, G; Wang, Y; Yuan, S | 1 |
| Gerdts, E; Lønnebakken, MT; Pedersen, OM | 1 |
| Witzenbichler, B | 1 |
| Alfonso, F; Batalla, N; Carrillo, X; Cascant, P; Cequier, A; de la Torre, JM; Ferreira-González, I; García-Del Blanco, B; García-Dorado, D; Gómez-Hospital, JA; Larrousse, E; Marsal, JR; Martí, G; Martín, E; Martín-Yuste, V; Masotti-Centol, M; Mauri, J; Permanyer-Miralda, G; Ribera, A; Ruiz-Salmerón, R; Rumoroso, JR; Sabatè, M; Serra, A | 1 |
| Benedetti, G; Biondi-Zoccai, G; Calcagno, S; Canali, E; Di Roma, A; Fedele, F; Guadagni, F; Lucisano, L; Mancone, M; Palmirotta, R; Pennacchi, M; Sardella, G; Stio, RE | 1 |
| Bednar, F; Benesova, L; Kocka, V; Minarik, M; Motovska, Z; Osmancik, P; Paulu, P; Tousek, P; Widimsky, P | 1 |
| Chen, X; Fang, R; Hu, J; Li, X; Su, J; Xu, J; Zhang, H | 1 |
| Bal dit Sollier, C; Dillinger, JG; Drissa, A; Drouet, L; Henry, P; Logeart, D; Manzo Silberman, S; Sideris, G; Voicu, S | 1 |
| Alexander, JH; Alexander, KP; Broderick, S; Granger, CB; Hess, CN; Lopes, RD; Mahaffey, KW; Newby, LK; Peterson, ED; Piccini, JP; Shaw, LK | 1 |
| Darwish, OS; Iqbal, E | 1 |
| Angiolillo, DJ; Bergmeijer, T; Brown, PB; Erlinge, D; Foley, D; Jakubowski, JA; James, S; Luo, J; Moser, B; Small, DS; Ten Berg, J; Wagner, H; Winters, KJ; Zhou, C | 1 |
| Anstrom, KJ; Brennan, JM; Califf, RM; Douglas, PS; Eisenstein, EL; Peterson, ED; Wojdyla, D | 1 |
| Bliden, KP; Chai, S; Figg, WD; Gibson, Q; Gurbel, PA; Horenstein, RB; Lewis, JP; Mitchell, BD; O'Connell, JR; Pacanowski, MA; Peer, CJ; Ryan, K; Shuldiner, AR; Spencer, SD; Tanner, K; Tantry, US | 1 |
| Angiolillo, DJ; Bass, TA; Capodanno, D; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Kodali, MK; Patel, R; Rollini, F; Tello-Montoliu, A; Tomasello, SD; Ueno, M | 1 |
| Kozan, Ö | 1 |
| Bennett, MR | 1 |
| Gao, RL; Han, YL; Jiang, TM; Jing, QM; Li, SM; Li, WM; Li, Y; Liu, HL; Qu, P; Xu, B; Yang, LX; Zhang, L; Zhang, QY | 1 |
| Lee, HL; Lee, KN; Lee, SP | 1 |
| Abizaid, A; Bhatt, DL; Botelho, RV; Castello, H; Costa, RA; de Paula, JE; Devito, FS; Feres, F; Gusmão, MO; King, SB; Leon, MB; Mangione, JA; Marin-Neto, JA; Nicolela, E; Perin, MA; Salvadori, D | 1 |
| Abbott, JD; Faxon, D; Holper, E; Kelsey, S; Khandhar, S; Kip, KE; Kutcher, M; Lee, JS; Marroquin, OC; Mulukutla, SR; Selzer, F; Smith, C; Toma, C; Vlachos, HA; Williams, DO | 1 |
| Ahn, JM; Kang, SJ; Kim, WJ; Kim, YH; Lee, CW; Lee, JY; Lee, SW; Park, DW; Park, SJ; Park, SW; Song, HG; Yun, SC | 1 |
| Fujimoto, Y; Iwata, Y; Kadohira, T; Kitahara, H; Kobayashi, Y; Morino, T; Ohkubo, K; Sugimoto, K | 1 |
| Albertal, M; Belardi, JA | 1 |
| Cao, Y; Huang, Y; Ji, Q; Lin, Y; Liu, L; Lu, Z; Luo, C; shi, Y; Wang, X; Zeng, Q | 1 |
| Ang, L; Ilapakurti, M; Lee, MS; Mahmud, E; Palakodeti, V; Thani, KB | 1 |
| Barthélémy, O; Bellemain-Appaix, A; Bernasconi, F; Beygui, F; Collet, JP; Cucherat, M; Jacq, L; Montalescot, G; O'Connor, SA; Silvain, J | 1 |
| Badr Eslam, R; Kaider, A; Lang, IM; Panzer, S | 1 |
| Choi, WG; Kim, HS; Kim, SY; Koo, BK; Kwan, J; Park, CG; Park, J; Park, JB | 1 |
| Chang, FY; Chen, TS; Hou, MC; Huang, CC; Huang, KW; Lee, FY; Leu, HB; Lin, HC; Lu, CL; Luo, JC | 1 |
| Chai, H; Chen, M; Huang, DJ; Li, Q; Liu, W; Liu, XJ; Luo, XL; Peng, Y; Ren, X; Wang, XQ; Zhang, C; Zhao, ZG | 1 |
| Cao, J; Cong, YL; Cui, H; Fan, L; Hu, GL; Hu, QQ; Leng, WX; Niu, H; Ren, JW | 1 |
| Feng, CH; Stevenson, DD; White, AA | 1 |
| Berg, R; Bolla, VH; Singh, M | 1 |
| Beitelshees, AL; Bliden, KP; Damcott, CM; Faraday, N; Gibson, Q; Gong, Y; Gurbel, PA; Herzog, W; Horenstein, RB; Johnson, JA; Lewis, JP; Mitchell, BD; O'Connell, JR; Pakzy, R; Parsa, A; Pepine, CJ; Pollin, TI; Post, WS; Ryan, K; Shuldiner, AR; Tanner, K; Tantry, US | 1 |
| Kübler, W | 1 |
| Jagroop, IA; Malley, M; Mikhailidis, DP | 1 |
| Bahrmann, P; Figulla, HR; Sigusch, HH; Surber, R | 1 |
| Adams, J; Bauersachs, R; Graff, J; Harder, S; Klinkhardt, U; Lindhoff-Last, E | 1 |
| Buettner, HJ; Hunziker, P; Marsch, S; Mueller, C; Neumann, FJ; Perruchoud, A; Roskamm, H | 1 |
| Hildebrandt, PR; Husted, SE; Kristensen, SD; Nielsen, HK; Rasmussen, LH; Ziegler, BK | 1 |
| Bliden, KP; Gurbel, PA; Hiatt, BL; O'Connor, CM | 1 |
| Rebrov, AP; Voskoboĭ, VI | 1 |
| Berger, PB; Brennan, D; Kereiakes, DJ; Saw, J; Serebruany, VL; Steinhubl, SR; Topol, EJ | 1 |
| Averkov, OV | 1 |
| Shalaev, SV | 1 |
| Helenius, I; Remes, V | 1 |
| Tendera, M; Wojakowski, W | 1 |
| Roffi, M; Topol, EJ | 1 |
| Chen, WH; Lau, CP; Lee, PY; Ng, W; Tse, HF | 1 |
| Cavuşoğlu, E | 1 |
| Santa-Cruz, RA; Steinhubl, SR | 1 |
| Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D | 1 |
| Ergun, MA; Erkan, A; Yalcin, R; Yurtcu, E | 1 |
| Gandhi, PJ; Kiyanista, VA; Vishnevetsky, D | 1 |
| Becker, RC; Ezekowitz, M; Guyatt, GH; Harrington, RA; Meade, TW; O'Connor, CM; Vorchheimer, DA | 1 |
| De Jonghe, B; Fangio, P; Lachérade, JC; Outin, H; Terville, JP | 1 |
| Diehm, C; Huber, R; Lawall, H | 1 |
| André-Fouët, X; Boschat, J; Finet, G; Gilard, M; Ginon, I; Rioufol, G | 1 |
| Füessl, HS | 1 |
| Anand, SS; Tran, H | 1 |
| Schulman, SP | 1 |
| Gawaz, M; Gorchakova, O; Joost, A; Kastrati, A; Mocz, A; Schömig, A; von Beckerath, N | 1 |
| Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bernardo, E; Escaned, J; Fernández-Ortiz, A; Hernández-Antolín, R; Macaya, C; Moreno, R; Ramírez, C; Sabaté, M | 1 |
| Berger, PP; Bollwein, H; Dibra, A; Dirschinger, J; Dotzer, F; Kastrati, A; Mehilli, J; Pache, J; Schömig, A; Schühlen, H; von Beckerath, N | 1 |
| Frogley, M; Kubler, PA; Marrinan, MC; Pillans, PI | 1 |
| Goldberg, SL | 1 |
| Cheneau, E; Corso, P; Haile, E; Kapetanakis, EI; Kent, KM; Kuchulakanti, P; Lew, R; Pakala, R; Pichard, AD; Rha, SW; Satler, LF; Suddath, WO; Waksman, R | 1 |
| Raja, SG | 1 |
| Neukirch-Stoop, C; Silberman, S; Steg, PG | 1 |
| Borja, J | 1 |
| Albers, GW; Bernstein, RA | 1 |
| Horváth, IG; Komócsi, A; Pintér, T | 1 |
| Judge, HM; Peters, G; Smith, SM; Storey, RF | 1 |
| Bavry, AA; Bhatt, DL; Helton, TJ; Kumbhani, DJ | 1 |
| Dubiel, JS; Dudek, D; Dziewierz, A; Heba, G; Mielecki, W; Rakowski, T | 1 |
| Ambrosini, V; Bolognese, L; Bongo, AS; Gaglione, A; Galassi, AR; Marzocchi, A; Petronio, AS; Savonitto, S; Tolaro, S | 1 |
| Salam, AM | 1 |
| Baumann, PQ; Schneider, DJ; Sobel, BE; Whitaker, DA | 1 |
| Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Cavallari, U; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Hernández, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Pignatti, PF; Ramírez, C; Sabaté, M; Trabetti, E | 1 |
| Blann, A | 1 |
| Aleil, B; Cazenave, JP; Gachet, C; Meyer, N; Mossard, JM | 1 |
| Almsherqi, ZA; Deng, Y; McLachan, C | 1 |
| Baggish, AL; Sabatine, MS | 1 |
| Dropinski, J; Jakiela, B; Musial, J; Sanak, M; Szczeklik, A; Wegrzyn, W | 1 |
| Aboujaoudé, S; Azar, RR; El-Osta, H; Germanos, M; Ghorra, P; Kassab, R; Salamé, E; Zoghbi, A | 1 |
| Ekman, M; James, S; Sjögren, I | 1 |
| Binkley, PF; Bray, PF; Cooke, GE; Ferketich, AK; Frid, DJ; Goldschmidt-Clermont, PJ; Liu-Stratton, Y; Magorien, RD; Moeschberger, ML | 1 |
| Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Hernández, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Ramírez, C; Sabaté, M | 1 |
| Goldhaber, SZ; Vallurupalli, NG | 1 |
| Hsu, A; Kelly, RV; Steinhubl, S; Topol, E | 1 |
| Gulba, DC; Klutmann, M; Tillmanns, C | 1 |
| Bauriedel, G; Lüderitz, B; Nickenig, G; Schneider-Schmitt, M; Skowasch, D; Viktor, A | 1 |
| Frundi, D; Hochholzer, W; Neumann, FJ; Trenk, D | 1 |
| Bliden, KP; Gurbel, PA; Lau, WC; Tantry, US | 1 |
| Hoffmann, R; Kaiser, A; Radke, PW; Schunkert, H; Weber, C; Zernecke, A | 1 |
| Brandt, JT; Darstein, C; Jakubowski, JA; Jernberg, T; Naganuma, H; Payne, CD; Siegbahn, A; Wallentin, L; Winters, KJ | 1 |
| Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Cavallari, U; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Hernández, R; Macaya, C; Moreno, R; Pignatti, PF; Ramírez, C; Sabaté, M; Trabetti, E | 1 |
| Baldus, S; Böger, R; Heitzer, T; Karstens, M; Meinertz, T; Ortak, M; Rudolph, V; Schwedhelm, E; Sydow, K; Tschentscher, P | 1 |
| Gadhvi, D; Lee-Wong, M; Resnick, D | 1 |
| Hollman, JL; Olivier, AC | 1 |
| Barnard, MR; Fox, ML; Frelinger, AL; Furman, MI; Li, Y; Linden, MD; Michelson, AD | 1 |
| Chen, WH | 1 |
| Andreassen, AK; Aukrust, P; Brosstad, F; Damås, JK; Frøland, SS; Gjertsen, E; Gullestad, L; Hansteen, V; Pedersen, TM; Semb, AG; Solum, NO; Ueland, T; Waehre, T; Yndestad, A | 1 |
| Granitskiĭ, NA | 1 |
| Fehér, G; Horváth, B; Késmárky, G; Koltai, K; Tóth, K | 1 |
| Kastrati, A; Schömig, A; Sibbing, D; von Beckerath, N; von Beckerath, O | 1 |
| Barnard, MR; Fox, ML; Frelinger, AL; Furman, MI; Lau, WC; Li, Y; Linden, MD; McLaughlin, TJ; Michelson, AD | 1 |
| Miao, F; Wang, XY | 1 |
| Bigalke, B; Gawaz, M; Geisler, T; Göhring, K; Langer, H; May, AE; Stellos, K; Wydymus, M; Zürn, C | 1 |
| Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Ozcan, M; Pamukcu, B; Umman, B | 1 |
| Alessi, MC; Bonnet, JL; Carvajal, J; Cuisset, T; Frere, C; Lambert, M; Lehmann, A; Morange, PE; Nait-Saidi, L; Quilici, J | 1 |
| Faxon, DP; Nesto, RW | 1 |
| Goeser, T; Grimberg, G; Jung, N; Kastrati, A; Lazar, A; Schömig, A; Schömig, E; Taubert, D; von Beckerath, N | 1 |
| Anstrom, KJ; Califf, RM; Eisenstein, EL; Harrington, RA; Kandzari, DE; Kong, DF; Kramer, JM; Mark, DB; Matchar, DB; Peterson, ED; Schulman, KA; Shaw, LK; Tuttle, RH | 1 |
| Bhatt, DL; Cannon, CP | 1 |
| Kereiakes, DJ | 1 |
| Munzel, T; Ostad, MA; Schinzel, R; Trautmann, C; Velich, N; Walter, U; Warnholtz, A | 1 |
| Lepor, NE | 1 |
| Domanovits, H; Edes, I; Edes, IF; Facskó, A; Farhan, S; Glogar, D; Gyöngyösi, M; Homorodi, N; Huber, K; Király, C; Kristóf, E; Maurer, G; Pavo, N; Sodeck, G; Strehblow, C; Szük, T | 1 |
| Angiolillo, DJ; Bass, TA; Bernardo, E; Charlton, RK; Costa, MA; Desai, B; Guzman, LA; Shoemaker, SB; Yuan, H; Zenni, MM | 1 |
| Atar, D; Malinin, AI; Serebruany, VL | 1 |
| Bauersachs, J; Eigenthaler, M; Schäfer, A | 1 |
| Avila, A; Brosius, S; Byrd, J; Dippel, EJ; Farland, L; Gehbauer, L; Jerin, M; Majetic, L; Robken, J; Shammas, G; Shammas, NW; Sharis, P; Stoakes, P; Winter, M | 1 |
| Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Onur, I; Ozcan, M; Pamukcu, B; Umman, B | 1 |
| Ayral, Y; Boltzen, U; Piorkowski, M; Rauch, U; Schultheiss, HP; Stellbaum, C; Szotowski, B; Willich, T | 1 |
| Giannitsis, E; Hohlfeld, T; Ivandic, BT; Katus, HA; Schlick, P; Staritz, P | 1 |
| Amin, S; Diamond, GA; Eshaghian, S; Kaul, S; Shah, PK | 1 |
| Abbate, A; Agostoni, P; Biondi-Zoccai, GG; Lotrionte, M; Moretti, C; Sangiorgi, G; Sheiban, I; Valgimigli, M | 1 |
| Csejtei, A; Feher, G; Kiss, I; Tettinger, A; Tibold, A | 1 |
| Breall, JA; Kalaria, V; Karlsson, G; Rehman, J | 1 |
| Cheng, JW | 1 |
| Falcone, EL; Tangri, N | 1 |
| Cannon, CP; Gibler, WB; Milford-Beland, S; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Tickoo, S | 1 |
| Buch, AN; George, CE; Javaid, A; Kent, KM; Pichard, AD; Roy, P; Satler, LF; Singh, S; Smith, KA; Suddath, WO; Waksman, R | 1 |
| Bigalke, B; Daub, K; Dösch, C; Gawaz, M; Geisler, T; Göhring-Frischholz, K; Herdeg, C; Kapp, M; Langer, H | 1 |
| Belli, G; Presbitero, P; Rossi, M; Zavalloni, D | 1 |
| Aydinalp, A; Ertan, C; Gulmez, O; Kaynar, G; Konas, D; Muderrisoglu, H; Ozin, B; Yildirir, A | 1 |
| Biernat, M; Dropinski, J; Dziedzina, S; Jakiela, B; Plutecka, H; Sanak, M; Szczeklik, A; Wegrzyn, W | 1 |
| Beckman, JA; Parikh, SA | 1 |
| Bocksch, W; Boxberger, M; Degenhardt, R; Gross, M; Horstkotte, D; Nienaber, C; Schneider, H; Unverdorben, M; Vallbracht, C; Wiemer, M | 1 |
| Abbate, R; Antoniucci, D; Antonucci, E; Gensini, GF; Giglioli, C; Gori, AM; Marcucci, R; Paniccia, R; Prisco, D | 1 |
| Joyal, D; Rudski, L | 1 |
| Banares, M; Gollapudi, RR; Lee, SS; Price, MJ; Sawhney, N; Schatz, RA; Teirstein, PS; Valencia, R; Wong, GB | 1 |
| Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC | 2 |
| Alviar, CL; Arikan, ME; Builes, A; del Conde, I; Granada, JF; Kleiman, NS; Lev, EI; Mathuria, N; Tellez, A; Vaduganathan, M | 1 |
| Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Palazuelos, J; Sabaté, M | 1 |
| Schmaier, AH; Simon, DI | 1 |
| Banning, AP; Buellesfeld, L; Colombo, A; Dawkins, KD; Grube, E; Guagliumi, G; Hauptman, K; Koglin, J; Marco, J; Popma, JJ; Russell, ME; Thuesen, L; Wijns, W; Zmudka, K | 1 |
| Bigalke, B; Dietz, K; Drosch, T; Gawaz, M; Geisler, T; Grass, D; Herdeg, C; Stellos, K | 1 |
| Gebel, JM | 1 |
| Christiaens, L; Macchi, L | 1 |
| Becker, RC; Gurbel, PA; Mann, KG; Michelson, AD; Steinhubl, SR | 1 |
| Bierend, A; Böger, RH; Maas, R; Rau, T; Schwedhelm, E | 1 |
| Ludington, KJ; Price, MJ; Simon, RA; Teirstein, PS; Valencia, R; von Tiehl, KF | 1 |
| Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ | 1 |
| Hjemdahl, P; Hofman-Bang, C; Ivert, T; Li, N; Perneby, C; Tornvall, P; Wallén, NH | 1 |
| Chen, YD; Lü, SZ; Lu, YL | 1 |
| Dawley, CA; Fletcher, SF; Walker, CW | 1 |
| Ahn, TH; Ahn, Y; Bae, JH; Chae, IH; Hur, SH; Jeong, JW; Jeong, MH; Kang, WC; Kim, JH; Kim, KH; Kim, KY; Nam, CW; Oh, SK; Park, CG | 1 |
| Arora, R; Bahekar, A; Handa, K; Khosla, S; Khraisat, A; Singh, S; Trivedi, A | 1 |
| Amit, G; Leibowitz, D; Rott, D; Weiss, AT; Zahger, D | 1 |
| Delate, T; Johnson, SG; Rogers, K; Witt, DM | 1 |
| Alfonso, F; Angiolillo, DJ; Bass, TA; Bernardo, E; Desai, B; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Macaya, C; Palazuelos, J; Weisberg, I; Zenni, MZ | 1 |
| Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M | 1 |
| Garner, J; Hergott, L; Owen, P; Page, RL | 1 |
| LeLorier, J; Rinfret, S; Sheehy, O | 1 |
| Engelhardt, A; Lask, S; Mügge, A; Neubauer, H | 1 |
| Hobbs, L; Lyle, B | 1 |
| Bertrand, OF; Costerousse, O; De Larochellière, R; Déry, JP; Faurie, B; Gleeton, O; Larose, E; Nguyen, CM; Noël, B; Proulx, G; Rodés-Cabau, J; Roy, L | 1 |
| Beyar, R; Nikolsky, E | 1 |
| Hackeng, CM; Kelder, JC; Postma, S; ten Berg, JM; Topcu, Y; van Werkum, JW; Verheugt, FW | 1 |
| Azzari, F; Berry, C; Doucet, S; Ducrocq, G; Grégoire, JC; Ibrahim, R; L'Allier, PL; Labarthe, B; Noble, S; Nozza, A; Pranno, N; Tardif, JC; Théroux, P | 1 |
| Brewster, JB; Kedar, V; Sundaram, CP; Vincent, C | 1 |
| Al Ali, A; Andrade, J; Saw, J; Wong, GC | 1 |
| Colombo, A | 1 |
| Jamieson, DG; Skliut, M | 1 |
| Batchelor, WB; Buchbinder, M; Dubois, CL; Fitzgerald, PJ; Gammon, R; Garg, J; Hasselblad, V; Hermiller, JB; Kereiakes, DJ; Krucoff, MW; Lansky, AJ; Mehran, R; O'Shaughnessy, CD; Petersen, JL; Schofer, J; Simonton, CA; Turco, MA; Verheye, S; Wijns, W | 1 |
| Kastrati, A; Mann, JF; Mehilli, J; Ndrepepa, G; Pinkau, T; Schömig, A; Schulz, S | 1 |
| Cannon, CP; Fox, KA; Hamdalla, HN; Mehta, SR; Sabatine, MS; Steinhubl, SR; Topol, EJ | 1 |
| Aberle, LG; Alexander, JH; Becker, RC; Chan, MY; Chronos, N; Cohen, MG; Dyke, CK; Gilchrist, IC; Harrington, RA; Kleiman, NS; Lin, M; Melloni, C; Myles, SK; Rusconi, CP; Steinhubl, SR; Tonkens, RM; Vorchheimer, DA; Walder, J | 1 |
| Coukell, AJ; Markham, A | 1 |
| Jackson, A; Luisi, AF | 1 |
| Berger, PB | 1 |
| Blows, LJ; Calver, AL; Dawkins, KD; Gray, HH; Harmer, S; Morgan, JH; Simpson, IA | 1 |
| Badimon, JJ; Chesebro, JH; Farkouh, ME; Fuster, V; Helft, G; Lev, EI; Osende, JI; Rodriguez, OJ; Worthley, SG; Zaman, AG | 1 |
| Marks, AR; Marx, SO | 1 |
| Golledge, P; Robinson, N; Timmis, A | 1 |
| Braun, S; Dirschinger, J; Gawaz, M; Hall, D; Kastrati, A; Mehilli, J; Neumann, FJ; Pache, J; Schömig, A; Seyfarth, M | 1 |
| Fonarow, GC; Horwich, TB | 1 |
| Blankenberg, S; Espinola-Klein, C; Meyer, J; Rupprecht, HJ | 1 |
| Gilchrist, IC; Momplaisir, T; Nickolaus, MJ | 1 |
| Bertolet, BD; Gupta, A; Miller, L | 1 |
| Gersh, BJ; Verheugt, FW | 1 |
152 review(s) available for clopidogrel and Coronary Artery Disease
| Article | Year |
|---|---|
Prevalence and clinical impact of high platelet reactivity in patients with chronic kidney disease treated with percutaneous coronary intervention: An updated systematic review and meta-analysis.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prevalence; Renal Insufficiency, Chronic; Risk Factors; Thrombosis; Treatment Outcome | 2022 |
Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and network meta-analysis.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
Platelet Function and Genotype after DES Implantation in East Asian Patients: Rationale and Characteristics of the PTRG-DES Consortium.
Topics: Clinical Studies as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Genotype; Humans; Platelet Function Tests | 2022 |
Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events.
Topics: Cardiovascular Agents; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Hemostatics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Lipids; Organosilicon Compounds; Warfarin | 2022 |
Efficacy of ticagrelor compared to clopidogrel in improving endothelial function in patients with coronary artery disease: a systematic review.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
De-escalation of antiplatelet therapy in patients with coronary artery disease: Time to change our strategy?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome | 2023 |
Immature platelet fraction in cardiovascular diagnostics and antiplatelet therapy monitoring.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride | 2023 |
Comparison of Different Chronic Maintenance Antithrombotic Strategies in Patients with Coronary Artery Disease: A Systematic Review and Network Meta-Analysis.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Humans; Ischemic Stroke; Network Meta-Analysis; Platelet Aggregation Inhibitors; Rivaroxaban; Ticagrelor | 2023 |
Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective.
Topics: Acute Coronary Syndrome; Anticoagulants; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Heart Diseases; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Ticagrelor | 2020 |
Assessing platelet reactivity after drug eluting stent implantation: state of the art.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists | 2020 |
Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis.
Topics: Acute Coronary Syndrome; Alleles; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2020 |
Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review.
Topics: Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Lower Extremity; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Treatment Outcome | 2020 |
Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists | 2020 |
Effects of the
Topics: Acute Coronary Syndrome; ATP Binding Cassette Transporter, Subfamily B; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide | 2020 |
Meta-Analysis Comparing Ticagrelor or Prasugrel Versus Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention.
Topics: Clopidogrel; Coronary Artery Disease; Elective Surgical Procedures; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2021 |
Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis.
Topics: Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2021 |
Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2C19 loss-of-function alleles: meta-analysis.
Topics: Alleles; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk Factors; Ticlopidine | 2021 |
Risk of stroke in CYP2C19 LoF polymorphism carrier coronary artery disease patients undergoing clopidogrel therapy: An ethnicity-based updated meta-analysis.
Topics: Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Ethnicity; Genotype; Humans; Platelet Aggregation Inhibitors; Stroke; Treatment Outcome | 2021 |
Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease.
Topics: Asian People; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Risk Factors; Ticlopidine | 2017 |
Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recurrence; Ticlopidine | 2017 |
Antithrombotic therapy: Dual therapy after PCI in AF.
Topics: Antithrombins; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Thromboembolism | 2017 |
CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis.
Topics: Aged; Asian People; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention | 2019 |
Association between P2RY12 gene polymorphisms and adverse clinical events in coronary artery disease patients treated with clopidogrel: A systematic review and meta-analysis.
Topics: Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Mutation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Receptors, Purinergic P2Y12; Research Design; Ticlopidine | 2018 |
Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Stents; Ticlopidine | 2018 |
Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis.
Topics: Administration, Oral; Aged; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2018 |
Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; DNA; Drug Therapy, Combination; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Histones; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Thrombosis; Warfarin | 2018 |
Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Humans; Observational Studies as Topic; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2018 |
CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.
Topics: Clinical Decision-Making; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Dosage Calculations; Drug Resistance; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stents; Treatment Outcome | 2019 |
Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis | 2019 |
Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke | 2019 |
Monitoring aspirin and clopidogrel response: testing controversies and recommendations.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Precision Medicine; Stents; Thrombosis; Ticlopidine | 2013 |
Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis.
Topics: Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Tetrazoles; Thromboembolism; Ticlopidine | 2013 |
Perioperative management of antiplatelet therapy in patients with a coronary stent who need noncardiac surgery: a systematic review of clinical practice guidelines.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Elective Surgical Procedures; Hemorrhage; Humans; Metals; Perioperative Care; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Stents; Thromboembolism; Ticlopidine; Time Factors; Withholding Treatment | 2013 |
New antiplatelet agents for cardiovascular disease.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Use of antiplatelet agents in patients with atherosclerotic disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2014 |
Unravelling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y₁₂ inhibitors.
Topics: Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Reduction Behavior; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Combining antiplatelet and antithrombotic therapy (triple therapy): what are the risks and benefits?
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Risk Assessment; Ticlopidine; Warfarin | 2014 |
Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Ticlopidine | 2014 |
Pharmacogenomics of oral antiplatelet drugs.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Meta-Analysis as Topic; Pharmacogenetics; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-
Topics: Administration, Oral; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Follow-Up Studies; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Thrombolytic Therapy; Ticlopidine | 2014 |
A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users.
Topics: Alleles; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Genotype; Humans; Pharmacogenetics; Platelet Aggregation Inhibitors; Publication Bias; Ticlopidine; Treatment Outcome | 2015 |
Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis.
Topics: Aged; China; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; France; Humans; Middle Aged; Odds Ratio; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Republic of Korea; Ticlopidine | 2014 |
Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Ticlopidine; Vitamin K; Warfarin | 2014 |
Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity.
Topics: Adenosine; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Research Design; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Dual antiplatelet therapy for coronary artery disease.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2015 |
Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel.
Topics: Clopidogrel; Coronary Artery Disease; Global Health; Hemorrhage; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine | 2015 |
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stents; Tetrazoles; Thrombosis; Ticlopidine | 2015 |
Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review.
Topics: Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Observational Studies as Topic; Odds Ratio; Patient Safety; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk Assessment; Risk Factors; Ticlopidine; Treatment Outcome | 2015 |
Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2016 |
Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials.
Topics: Clopidogrel; Coronary Artery Disease; Humans; Medication Adherence; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Retrospective Studies; Ticlopidine | 2016 |
[Cholestasic toxic hepatitis due to clopidogrel in a patient with multiple conditions].
Topics: Chemical and Drug Induced Liver Injury; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2016 |
Antiplatelet Management for Coronary Heart Disease: Advances and Challenges.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stents; Ticlopidine; United States | 2016 |
Use of prasugrel in the setting of clopidogrel hypersensitivity: Case report and systematic review of the literature.
Topics: Adult; Clopidogrel; Coronary Artery Disease; Drug Hypersensitivity; Drug Substitution; Drug-Eluting Stents; Humans; Male; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine | 2016 |
Aspirin, Plavix, and Other Antiplatelet Medications: What the Oral and Maxillofacial Surgeon Needs to Know.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Medication Therapy Management; Oral Surgical Procedures; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Ticlopidine | 2016 |
Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk; Stents; Ticlopidine; Warfarin | 2016 |
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Stroke; Ticlopidine; Treatment Outcome | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Kaplan-Meier Estimate; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Stents; Ticlopidine; Treatment Outcome | 2017 |
Clinical implications of clopidogrel resistance.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Drug Resistance; Drug-Eluting Stents; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
Revascularization treatment recommendations based on atherosclerotic disease distribution: coronary artery bypass grafting versus stenting.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Diabetic Angiopathies; Drug-Eluting Stents; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Reoperation; Stents; Ticlopidine; Treatment Outcome | 2008 |
Clopidogrel and aspirin in cardiovascular medicine: responders or not--current best available evidence.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
Aspirin and clopidogrel response variability: review of the published literature.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Secondary Prevention; Ticlopidine | 2008 |
Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Variability in platelet response to the antiplatelet agents aspirin and clopidogrel: mechanisms, measurement, and clinical relevance.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Probability; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Ticlopidine; Treatment Outcome | 2009 |
Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Registries; Risk Assessment; Ticlopidine | 2008 |
Recent advances in the management of coronary artery disease: highlights from the literature.
Topics: Blood Vessels; Clopidogrel; Coronary Angiography; Coronary Artery Bypass, Off-Pump; Coronary Artery Disease; Exercise Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Revascularization; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Tomography, Emission-Computed; Treatment Outcome | 2009 |
Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Risk Factors; Stents; Ticlopidine | 2009 |
Significant gastrointestinal bleeding in patients at risk of coronary stent thrombosis.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer Hemorrhage; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Proton Pump Inhibitors; Risk Assessment; Risk Factors; Thrombosis; Ticlopidine; Treatment Outcome | 2009 |
New antiplatelet drugs: beyond aspirin and clopidogrel.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Factors; Ticlopidine; Withholding Treatment | 2009 |
Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Hemorrhage; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Thrombin; Ticlopidine; Treatment Outcome | 2008 |
Platelet resistance to antiplatelet drugs.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Resistance, Multiple; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2009 |
Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Prognosis; Ticlopidine | 2009 |
Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.
Topics: Adult; Clopidogrel; Coronary Artery Disease; Data Collection; Female; Humans; Kinetics; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Young Adult | 2009 |
Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Humans; Kidney Diseases; Platelet Aggregation Inhibitors; Proteinuria; Receptors, Thrombin; Thrombosis; Thromboxane A2; Thromboxane-A Synthase; Ticlopidine | 2009 |
Current controversies in the pharmacogenomics of clopidogrel.
Topics: Clopidogrel; Confidence Intervals; Coronary Artery Disease; Genotype; Humans; Myocardial Infarction; Pharmacogenetics; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2009 |
Clopidogrel before elective percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Elective Surgical Procedures; Humans; Postoperative Complications; Preoperative Care; Randomized Controlled Trials as Topic; Ticlopidine | 2010 |
Dual antiplatelet therapy in coronary artery disease: a case-based approach.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine | 2009 |
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Recurrence; Risk Assessment; Risk Factors; Stents; Thrombosis; Ticlopidine; Treatment Outcome | 2009 |
Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Resistance; Evidence-Based Medicine; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Publication Bias; Recurrence; Risk Assessment; Risk Factors; Ticlopidine; Treatment Outcome | 2010 |
Factors associated with clopidogrel nonresponsiveness.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Proton Pump Inhibitors; Smoking; Ticlopidine; Treatment Failure | 2010 |
Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Artery Disease; Electrocardiography; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recombinant Proteins; Ticlopidine | 2010 |
Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis.
Topics: Adolescent; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Genetic Association Studies; Genotype; Humans; Middle Aged; Polymorphism, Genetic; Recurrence; Risk Factors; Thrombosis; Ticlopidine; United States | 2011 |
The role of antiplatelet therapy in the secondary prevention of coronary artery disease.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Secondary Prevention; Thiophenes; Thromboxane A2; Ticagrelor; Ticlopidine | 2010 |
Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Platelet P2Y₁₂ receptor inhibition: an update on clinical drug development.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2Y12; Ticlopidine | 2010 |
[Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Thiophenes; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2010 |
[Platelet inhibition with prasugrel].
Topics: Acute Coronary Syndrome; Administration, Oral; Angina, Unstable; Biological Availability; Clopidogrel; Coronary Artery Disease; Humans; Metabolic Clearance Rate; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Secondary Prevention; Thiophenes; Ticlopidine | 2010 |
Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Humans; Intention to Treat Analysis; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Predictive Value of Tests; Prognosis; Stents; Thrombosis; Ticlopidine | 2010 |
Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Myocardial Infarction; Myocardial Ischemia; Odds Ratio; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Stents; Stroke; Thrombosis; Ticlopidine; Treatment Outcome | 2011 |
[Dilemma between gastroprotection and cardiovascular prevention].
Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Long-Term Care; Mutation; Omeprazole; Peptic Ulcer Hemorrhage; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Survival Analysis; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor: from discovery to Phase III clinical trial.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Clinical Trials, Phase III as Topic; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2010 |
The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data.
Topics: Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors | 2011 |
Genetic variability in response to clopidogrel therapy and its clinical implications.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; DNA Mutational Analysis; Genetic Variation; Humans; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Precision Medicine; Predictive Value of Tests; Ticlopidine | 2011 |
Platelet function variability and non-genetic causes.
Topics: Blood Platelets; Clinical Trials as Topic; Clopidogrel; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Drug Interactions; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
Personalized antiplatelet therapy: review of the latest clinical evidence.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Cytochrome P-450 CYP2C19; Drug Resistance; Evidence-Based Medicine; Humans; Platelet Aggregation Inhibitors; Primary Prevention; Stents; Ticlopidine | 2011 |
Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Pharmacogenetics; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2011 |
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Genotype; Hemorrhage; Humans; Pharmacogenetics; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Risk Factors; Ticlopidine | 2012 |
Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies.
Topics: Blood Transfusion; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Drug Administration Schedule; Evidence-Based Medicine; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Reoperation; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Anticipating and managing bleeding complications in patients with coronary stents who are receiving dual antiplatelet treatment.
Topics: Blood Component Transfusion; Catheters, Indwelling; Clopidogrel; Coagulants; Coronary Artery Disease; Coronary Restenosis; Drug Interactions; Drug Therapy, Combination; Drug-Eluting Stents; Endoscopy, Gastrointestinal; Fibrinolytic Agents; Forecasting; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Proton Pump Inhibitors; Risk Factors; Stents; Ticlopidine; Treatment Outcome | 2011 |
Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists.
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Female; Genetic Association Studies; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Design; Drug Interactions; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Ticlopidine | 2012 |
Variability of clopidogrel response in patients with type 2 diabetes mellitus.
Topics: Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticlopidine; Treatment Outcome | 2011 |
Antiplatelet therapy in the era of percutaneous coronary intervention with drug-eluting balloons.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Drug Delivery Systems; Drug Therapy, Combination; Equipment Design; Evidence-Based Medicine; Humans; Patient Selection; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis.
Topics: Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Proton Pump Inhibitors; Ticlopidine; Treatment Outcome | 2012 |
The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Confidence Intervals; Coronary Artery Disease; Coronary Restenosis; Drug Therapy, Combination; Humans; Odds Ratio; Platelet Aggregation Inhibitors; Tetrazoles; Ticlopidine | 2012 |
Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cohort Studies; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Ethnicity; Humans; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prospective Studies; Randomized Controlled Trials as Topic; Risk Assessment; Ticlopidine; Treatment Outcome | 2012 |
Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Biomarkers, Pharmacological; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine; Translational Research, Biomedical; Treatment Outcome | 2012 |
Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease.
Topics: Aspirin; Blood Glucose; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Insulin; Insulin Resistance; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Treatment Outcome | 2012 |
A brief review of the past and future of platelet P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Precision Medicine; Risk; Thrombosis; Ticlopidine | 2012 |
Clopidogrel in coronary artery disease: update 2012.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2012 |
The discovery of a new class of synaptic transmitters in smooth muscle 50 years ago and amelioration of coronary artery thrombosis.
Topics: Adenosine; Animals; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; History, 20th Century; Humans; Muscle, Smooth; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y; Ticagrelor; Ticlopidine | 2013 |
Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Cost Savings; Drug Monitoring; Drug Resistance; Drug Substitution; Drug Therapy, Combination; Humans; Ischemia; Platelet Aggregation Inhibitors; Secondary Prevention; Thrombosis; Ticlopidine | 2013 |
Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Endpoint Determination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Preoperative Care; Randomized Controlled Trials as Topic; Registries; Stroke; Ticlopidine; Treatment Outcome | 2012 |
[Secondary and primary prevention of coronary heart disease: platelet aggregation inhibitors and anticoagulants].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Interactions; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Ticlopidine | 2002 |
[Clopidogrel: background information and use in clinical practice].
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Thrombosis; Ticlopidine | 2003 |
[Antiplatelet drugs in prevention and treatment of coronary heart disease: aspirin is obligatory, quite sufficient, and safe].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Resistance; Drug Tolerance; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2003 |
[Antiplatelet drugs in prevention of complications of arteriosclerotic diseases: it is necessary to move beyond aspirin].
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2003 |
Role of antiplatelet drugs in the prevention of cardiovascular events.
Topics: Aspirin; Benzamidines; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Oximes; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Stroke; Ticlopidine; Treatment Outcome | 2003 |
Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Coronary Restenosis; Diabetic Angiopathies; Drug Implants; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Syndrome; Thiazolidinediones; Ticlopidine | 2004 |
The use of clopidogrel in patients with coronary artery disease.
Topics: Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2004 |
Clopidogrel: how good is it and how does it work?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Endothelium, Vascular; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Recurrence; Ticlopidine; Treatment Outcome | 2004 |
CD40 ligand: a novel target in the fight against cardiovascular disease.
Topics: Cardiovascular Agents; Cardiovascular Diseases; CD40 Ligand; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thiazolidinediones; Ticlopidine | 2004 |
Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Antithrombins; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Coronary Thrombosis; Electrocardiography; Evidence-Based Medicine; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Ticlopidine | 2004 |
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Topics: Administration, Oral; Angina Pectoris; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Artery Disease; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Stroke; Thrombosis; Ticlopidine | 2004 |
What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis.
Topics: Aged; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Postoperative Complications; Risk Factors; Stents; Ticlopidine; Treatment Outcome | 2005 |
The benefits of abciximab questioned in percutaneous coronary interventions following pretreatment with high-dose clopidogrel.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Immunoglobulin Fab Fragments; Ticlopidine | 2005 |
Clopidogrel use in coronary artery disease.
Topics: Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2006 |
Gastrointestinal complications of dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Digestive System; Gastrointestinal Diseases; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine | 2006 |
Clopidogrel resistance: implications for coronary stenting.
Topics: Animals; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Stents; Ticlopidine | 2006 |
Thienopyridines in percutaneous coronary interventions: standard procedures and high risk subsets.
Topics: Angioplasty, Balloon, Coronary; Biocompatible Materials; Brachytherapy; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Humans; Metals; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine | 2006 |
Antiplatelet resistance with aspirin and clopidogrel: is it real and does it matter?
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2006 |
Impact of chronic kidney disease and diabetes on percutaneous coronary intervention outcomes.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Drug-Eluting Stents; Glucose; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Ticlopidine; Treatment Outcome | 2006 |
Variable response to clopidogrel in patients with coronary artery disease.
Topics: Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2007 |
Role of clopidogrel in managing atherothrombotic cardiovascular disease.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2007 |
Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression.
Topics: Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Regression Analysis; Stents; Ticlopidine | 2007 |
Pharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery disease.
Topics: Clopidogrel; Coronary Artery Disease; Cost-Benefit Analysis; Economics, Pharmaceutical; Humans; Ticlopidine; United States | 2007 |
Contemporary use of clopidogrel in patients with coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Treatment Outcome | 2007 |
Monitoring of the antiplatelet drugs effect in patients with coronary artery disease: what is the real clinical impact?
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Monitoring; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine | 2007 |
Platelet function monitoring in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Disease; Drug Resistance; Humans; Monitoring, Physiologic; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Ticlopidine; Treatment Outcome | 2007 |
Aspirin combined with clopidogrel (Plavix) decreases cardiovascular events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Evidence-Based Medicine; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Thrombosis; Ticlopidine | 2007 |
Increased incidence of in-stent thrombosis related to cocaine use: case series and review of literature.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cocaine; Cocaine-Related Disorders; Coronary Artery Disease; Coronary Thrombosis; Female; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Ticlopidine; Treatment Outcome | 2007 |
Clopidogrel desensitization: case report and review of published protocols.
Topics: Cardiac Catheterization; Clinical Protocols; Clopidogrel; Coronary Artery Disease; Desensitization, Immunologic; Drug Hypersensitivity; Drug-Eluting Stents; Exanthema; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine | 2008 |
Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome | 2008 |
Clopidogrel.
Topics: Animals; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 1997 |
Antiplatelet agents and the role of clopidogrel in the prevention of secondary atherosclerotic events.
Topics: Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 1999 |
Prevention of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Disease Progression; Health Behavior; Heart Failure; Humans; Hyperlipidemias; Hypertension; Platelet Aggregation Inhibitors; Prevalence; Renal Insufficiency; Risk Factors; Smoking; Ticlopidine; Ventricular Dysfunction, Left | 2002 |
[Modern therapy in acute coronary syndrome].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Survival Rate; Ticlopidine | 2002 |
Aspirin beyond platelet inhibition.
Topics: Abciximab; Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine | 2002 |
274 trial(s) available for clopidogrel and Coronary Artery Disease
| Article | Year |
|---|---|
Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Comparative evaluation of standard maintenance-dose clopidogrel versus low-dose prasugrel in patients with stable coronary artery disease after percutaneous coronary intervention.
Topics: Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome | 2022 |
Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention.
Topics: Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2022 |
Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2022 |
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor | 2022 |
Effect of cocoa (
Topics: Aspirin; Cacao; Chocolate; Clopidogrel; Coronary Artery Disease; Humans; Pilot Projects; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2022 |
Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority ra
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Gastrointestinal Diseases; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome | 2023 |
Genetic-Guided Oral P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2023 |
Sex Differences in Midterm Prognostic Implications of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents in East Asian Patients: Results From the PTRG-DES (Platelet Function and Genotype-Related Long-Term Prognosis
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; East Asian People; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Risk Factors; Sex Factors; Treatment Outcome | 2023 |
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.
Topics: Aged; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; Coronary Artery Disease; Cyclooxygenase 1; Drug Interactions; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Pyridines; Receptors, Purinergic P2Y12; Survival Analysis; Thiazoles | 2020 |
Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Substitution; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease: the switching from clopidogrel to ticagrelor (SHIFT-CACS) study.
Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor | 2019 |
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2019 |
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Diabetes Mellitus; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2019 |
The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention.
Topics: Aged; Aryldialkylphosphatase; Asian People; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic | 2020 |
β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease.
Topics: Aged; Amyloid beta-Peptides; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Male; Malondialdehyde; Middle Aged; Mitochondrial Proteins; Myocardial Revascularization; Platelet Activation; Risk Factors | 2020 |
Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial.
Topics: Adolescent; Adult; Aged; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Female; Fractional Flow Reserve, Myocardial; Humans; Ischemic Preconditioning, Myocardial; Male; Microvessels; Middle Aged; Myocardial Reperfusion Injury; Percutaneous Coronary Intervention; Pilot Projects; Preoperative Care; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome; Vascular Resistance; Young Adult | 2020 |
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Risk Factors; Stents; Thromboembolism; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2020 |
The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2021 |
Optimal antiplatelet therapy for prevention of gastrointestinal injury evaluated by ANKON magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial.
Topics: Adult; Aspirin; Capsule Endoscopy; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Double-Blind Method; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Gastrointestinal Hemorrhage; Humans; Male; Outcome and Process Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Adjustment | 2020 |
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Female; Genotype; Genotyping Techniques; Hemorrhage; Heterozygote; Humans; Loss of Function Mutation; Male; Middle Aged; Percutaneous Coronary Intervention; Point-of-Care Testing; Precision Medicine; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
Efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease undergoing percutaneous coronary intervention.
Topics: Aged; Asian People; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Preoperative Care; Ticagrelor; Treatment Outcome | 2020 |
Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial.
Topics: Aged; Aspirin; Biodegradable Plastics; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Humans; Immunosuppressive Agents; Male; Outcome and Process Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Sirolimus | 2021 |
Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Outcome and Process Assessment, Health Care; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Adjustment; Rivaroxaban; Stroke | 2021 |
CD36+/CD61+ Microparticles Correlate with the Risk of Percutaneous Cardiac Interventions in Coronary Artery Disease Patients and the Effects of Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Republic of Korea | 2021 |
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.
Topics: Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Prospective Studies; Renal Insufficiency, Chronic; Ticagrelor | 2022 |
Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease.
Topics: Adenosine; Aged; Anticoagulants; Apoptosis; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytokines; Endothelium, Vascular; Female; Human Umbilical Vein Endothelial Cells; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Nitric Oxide; Percutaneous Coronary Intervention; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Reactive Oxygen Species; Ticagrelor; Ticlopidine | 2017 |
Impact of dual antiplatelet therapy after coronary artery bypass surgery on 1-year outcomes in the Arterial Revascularization Trial.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Propensity Score; Survival Rate; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Risk Factors; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
PRotective Effect on the coronary microcirculation of patients with DIabetes by Clopidogrel or Ticagrelor (PREDICT): study rationale and design. A randomized multicenter clinical trial using intracoronary multimodal physiology.
Topics: Adenosine; Blood Platelets; Clinical Protocols; Clopidogrel; Coronary Artery Disease; Coronary Circulation; Diabetes Mellitus, Type 2; Humans; Microcirculation; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Research Design; Risk Factors; Spain; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Vasodilation | 2017 |
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.
Topics: Adenosine Monophosphate; Administration, Oral; Aged; Cause of Death; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Global Health; Humans; Incidence; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Survival Rate; Ticlopidine; Time Factors | 2017 |
Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Genotype; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Stents; Ticlopidine | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Ticlopidine; Treatment Outcome | 2017 |
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Intention to Treat Analysis; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; France; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Eight-year follow-up of the Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) trial.
Topics: Aged; Aspirin; Clopidogrel; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Coronary Restenosis; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Outcome and Process Assessment, Health Care; Platelet Aggregation Inhibitors; Survival Analysis; Vascular Patency | 2018 |
Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy.
Topics: Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Prosthesis Design; Republic of Korea; Sirolimus; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2018 |
Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREA
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Endpoint Determination; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Republic of Korea; Stroke; Survival Rate; Treatment Outcome | 2018 |
Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thienopyridines; Ticagrelor | 2018 |
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.
Topics: Aged; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Aggregation; Platelet Function Tests; Prospective Studies; Ticagrelor | 2018 |
Vasodilator-stimulated phosphoprotein-guided Clopidogrel maintenance therapy reduces cardiovascular events in atrial fibrillation patients requiring anticoagulation therapy and scheduled for percutaneous coronary intervention: a prospective cohort study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Biomarkers; Blood Coagulation; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Drug Monitoring; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2018 |
Lower on-treatment platelet reactivity during everolimus-eluting stent implantation contributes to the resolution of post-procedural intra-stent thrombus: serial OCT observation in the PRASFIT-Elective study.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Tomography, Optical Coherence; Treatment Outcome | 2018 |
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
Topics: Aged; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Stents; Stroke; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2018 |
Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention.
Topics: Aged; Aspirin; Brazil; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Europe; Female; Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Treatment Outcome; United States | 2018 |
Predictors of strut coverage of drug eluting stent implantation in diabetic patients.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prosthesis Design; Sirolimus; Tomography, Optical Coherence; Treatment Outcome | 2019 |
Platelet MicroRNA 365-3p Expression Correlates with High On-treatment Platelet Reactivity in Coronary Artery Disease Patients.
Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; MicroRNAs; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Stents; Taiwan; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Elective Surgical Procedures; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Ticagrelor; Warfarin | 2019 |
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Risk Assessment; Stroke; Thromboembolism; Ticagrelor; Warfarin | 2019 |
Effect of Ticagrelor Versus Clopidogrel on Aortic Stiffness in Patients With Coronary Artery Disease.
Topics: Aged; Aorta; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Single-Blind Method; Ticagrelor; Time Factors; Vascular Stiffness | 2019 |
High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
Topics: Age Factors; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Pyrroles; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticlopidine | 2013 |
Current medical management of stable coronary artery disease before and after elective percutaneous coronary intervention.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Clopidogrel; Coloring Agents; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Preoperative Care; Retrospective Studies; Severity of Illness Index; Ticlopidine; Treatment Outcome | 2013 |
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Reference Values; Severity of Illness Index; Single-Blind Method; Survival Rate; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Asian People; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Precision Medicine; Ticlopidine | 2013 |
Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Nervous System Diseases; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2013 |
Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Thromboxane; Ticlopidine | 2014 |
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Blood Platelets; Cell Adhesion Molecules; Cells, Cultured; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Piperazines; Platelet Activation; Polymorphism, Genetic; Prasugrel Hydrochloride; Prospective Studies; Pyridines; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2013 |
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Prosthesis Design; Republic of Korea; Risk Factors; Stroke; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials).
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Diabetes Complications; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prosthesis Implantation; Tetrazoles; Ticlopidine; Treatment Outcome | 2013 |
Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticlopidine; Treatment Outcome | 2014 |
Combination of high on-treatment platelet aggregation and low deaggregation better predicts long-term cardiovascular events in PCI patients under dual antiplatelet therapy.
Topics: Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Artery Disease; Disease-Free Survival; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Postoperative Complications; Predictive Value of Tests; Survival Rate; Ticlopidine | 2014 |
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study.
Topics: Adenosine; Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pneumonia; Sepsis; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention.
Topics: Blood Platelets; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Resistance; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Republic of Korea; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
Topics: Aspirin; Biomarkers; Blood Platelets; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Obesity; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk; Sirolimus; Stroke; Thrombosis; Ticlopidine | 2013 |
Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Thiophenes; Ticlopidine; Treatment Outcome | 2014 |
Effects of clopidogrel therapy on oxidative stress, inflammation, vascular function, and progenitor cells in stable coronary artery disease.
Topics: Aged; Biomarkers; Blood Vessels; Capillaries; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Double-Blind Method; Elasticity; Endothelium, Vascular; Female; Humans; Inflammation; Male; Middle Aged; Oxidative Stress; Platelet Aggregation Inhibitors; Prospective Studies; Stem Cells; Ticlopidine; Vascular Stiffness | 2014 |
Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Cytochrome P-450 CYP3A; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Quinolines; Ticlopidine | 2014 |
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease.
Topics: Adolescent; Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genetic Testing; Genotype; High-Throughput Screening Assays; Humans; Inactivation, Metabolic; International Cooperation; Male; Middle Aged; Point-of-Care Systems; Polymorphism, Genetic; Ticlopidine; Treatment Outcome; Young Adult | 2014 |
Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Point-of-Care Systems; Prasugrel Hydrochloride; Pyridines; Receptors, Purinergic P2Y12; Reproducibility of Results; ROC Curve; Sensitivity and Specificity; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease.
Topics: Aged; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Sirolimus; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb.
Topics: Adult; Chemistry, Pharmaceutical; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Treatment Outcome | 2015 |
Clopidogrel improves microvascular endothelial function in subjects with stable coronary artery disease.
Topics: Aged; Blood Coagulation; Clopidogrel; Coronary Artery Disease; Endothelium, Vascular; Female; Humans; Male; Microvessels; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Time Factors | 2014 |
Switching from clopidogrel to prasugrel in patients having coronary stent implantation.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Sex Factors; Stents; Thiophenes; Thrombosis; Ticlopidine | 2014 |
Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Croatia; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Incidence; Male; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Complications; Retrospective Studies; Survival Rate; Ticlopidine; Treatment Outcome | 2014 |
Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.
Topics: Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine; Time Factors | 2014 |
High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention.
Topics: Aged; China; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Resistance; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Renal Insufficiency, Chronic; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Young Adult | 2014 |
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Topics: Aged; Angina, Stable; Aspirin; Belgium; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Risk Factors; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Topics: Aged; Clinical Protocols; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Phenotype; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2014 |
Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.
Topics: Adult; Aged; Anti-Ulcer Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Interactions; Female; Humans; Lansoprazole; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2014 |
Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial.
Topics: Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2014 |
The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Purinergic P2Y Receptor Antagonists; Regression Analysis; Thiophenes; Ticlopidine | 2015 |
Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV.
Topics: Aged; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Predictive Value of Tests; Risk Assessment; Saphenous Vein; Ticlopidine; Vascular Patency | 2014 |
A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease.
Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Hispanic or Latino; Humans; Middle Aged; Platelet Activation; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Drug-Eluting Stents; Early Termination of Clinical Trials; Europe; Everolimus; Female; Hemorrhage; Humans; Immunosuppressive Agents; Male; Middle Aged; Middle East; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Assessment of the efficacy and tolerability of clopidogrel napadisilate in Korean patients with coronary stenting: a multicenter, prospective, open-label, randomized trial.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug Monitoring; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Republic of Korea; Ticlopidine; Treatment Outcome | 2015 |
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Failure; Stroke; Ticlopidine; Treatment Outcome | 2015 |
Impact of impaired glucose tolerance on clopidogrel response in patients with coronary artery disease.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Glucose Tolerance Test; Humans; Insulin Resistance; Male; Middle Aged; Ticlopidine; Time Factors | 2015 |
Comparison of the antiplatelet effect of clopidogrel hydrogenosulfate and clopidogrel besylate in patients with stable coronary artery disease.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Heterozygote; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prospective Studies; Ticlopidine | 2015 |
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
Topics: Adenosine Monophosphate; Aged; Anticoagulants; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recombinant Proteins; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Hemorrhage; Humans; Hyperplasia; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Stents; Stroke; Ticlopidine; Tunica Intima | 2015 |
Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
Topics: Aged; Aged, 80 and over; Aspirin; Biocompatible Materials; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hemorrhage; Humans; Immunosuppressive Agents; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Risk Assessment; Risk Factors; Sirolimus; Ticlopidine; Treatment Outcome | 2015 |
Reduced Effect of Aspirin and Clopidogrel Following Hybrid Coronary Revascularization.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Ticlopidine | 2015 |
Intrinsic platelet reactivity before start with clopidogrel as predictor for on-clopidogrel platelet function and long-term clinical outcome.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Germany; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Predictive Value of Tests; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention.
Topics: Adenosine; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Research Design; Rivaroxaban; Ticagrelor; Ticlopidine; Warfarin | 2015 |
Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trial.
Topics: Adenosine; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Genetic Variation; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alleles; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Genotype; Humans; Male; Middle Aged; Models, Biological; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2015 |
Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study.
Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Stopping antiplatelet medication before coronary artery bypass graft surgery: is there an optimal timing to minimize bleeding?
Topics: Aged; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Linear Models; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Platelet Transfusion; Postoperative Hemorrhage; Prospective Studies; Risk Assessment; Sensitivity and Specificity; Ticlopidine; Time Factors; Treatment Outcome; Withholding Treatment | 2015 |
Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation. An ADAPT-DES substudy.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Elective Surgical Procedures; Female; Germany; Humans; Male; Middle Aged; Observer Variation; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Receptors, Purinergic P2Y12; Ticlopidine | 2015 |
Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Substitution; Female; Genotype; Humans; Japan; Male; Middle Aged; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine; Treatment Outcome | 2015 |
Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment.
Topics: Aged; Aged, 80 and over; Aspirin; Brachial Artery; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Endothelium, Vascular; Female; Genotype; Humans; Inflammation; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Real-Time Polymerase Chain Reaction; Ticlopidine; Vascular Stiffness | 2015 |
Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial.
Topics: Acute Coronary Syndrome; Adult; Aftercare; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2016 |
Pharmacodynamic Effects When Clopidogrel is Given Before Cangrelor Discontinuation.
Topics: Adenosine Monophosphate; Adult; Aged; Biological Availability; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Interactions; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2015 |
Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention: The RECLOSE-3 Study (REsponsiveness to CLOpidogrel and StEnt Thrombosis).
Topics: Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Drug Substitution; Female; Historically Controlled Study; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Comparative effect on platelet function of a fixed-dose aspirin and clopidogrel combination versus separate formulations in patients with coronary artery disease: A phase IV, multicenter, prospective, 4-week non-inferiority trial.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Combinations; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Ticlopidine; Treatment Outcome | 2016 |
Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus.
Topics: Adenosine; Administration, Oral; Aged; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hispanic or Latino; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Regression Analysis; Risk Assessment; Severity of Illness Index; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2015 |
Antiplatelet Efficacy of Fixed-Dose Aspirin-Clopidogrel Combination in Patients with Stable Coronary Artery Disease Treated with Drug-Eluting Stent Implantation.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Combinations; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Ticlopidine; Treatment Outcome; Young Adult | 2015 |
Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 Enzyme System; Dabigatran; Double-Blind Method; Electrodes; Female; Humans; Light; Male; Middle Aged; Nephelometry and Turbidimetry; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Thrombelastography; Thrombosis; Ticlopidine; Vitamin K | 2016 |
A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.
Topics: Adenosine; Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor; Ticlopidine | 2016 |
Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial.
Topics: Aged; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug-Eluting Stents; Female; Humans; Linear Models; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Smoking; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS).
Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Troponin | 2016 |
Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Resistance; Drug Therapy, Combination; Female; Flow Cytometry; Gene Frequency; Haplotypes; Humans; Insulin Receptor Substrate Proteins; Male; Middle Aged; P-Selectin; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Single Nucleotide; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Genotype; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Ticlopidine | 2016 |
Comparison of dual antiplatelet therapy prescribed as one-pill versus two-pill regimen. A pooled analysis of individual patient data from the three MR-CAPCIS trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Combinations; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Republic of Korea; Ticlopidine | 2016 |
One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: A randomized, single-blind, crossover clinical study.
Topics: Adenosine; Aged; China; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation; Single-Blind Method; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study.
Topics: Aged; Anemia; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Europe; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk Assessment; Risk Factors; Survival Rate; Ticlopidine; United States | 2016 |
Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Humans; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Ticlopidine | 2016 |
Comparison of the antiplatelet effect of clopidogrel benzene sulfonate and clopidogrel hydrogen sulfate in stable coronary heart disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Combinations; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine | 2016 |
Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
Topics: Adenosine; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Comorbidity; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Drug Interaction Between Clopidogrel and Ranitidine or Omeprazole in Stable Coronary Artery Disease: A Double-Blind, Double Dummy, Randomized Study.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Ranitidine; Ticlopidine | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Graft Occlusion, Vascular; Hemorrhage; Humans; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans; Italy; Male; Middle Aged; Myocardial Infarction; Neointima; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Assessment; Risk Factors; Sex Factors; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients).
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2016 |
Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Republic of Korea; Risk Factors; Sirolimus; Ticlopidine; Time Factors | 2017 |
Platelet reactivity and clinical outcomes in patients using CYP3A4-metabolized statins with clopidogrel in percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Propensity Score; Prospective Studies; Republic of Korea; Ticlopidine; Treatment Outcome | 2017 |
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Neointima; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sirolimus; Tetrazoles; Ticlopidine; Treatment Outcome | 2017 |
Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective PCI patients: A pilot study: ONSIDE TEST pilot.
Topics: Adolescent; Adult; Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation; Platelet Function Tests; Point-of-Care Systems; Prasugrel Hydrochloride; Preoperative Care; Retrospective Studies; Ticlopidine; Young Adult | 2017 |
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Tetrazoles; Ticlopidine; Treatment Outcome | 2008 |
Effect of 150-mg vs 300-mg loading doses of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Asian People; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Dose-Response Relationship, Drug; Female; Humans; Japan; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Single-Blind Method; Ticlopidine; Treatment Outcome | 2008 |
Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Failure | 2008 |
Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Resistance, Multiple; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Incidence; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Radiography; Risk Factors; Ticlopidine | 2008 |
Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
Topics: Aged; Aspirin; Cell Size; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Flow Cytometry; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Ticlopidine | 2008 |
CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Cardiac Surgical Procedures; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Risk Factors; Stents; Ticlopidine | 2008 |
Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2008 |
Treatment of bifurcation lesions using dedicated bifurcation stents versus classic bare-metal stents. Randomized, controlled trial with 12-month angiographic follow up.
Topics: Adult; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Female; Fluoroscopy; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Ticlopidine | 2008 |
ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug Resistance; Female; Flow Cytometry; Humans; Incidence; Male; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Signal Transduction; Ticlopidine | 2008 |
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
Topics: Adult; Aspirin; Biomarkers; Blood Platelets; Cell Communication; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Monocytes; P-Selectin; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Necrosis; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Comparison of laboratory detection methods of aspirin resistance in coronary artery disease patients.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clinical Laboratory Techniques; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2010 |
Comparison of collagen versus adenosine diphosphate in detecting antiplatelet effect in patients with coronary artery disease.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Collagen; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Ticlopidine; Treatment Outcome | 2009 |
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Models, Biological; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
Topics: Adult; Aged; Clopidogrel; Comorbidity; Coronary Artery Disease; Diabetes Complications; Double-Blind Method; Drug Resistance; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prevalence; Pyridines; Thiophenes; Ticlopidine; Treatment Failure; Treatment Outcome | 2008 |
Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2009 |
Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox".
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Aspirin; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heparin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Microfilament Proteins; Phosphoproteins; Platelet Aggregation Inhibitors; Renal Insufficiency; Sex Factors; Smoking; Ticlopidine; Treatment Outcome | 2009 |
A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial.
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Saphenous Vein; Stents; Ticlopidine | 2009 |
Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel.
Topics: Adenosine Diphosphate; Aged; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine; Time Factors | 2009 |
Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Ticlopidine | 2009 |
Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Confidence Intervals; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Immunosuppressive Agents; Incidence; Male; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Risk; Sirolimus; Ticlopidine; Tubulin Modulators | 2009 |
Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Europe; Female; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Odds Ratio; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Risk Assessment; Stents; Ticlopidine; Time Factors | 2008 |
The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Gene Frequency; Genotype; Humans; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Thrombosis; Ticlopidine; Time Factors | 2008 |
The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Eptifibatide; Female; Heart Diseases; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Necrosis; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Disease-Free Survival; Drug Resistance; Drug Therapy, Combination; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk Assessment; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
Topics: Aged; Angioplasty, Balloon, Coronary; Asia; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Biocompatible; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymers; Product Surveillance, Postmarketing; Prospective Studies; Prosthesis Design; Registries; Risk Assessment; Sirolimus; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug Resistance; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2009 |
High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial.
Topics: Adenosine Diphosphate; Aged; Antigens, Human Platelet; Clopidogrel; Coronary Artery Disease; Female; Humans; Integrin beta3; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Ticlopidine; Time Factors | 2009 |
Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ticlopidine | 2009 |
Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cilostazol; Clopidogrel; Confidence Intervals; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Humans; Korea; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Tetrazoles; Ticlopidine | 2009 |
Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin.
Topics: Aspirin; Biomarkers; CD40 Ligand; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lacerations; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Punctures; Skin; Thrombin; Ticlopidine; Veins | 2009 |
Week-long high-maintenance dose clopidogrel regimen achieves better platelet aggregation inhibition than a standard loading dose before percutaneous coronary intervention: results of a double-blind, randomized clinical trial.
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Logistic Models; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2009 |
Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Parenteral; Injections; Length of Stay; Logistic Models; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors; Proportional Hazards Models; Radial Artery; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.
Topics: Adenosine Diphosphate; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Coagulation; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Collagen; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Humans; Male; Microfilament Proteins; Middle Aged; Phenotype; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Purinergic P2 Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Sulfonamides; Thrombelastography; Ticlopidine | 2010 |
Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Creatine Kinase, MB Form; Female; Follow-Up Studies; Hematoma; Hemorrhage; Heparin; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Count; Premedication; Retreatment; Sex Factors; Stents; Ticlopidine; Troponin T; Whole Blood Coagulation Time | 2009 |
Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST).
Topics: Administration, Oral; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Treatment Outcome | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Female; Humans; Leukocytes; Male; Obesity; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Ticlopidine | 2010 |
Reasonable duration of Clopidogrel use after drug-eluting stent implantation in Korean patients.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Korea; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
In-hospital outcomes of contemporary percutaneous coronary intervention in patients with chronic total occlusion insights from the J-CTO Registry (Multicenter CTO Registry in Japan).
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Female; Humans; Inpatients; Japan; Length of Stay; Male; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Predictive Value of Tests; Prospective Studies; Stents; Stroke; Thrombosis; Ticlopidine; Treatment Outcome | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Double-Blind Method; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2010 |
Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) st
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Blood Proteins; Cell Adhesion Molecules; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Follow-Up Studies; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Prognosis; Prospective Studies; Ticlopidine; Treatment Outcome | 2010 |
Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Esomeprazole; Female; Humans; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Regression Analysis; Stents; Ticlopidine | 2010 |
Ticagrelor, a new antiplatelet agent, for prevention of ischemic events in patients with coronary artery disease.
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ischemia; Male; Platelet Aggregation Inhibitors; Proportional Hazards Models; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC study.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Drug-Eluting Stents; Drugs, Generic; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Compliance; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine | 2010 |
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous
Topics: Administration, Oral; Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Tolerance; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Ticlopidine; Time Factors; Treatment Outcome; Troponin; Young Adult | 2010 |
Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: results of the double-blind, randomized CASSANDRA study.
Topics: Clopidogrel; Comorbidity; Coronary Artery Disease; Double-Blind Method; Endothelium, Vascular; Evidence-Based Medicine; Female; Germany; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Ticlopidine; Treatment Outcome; Vasculitis | 2011 |
A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atorvastatin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Drug-Eluting Stents; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Prosthesis Design; Pyrroles; Switzerland; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy.
Topics: Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Individuality; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2010 |
Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug-Eluting Stents; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Patient Readmission; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Renal Insufficiency; Self Medication; Thrombosis; Ticlopidine | 2010 |
Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Rabeprazole; Ticlopidine; Treatment Outcome | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2010 |
Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial.
Topics: Administration, Oral; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Saphenous Vein; Ticlopidine; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vascular Patency | 2010 |
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
Topics: Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Double-Blind Method; Genotype; Humans; Male; Middle Aged; Pharmacokinetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
Effect of omeprazole on the concentration of interleukin-6 and transforming growth factor-β1 in patients receiving dual antiplatelet therapy after percutaneous coronary intervention.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Biomarkers; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Expression Regulation; Humans; Interleukin-6; Male; Middle Aged; Omeprazole; Platelet Aggregation Inhibitors; Predictive Value of Tests; Ticlopidine; Transforming Growth Factor beta1; Treatment Outcome | 2010 |
Pretreatment with different loading doses of clopidogrel influences P-selectin levels in patients undergoing percutaneous coronary intervention: results from the ARMYDA-2 (antiplatelet therapy for reduction of myocardial damage during angioplasty) SELECT
Topics: Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Biomarkers; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Female; Heart Diseases; Humans; Italy; Male; Middle Aged; P-Selectin; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Time Factors; Treatment Outcome; Troponin I | 2011 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Hyperplasia; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Saphenous Vein; Ticlopidine; Treatment Outcome; Tunica Intima; Ultrasonography, Interventional | 2010 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine; Treatment Outcome; Young Adult | 2011 |
Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.
Topics: Acute Coronary Syndrome; Administration, Cutaneous; Age Factors; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Stents; Stroke; Thrombocytopenia; Ticlopidine; Treatment Outcome | 2011 |
A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Sten
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Radiography; Tetrazoles; Ticlopidine; Treatment Outcome | 2011 |
Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot).
Topics: Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Coagulation; C-Reactive Protein; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Dinoprost; Double-Blind Method; Down-Regulation; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Fibrin; Humans; Linear Models; Male; Middle Aged; Oxidative Stress; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Poland; Prospective Studies; Prothrombin; Thrombin; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Cytochrome P-450 CYP2C19; DNA; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Polymerase Chain Reaction; Polymorphism, Genetic; Preoperative Period; Prognosis; Prospective Studies; Stents; Ticlopidine | 2011 |
Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Confidence Intervals; Coronary Angiography; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Logistic Models; Male; Middle Aged; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Risk Factors; Sirolimus; Statistics as Topic; Statistics, Nonparametric; Switzerland; Ticlopidine; Titanium | 2011 |
Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors | 2011 |
The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies.
Topics: Adenosine; Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study.
Topics: Aged; Biomarkers; C-Reactive Protein; CD40 Ligand; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Inflammation; Interleukin-6; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Thromboxane B2; Ticlopidine; Time Factors; Withholding Treatment | 2011 |
CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention.
Topics: Clopidogrel; Comorbidity; Coronary Artery Disease; Cytokines; Female; Genetic Predisposition to Disease; Greece; Humans; Male; Platelet Activation; Platelet Aggregation Inhibitors; Prevalence; Stents; Thrombosis; Ticlopidine; Treatment Outcome | 2012 |
Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel.
Topics: Aged; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Pentoxifylline; Phosphodiesterase Inhibitors; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Receptors, Purinergic P2Y12; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP1A2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Smoking; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel.
Topics: Aged; Chronic Disease; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Thiophenes; Ticlopidine; Treatment Outcome | 2011 |
Incidence, predictors, and 30-day outcomes of new-onset atrial fibrillation after primary percutaneous coronary intervention: insight into the RISK-PCI trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Female; Hospital Mortality; Humans; Incidence; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Serbia; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney di
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Chronic Disease; Cilostazol; Clopidogrel; Coronary Artery Disease; Female; Humans; Kidney Diseases; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Renal Dialysis; Tetrazoles; Ticlopidine | 2011 |
Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Young Adult | 2012 |
Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease.
Topics: Adult; Aged; Blood Platelets; Cell Movement; Cell-Derived Microparticles; Clopidogrel; Coronary Artery Disease; Endothelial Cells; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Protective Agents; Purinergic P2Y Receptor Antagonists; Stem Cells; Ticlopidine | 2012 |
Description of response to aspirin and clopidogrel in outpatients with coronary artery disease using multiple electrode impedance aggregometry.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Placental Function Tests; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2012 |
A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.
Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetic Angiopathies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Radiography; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Tetrazoles; Ticlopidine; Treatment Outcome | 2013 |
[High maintenance dose of clopidogrel improves long-term clinical outcomes in patients with elective percutaneous coronary intervention].
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Treatment Outcome | 2012 |
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
Topics: Adenosine Diphosphate; Aspirin; Atorvastatin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Drug Substitution; Drug Therapy, Combination; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ticlopidine | 2012 |
Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies.
Topics: Adenosine; Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Interactions; Female; Humans; Male; Middle Aged; Platelet Aggregation; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2012 |
A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2012 |
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.
Topics: Adenosine Monophosphate; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Survival Analysis; Ticlopidine; Treatment Outcome | 2012 |
Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism.
Topics: Administration, Cutaneous; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Synergism; Fatty Acids, Omega-3; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prospective Studies; Ticlopidine | 2012 |
Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prodrugs; Ticlopidine; Time Factors | 2012 |
Tranexamic Acid in on-pump coronary artery bypass grafting without clopidogrel and aspirin cessation: randomized trial and 1-year follow-up.
Topics: Antifibrinolytic Agents; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Time Factors; Tranexamic Acid; Treatment Outcome | 2013 |
Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Topics: Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Substitution; Female; Genotype; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Rome; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prospective Studies; Stroke; Survival Rate; Ticlopidine | 2013 |
Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease.
Topics: Analysis of Variance; Arachidonic Acid; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administration Schedule; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2012 |
Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2013 |
Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: rationale and design of a large-scale, randomized, multicenter study.
Topics: Adult; Aspirin; Brazil; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Period; Prospective Studies; Research Design; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome; Young Adult | 2012 |
Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry.
Topics: Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Follow-Up Studies; Humans; Immunosuppressive Agents; Paclitaxel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recurrence; Registries; Retrospective Studies; Sirolimus; Survival Rate; Ticlopidine; Time Factors; Treatment Outcome; United States | 2013 |
Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial.
Topics: Aged; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2014 |
Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninfe
Topics: Aged; Blood Platelets; Cerebrovascular Disorders; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Republic of Korea; Therapeutic Equivalency; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes.
Topics: Adult; Aged; Alleles; Chromosomes, Human, Pair 1; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Genome-Wide Association Study; Genotype; Humans; Male; Middle Aged; Odds Ratio; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Receptors, Cell Surface; Ticlopidine | 2013 |
Oral antiplatelet therapies have no effect on circulating levels of RANTES in patients with coronary artery disease.
Topics: Aged; Angina, Unstable; Chemokine CCL5; Chemokines; Clopidogrel; Coronary Artery Disease; Female; Heart Failure; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine | 2002 |
A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents.
Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Stents; Survival Rate; Ticlopidine; Time Factors | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Resistance; Female; Flow Cytometry; Genetic Variation; Humans; Male; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Ticlopidine | 2003 |
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Female; Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Stroke; Ticlopidine; Treatment Outcome | 2003 |
Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Diabetes Complications; Elective Surgical Procedures; Endpoint Determination; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk; Stents; Ticlopidine | 2004 |
What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis.
Topics: Aged; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Postoperative Complications; Risk Factors; Stents; Ticlopidine; Treatment Outcome | 2005 |
Inter-individual variability in response to clopidogrel in patients with coronary artery disease.
Topics: Adult; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors; Treatment Outcome | 2005 |
High stability of blood samples for flow cytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Ticlopidine | 2005 |
Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Genotype; Humans; Integrin beta3; Male; P-Selectin; Peptide Fragments; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Prothrombin; Thrombosis; Ticlopidine; Time Factors | 2005 |
Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease.
Topics: Aged; Biomarkers; C-Reactive Protein; CD40 Ligand; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine | 2006 |
Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination.
Topics: Adenosine Diphosphate; Antigens, Human Platelet; Aspirin; Blood Platelets; Clopidogrel; Collagen; Coronary Artery Disease; Cytoplasmic Granules; Epinephrine; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Ticlopidine | 2006 |
The influence of body mass index on outcomes and the benefit of antiplatelet therapy following percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Body Mass Index; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Regression Analysis; Ticlopidine; Time Factors; Treatment Outcome | 2006 |
Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Monitoring, Physiologic; Platelet Aggregation; Platelet Function Tests; Predictive Value of Tests; Ticlopidine; Whole Blood Coagulation Time | 2007 |
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2006 |
Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects.
Topics: Acetylcholine; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Biological Availability; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Inhibitors; Humans; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Ticlopidine; Vasodilation; Vasodilator Agents | 2006 |
Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study.
Topics: Aged; Cells, Cultured; Chemokines; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Endothelium, Vascular; Female; Gene Expression Regulation; Humans; Immunoenzyme Techniques; Leukocytes, Mononuclear; Male; Middle Aged; Placebos; Platelet Aggregation Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Ticlopidine | 2006 |
Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Collagen; Coronary Artery Disease; Diabetes Complications; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Receptors, Thrombin; Thrombosis; Ticlopidine | 2006 |
Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'.
Topics: Adenosine Diphosphate; Adult; Aspirin; Bayes Theorem; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Resistance; Female; Humans; Male; Middle Aged; Models, Cardiovascular; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Reference Values; Severity of Illness Index; Ticlopidine; Time Factors | 2007 |
Effects of Erigeron injection on vascular endothelium in patients after intracoronary stenting.
Topics: C-Reactive Protein; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Endothelin-1; Endothelium, Vascular; Erigeron; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nitric Oxide; Phytotherapy; Plant Preparations; Platelet Aggregation Inhibitors; Stents; Superoxide Dismutase; Ticlopidine | 2006 |
Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation.
Topics: Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Disease-Free Survival; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Regression Analysis; Stents; Ticlopidine; Treatment Failure | 2006 |
The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Ticlopidine; Treatment Outcome | 2006 |
Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Stents; Ticlopidine; Treatment Outcome | 2006 |
Impact of P-glycoprotein on clopidogrel absorption.
Topics: Administration, Oral; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Caco-2 Cells; Cell Membrane Permeability; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression; Genotype; Humans; Intestinal Absorption; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; RNA, Messenger; Ticlopidine | 2006 |
A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study.
Topics: Aged; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Dilatation, Pathologic; Double-Blind Method; Endothelium, Vascular; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Superoxides; Ticlopidine | 2008 |
Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort.
Topics: Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myocardial Revascularization; Platelet Aggregation Inhibitors; Preoperative Care; Prospective Studies; Registries; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine | 2007 |
Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR).
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Artery Disease; Death; Drug Resistance; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Function Tests; Prevalence; Stroke; Survival Analysis; Ticlopidine; Treatment Outcome | 2007 |
Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Creatine Kinase, MB Form; Drug Resistance; Female; Humans; Male; Middle Aged; Myocardium; Necrosis; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Tablets, Enteric-Coated; Thrombosis; Ticlopidine; Time Factors; Troponin I; Up-Regulation | 2008 |
The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Biomarkers; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Treatment Outcome | 2007 |
The paclitaxel-eluting Coroflex Please stent pilot study (PECOPS I) : the one-year clinical follow-up.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Death; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Paclitaxel; Pilot Projects; Platelet Aggregation Inhibitors; Prospective Studies; Survival Rate; Thrombosis; Ticlopidine; Tubulin Modulators | 2007 |
Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Eptifibatide; Female; Heparin; Humans; Male; Middle Aged; Peptides; Pilot Projects; Platelet Aggregation Inhibitors; Prospective Studies; Pyridines; Ticlopidine; Treatment Outcome | 2007 |
Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial).
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug Delivery Systems; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Stents; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome; Tunica Intima | 2007 |
TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; Epidemiologic Methods; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Revascularization; Paclitaxel; Platelet Aggregation Inhibitors; Polymers; Ticlopidine | 2007 |
Clopidogrel desensitization after drug-eluting stent placement.
Topics: Clopidogrel; Coronary Artery Disease; Desensitization, Immunologic; Drug Hypersensitivity; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2007 |
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; C-Reactive Protein; CD40 Ligand; Clopidogrel; Collagen; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Electrocardiography, Ambulatory; Exercise Test; Flow Cytometry; Heart Rate; Humans; Interleukin-6; Leukocytes; Male; Middle Aged; Myocardial Ischemia; P-Selectin; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Research Design; Stress, Physiological; Thrombin; Ticlopidine; Treatment Outcome | 2007 |
[Effects of intensive antiplatelet therapy in patients with high platelet aggregability after percutaneous coronary intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Ticlopidine | 2007 |
Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Diabetes Complications; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Male; Middle Aged; Tetrazoles; Ticlopidine; Treatment Outcome | 2008 |
Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Florida; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Research Design; Spain; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events.
Topics: Age Factors; Aged; Anti-Inflammatory Agents; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Collagen; Coronary Artery Disease; Dipyridamole; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Odds Ratio; Platelet Aggregation; Recurrence; Stroke; Ticlopidine; Time Factors; Treatment Failure | 2008 |
Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2008 |
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Diabetes Mellitus; Diabetic Angiopathies; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Hyperplasia; Male; Middle Aged; Platelet Aggregation Inhibitors; Tetrazoles; Ticlopidine; Treatment Outcome; Tunica Intima | 2008 |
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Chromium Alloys; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Polymers; Risk; Thromboembolism; Ticlopidine; Time Factors | 2008 |
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
Topics: Aged; Antidotes; Aptamers, Nucleotide; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Combinations; Factor IXa; Female; Humans; Male; Middle Aged; Oligonucleotides; Ticlopidine; Treatment Outcome | 2008 |
Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Fibrinogen; Fibrinolytic Agents; Humans; Perfusion; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2000 |
Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Preoperative Care; Stents; Ticlopidine | 2002 |
Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the setting of early percutaneous coronary intervention for acute coronary syndromes.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Peptides; Pilot Projects; Platelet Aggregation Inhibitors; Preoperative Care; Ticlopidine; Treatment Outcome | 2002 |
561 other study(ies) available for clopidogrel and Coronary Artery Disease
| Article | Year |
|---|---|
Platelet reactivity and clinical outcomes following percutaneous coronary intervention in complex higher-risk patients.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Assessment; Thrombosis | 2022 |
In-hospital Bleeding Outcomes of Oral Anticoagulant and Dual Antiplatelet Therapy During Percutaneous Coronary Intervention: An Analysis From the Japanese Nationwide Registry.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Japan; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Registries; Retrospective Studies; Warfarin | 2021 |
Influence of
Topics: Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; MicroRNAs; Platelet Aggregation Inhibitors; Ticlopidine | 2021 |
Association between Paraoxonase-1 p.Q192R Polymorphism and Coronary Artery Disease susceptibility in the Colombian Population.
Topics: Aryldialkylphosphatase; Clopidogrel; Colombia; Coronary Artery Disease; Genotype; Humans; Platelet Aggregation Inhibitors | 2021 |
Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Retrospective Studies; Ticlopidine; Treatment Outcome | 2022 |
Clopidogrel Monotherapy More Effective Than Aspirin to Prevent Coronary Events After PCI With Drug-Eluting Stents.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Treatment Outcome | 2022 |
Circadian variations of platelet reactivity on clopidogrel in patients treated with elective percutaneous coronary intervention.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2022 |
Dual Antiplatelet Therapy Discontinuation, Platelet Reactivity, and Adverse Outcomes After Successful Percutaneous Coronary Intervention.
Topics: Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Treatment Outcome | 2022 |
Future of antithrombotic therapy for heart failure with coronary artery disease.
Topics: Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Heart Failure; Humans; Ticlopidine | 2022 |
New Insights Into Long- Versus Short-Term Dual Antiplatelet Therapy Duration in Patients After Stenting for Left Main Coronary Artery Disease: Findings From a Prospective Observational Study.
Topics: Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stents; Treatment Outcome | 2022 |
Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Cholesterol; Clopidogrel; Cohort Studies; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Elevated serum C1q is an independent predictor of high residual platelet reactivity in CAD patients receiving clopidogrel therapy.
Topics: Adenosine; Adenosine Diphosphate; Clopidogrel; Complement C1q; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor; Ticlopidine | 2022 |
On-Treatment Platelet Reactivity and Ischemic Outcomes in Patients With Diabetes Mellitus: Two-Year Results From ADAPT-DES.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Humans; Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Treatment Outcome | 2023 |
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneou
Topics: Aspirin; Cardiology; Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Stroke; Ticagrelor | 2023 |
Decreased platelet miR-199a-5p level might lead to high on-clopidogrel platelet reactivity in patients with coronary artery disease.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; MicroRNAs; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine | 2023 |
[Debate on dual pathway inhibition: Antiplatelet therapy in patients with peripheral artery disease: old but gold?]
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors | 2023 |
Impact of the Xinsorb Scaffold-Related Parameters on Platelet Reactivity in Patients with Single De Novo Coronary Artery Lesions Undergoing Clopidogrel Treatment.
Topics: Cholesterol; Clopidogrel; Coronary Artery Disease; Humans; Lipoproteins, HDL; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Prescription patterns of P2Y12 inhibitors following revascularization in the United States: 2013-2018.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Prescriptions; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome; United States | 2023 |
[Comparison of Various Regimens of Antithrombotic Therapy in Patients With Valvular Heart Disease and Coronary Artery Disease After Surgical and Interventional Interventions].
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Fibrinolytic Agents; Heart Valve Diseases; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thromboembolism; Treatment Outcome | 2023 |
Understanding the Effects of NOAC Combined with Antiplatelet Therapy on Clot Kinetics.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Dimaprit; Humans; Kinetics; Platelet Aggregation Inhibitors; Pyridines; Thiazoles | 2020 |
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.
Topics: Aged; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Decision Support Techniques; Europe; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Predictive Value of Tests; Risk Assessment; Risk Factors; Stents; Stroke; Treatment Outcome | 2020 |
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndrome and Stable Coronary Artery Disease.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticagrelor; Ticlopidine | 2019 |
Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention.
Topics: Aged; Biomarkers; Blood Glucose; Blood Platelets; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Treatment Outcome | 2019 |
Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Germany; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Registries; Renal Dialysis; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Interaction Between Diabetes Mellitus and Platelet Reactivity in Determining Long-Term Outcomes Following Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Diabetes Mellitus; Drug Resistance; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Risk Factors; Stents; Time Factors; Treatment Outcome | 2020 |
Long-Term Efficacy of Extended Dual Antiplatelet Therapy After Left Main Coronary Artery Bifurcation Stenting.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Registries; Republic of Korea; Retrospective Studies; Survival Rate; Time Factors | 2020 |
MAPT (Mono Antiplatelet Therapy) as Regular Regimen After COBRA PzF™ NanoCoated Coronary Stent (NCS) Implantation.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Chromium Alloys; Clopidogrel; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thrombosis; Female; Hemorrhage; Humans; Male; Organophosphorus Compounds; Platelet Aggregation Inhibitors; Polymers; Prospective Studies; Prosthesis Design; Registries; Risk Assessment; Risk Factors; Stents; Time Factors; Treatment Outcome | 2020 |
Clopidogrel Responsiveness in Patients With Decompensated Cirrhosis of the Liver Undergoing Pre-Transplant PCI.
Topics: Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Resistance; Humans; Liver Cirrhosis; Liver Transplantation; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Waiting Lists | 2020 |
Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Thromboembolism; Ticagrelor; Treatment Outcome; Warfarin | 2020 |
Impact of Anemia on the Risk of Bleeding Following Percutaneous Coronary Interventions in Patients ≥75 Years of Age.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Angina, Unstable; Anticoagulants; Antithrombins; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug-Eluting Stents; Female; Gastrointestinal Hemorrhage; Hemorrhage; Heparin; Hirudins; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Hemorrhage; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Risk Assessment; Stents; Ticagrelor; Urologic Diseases | 2020 |
Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR).
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor | 2021 |
Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Genetic polymorphisms of high platelet reactivity in Chinese patients with coronary heart disease under clopidogrel therapy.
Topics: Aged; Asian People; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide | 2020 |
Ischemic Versus Bleeding Outcomes After Percutaneous Coronary Interventions in Patients With High Bleeding Risk.
Topics: Aged; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Artery Disease; Dual Anti-Platelet Therapy; Female; Gastrointestinal Hemorrhage; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prevalence; Renal Insufficiency; Risk; Risk Assessment; Stents; Thrombosis | 2020 |
Coronary stent embolism to the right posterior cerebral artery.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Atropine; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Coronary Vessels; Drug Therapy, Combination; Embolism; Follow-Up Studies; Heart Arrest; Humans; Male; Middle Aged; Parasympatholytics; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Posterior Cerebral Artery; Prosthesis Failure; Stents; Treatment Outcome | 2020 |
Early dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass surgery: survival and safety outcomes.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium.
Topics: Aged; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genome-Wide Association Study; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Risk Assessment; Risk Factors; Treatment Outcome | 2020 |
Reduction in Osteoarthritis Risk After Treatment With Ticagrelor Compared to Clopidogrel: A Propensity Score-Matching Analysis.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Female; Humans; Incidence; Male; Middle Aged; Osteoarthritis; Platelet Aggregation Inhibitors; Propensity Score; Purinergic P2Y Receptor Antagonists; Risk; Ticagrelor; Treatment Outcome | 2020 |
Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Coronary Artery Disease; Dual Anti-Platelet Therapy; Endarterectomy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2020 |
CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019.
Topics: Aged; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfamily B; China; Clopidogrel; Comorbidity; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Ethnicity; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Purinergic P2Y Receptor Antagonists | 2020 |
Clinical outcomes of patients treated using very short duration dual antiplatelet therapy after implantation of biodegradable-polymer drug-eluting stents: rationale and design of a prospective multicenter REIWA registry.
Topics: Absorbable Implants; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Observational Studies as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Prasugrel Hydrochloride; Prospective Studies; Registries; Time Factors; Treatment Outcome | 2020 |
Thrombosis of a Percutaneous Transcatheter Mitral Valve Implant and Its Treatment.
Topics: Anticoagulants; Bioprosthesis; Cardiac Catheterization; Clopidogrel; Coronary Artery Disease; Echocardiography; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Male; Middle Aged; Mitral Valve; Mitral Valve Insufficiency; Postoperative Complications; Pulmonary Disease, Chronic Obstructive; Pyrazoles; Pyridones; Thrombosis; Treatment Outcome; Withholding Treatment | 2020 |
Distribution of CYP2C19, ABCB1 and PON1 polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease.
Topics: Adult; Aged; Alleles; Aryldialkylphosphatase; Asian People; ATP Binding Cassette Transporter, Subfamily B; China; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Ethnicity; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Phenotype; Polymorphism, Single Nucleotide | 2020 |
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Platelet Aggregation Inhibitors; Precision Medicine; Risk Assessment; Risk Factors; Thrombosis; Time Factors; Treatment Outcome; United States | 2021 |
Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Ticagrelor; Treatment Outcome | 2021 |
Serum uric acid level negatively correlated with the prevalence of clopidogrel low response in patients undergoing antiplatelet treatment with aspirin and clopidogrel.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Drug Resistance; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Treatment Outcome; Up-Regulation; Uric Acid | 2020 |
Association of fractalkine with functional severity of heart failure and impact on clopidogrel efficacy in patients with ischemic heart disease.
Topics: Blood Platelets; Chemokine CX3CL1; Clopidogrel; Coronary Artery Disease; Heart Failure; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Stroke Volume; Ticlopidine; Ventricular Function, Left | 2020 |
Ticagrelor in the management of coronary artery disease.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2021 |
Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease.
Topics: Aged; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Dual Anti-Platelet Therapy; Female; Genotype; Humans; Male; Middle Aged; Oxygenases; Platelet Aggregation Inhibitors; Polymorphism, Genetic | 2021 |
Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI.
Topics: Anticoagulants; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Dual Anti-Platelet Therapy; Duration of Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Mortality; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Proportional Hazards Models; Registries; Risk Assessment; Stroke | 2021 |
CARDIOVASCULAR EVENT ASSESSMENT IN PATIENTS WITH NONOBSTRUCTIVE CORONARY ARTERY DISEASE UNDERGOING DUAL ANTIPLATELET TREATMENT.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2020 |
Intermittent concurrent use of clopidogrel and proton pump inhibitors did not increase risk of adverse clinical outcomes in Chinese patients with coronary artery disease.
Topics: China; Clopidogrel; Coronary Artery Disease; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2021 |
The expression profile of platelet-derived miRNA in coronary artery disease patients with clopidogrel resistance.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Resistance; Dual Anti-Platelet Therapy; Female; Gene Expression Profiling; Humans; Male; MicroRNAs; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation | 2021 |
TMAO: a potential mediator of clopidogrel resistance.
Topics: Animals; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Disease; Disease Models, Animal; Drug Resistance; Male; Methylamines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Rats | 2021 |
Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Republic of Korea; Stroke; Thrombosis; Treatment Outcome | 2021 |
Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery.
Topics: Aspirin; Beijing; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Dual Anti-Platelet Therapy; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Survival Rate; Treatment Outcome | 2021 |
The association of polymorphisms in related circadian rhythm genes and clopidogrel resistance susceptibility.
Topics: Adult; Aged; Aged, 80 and over; Calcium Channels, L-Type; Circadian Rhythm; CLOCK Proteins; Clopidogrel; Cohort Studies; Coronary Artery Disease; Cryptochromes; Drug Resistance; Female; Genotype; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Protein Kinase C | 2021 |
Polymorphisms in the GCK gene increase the risk of clopidogrel resistance in stable coronary artery disease (SCAD) patients.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug Resistance; Glucokinase; Humans; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide | 2021 |
Differential Impact of Clinical and Genetic Factors on High Platelet Reactivity in Patients with Coronary Artery Disease Treated with Clopidogrel and Prasugrel.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Renal Insufficiency, Chronic; Ticlopidine | 2022 |
Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding: Insights from the Warfarin and Coronary Stenting (War-Stent) Registry.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Stents; Thrombolytic Therapy; Ticlopidine; Treatment Outcome; Warfarin; Young Adult | 2017 |
On-clopidogrel platelet reactivity as predictor for long-term clinical outcome in patients after planned discontinuation of clopidogrel.
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Administration Schedule; Drug Resistance; Female; Germany; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Heterozygote; Homozygote; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome; Vitamin D Deficiency; Vitamin D-Binding Protein | 2017 |
Total Thrombus-formation Analysis System Predicts Periprocedural Bleeding Events in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Intraoperative Complications; Male; Microchip Analytical Procedures; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Risk Assessment; Ticlopidine | 2017 |
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Fibrinolytic Agents; Hemorrhage; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prevalence; Proportional Hazards Models; Republic of Korea; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome; Warfarin | 2017 |
Platelet distribution width as the prognostic marker in coronary bifurcation treatment.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Myocardial Revascularization; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recurrence; Ticlopidine; Treatment Outcome | 2017 |
Impact of mean platelet aggregation degree on long-term clinical outcomes among patients undergoing a complex percutaneous coronary intervention.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Discussion.
Topics: Clopidogrel; Coronary Artery Disease; Follow-Up Studies; Humans | 2018 |
Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study).
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Female; Germany; Graft Occlusion, Vascular; Humans; Incidence; Israel; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Quebec; Registries; Risk Assessment; Risk Factors; Survival Rate; Ticlopidine; United States | 2017 |
Platelet reactivity unit (PRU) in patients undergoing elective PCI: Rethinking the optimal cut point.
Topics: Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors | 2017 |
Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Preoperative Care; Prospective Studies; Registries; Retrospective Studies; Ticlopidine; Time Factors; Withholding Treatment | 2017 |
The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients.
Topics: Asian People; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Humans; Male; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2017 |
Topics: Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Proton Magnetic Resonance Spectroscopy; Ticlopidine | 2017 |
Antiplatelet therapy after coronary bypass surgery: "Broken portions" and "uncertainty" in the search for "absolute truth".
Topics: Clopidogrel; Coronary Artery Disease; Follow-Up Studies; Humans; Platelet Aggregation Inhibitors; Uncertainty | 2018 |
Impact of Long-Term Dual Antiplatelet Therapy on Immature Platelet Count and Platelet Reactivity.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Ticagrelor | 2018 |
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2017 |
Pharmacometabolomics analysis of plasma to phenotype clopidogrel high on treatment platelets reactivity in coronary artery disease patients.
Topics: Aged; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Monitoring; Drug Resistance; Female; Genotype; Humans; Male; Metabolomics; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Phenotype; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Proton Magnetic Resonance Spectroscopy; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2018 |
CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention.
Topics: Adult; Aged; Aged, 80 and over; Clinical Decision-Making; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Gene Frequency; Genotype; Humans; Iraq; Male; Middle Aged; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Platelet Aggregation Inhibitors; Precision Medicine; Risk Factors; Treatment Outcome | 2018 |
Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response.
Topics: Aged; Arsenicals; Aspirin; Biomarkers; Blood Coagulation; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Resistance; Female; Flow Cytometry; Glutathione; Humans; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests | 2018 |
Platelet Inhibition and Bleeding in Patients Undergoing Non-Cardiac Surgery-The BIANCA Observational Study.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Hemorrhage; Preoperative Care; Prospective Studies; Risk Factors; Stents; Time Factors; Time-to-Treatment; Treatment Outcome | 2018 |
Do practice gaps exist in evidence-based medication prescription at hospital discharge in patients undergoing coronary artery bypass surgery & coronary angioplasty?
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angioplasty; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Coronary Vessels; Drug Prescriptions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Male; Middle Aged; Percutaneous Coronary Intervention; Professional Practice Gaps; Retrospective Studies; Ticlopidine | 2017 |
Impact of Clopidogrel on Mortality in Patients With Acute Heart Failure Stratified by Coronary Artery Disease: Findings From the Arabian Gulf Acute Heart Failure Registry (Gulf CARE).
Topics: Acute Disease; Aged; Clopidogrel; Coronary Artery Disease; Female; Heart Failure; Hospital Mortality; Humans; Male; Middle Aged; Prospective Studies; Registries; Risk Assessment; Risk Factors | 2018 |
Leukocyte miR-223-3p is not associated with
altered platelet responses to clopidogrel in patients with coronary artery disease.
Topics: Adenosine Diphosphate; Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Leukocytes; MicroRNAs; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2018 |
Relationship between high platelet reactivity on clopidogrel and long-term clinical outcomes after drug-eluting stents implantation (PAINT-DES): a prospective, propensity score-matched cohort study.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2018 |
Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Female; Heart Diseases; Hemorrhage; Humans; Male; MicroRNAs; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Vascular Diseases | 2019 |
Effect of Physical Exercise on Platelet Reactivity in Patients with Dual Antiplatelet Therapy.
Topics: Adenosine Diphosphate; Aspirin; Chromogranin A; Clopidogrel; Coronary Artery Disease; Electrocardiography; Exercise; Exercise Tolerance; Humans; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thrombosis; Ticlopidine | 2018 |
Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Germany; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; United States | 2018 |
Predictors of coronary stent thrombosis: a case-control study.
Topics: Aged; Aspirin; Brazil; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prognosis; Prosthesis Design; Risk Factors; Stents | 2018 |
Association between high on-treatment platelet reactivity to clopidogrel and hepatosteatosis in patients undergoing elective stent implantation.
Topics: Case-Control Studies; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Fatty Liver; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Preoperative Period; Prospective Studies; Stents; Ticlopidine; Treatment Outcome | 2018 |
High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Substitution; Female; Humans; Japan; Kidney Failure, Chronic; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Renal Dialysis | 2019 |
Extended Clopidogrel Therapy Beyond 12 Months and Long-Term Outcomes in Patients With Diabetes Mellitus Receiving Coronary Arterial Second-Generation Drug-Eluting Stents.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Treatment Outcome | 2018 |
Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype?
Topics: Adult; Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Cytochrome P-450 CYP2C19; Diabetes Mellitus; Diabetic Angiopathies; Female; Genotype; Heterozygote; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Young Adult | 2018 |
CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han.
Topics: Aged; Asian People; Cell Adhesion Molecules; China; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Ticlopidine; Treatment Outcome | 2018 |
Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Time Factors; Treatment Outcome | 2018 |
Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease.
Topics: Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Coronary Artery Disease; Denmark; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Risk Assessment; Stroke; Warfarin | 2018 |
Response to clopidogrel and of the cytochrome CYP2C19 gene polymorphism.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug-Related Side Effects and Adverse Reactions; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Genotyping Techniques; Hemorrhage; Heterozygote; Humans; Longitudinal Studies; Male; Middle Aged; Pharmacogenomic Testing; Polymorphism, Genetic; Tunisia | 2018 |
Standard- and Low-Dose Ticagrelor After Percutaneous Coronary Intervention: Finding the Balance for Patients With Stable Coronary Artery Disease.
Topics: Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Steel; Ticagrelor | 2018 |
Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Decision Support Techniques; Drug Therapy, Combination; Drug-Eluting Stents; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Registries; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2018 |
The association of clopidogrel and 2-oxo-clopidogrel plasma levels and the 40 months clinical outcome after primary PCI.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Chest Pain; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; ST Elevation Myocardial Infarction; Ticlopidine; Treatment Outcome | 2018 |
Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Effect of P2Y
Topics: Adenosine Monophosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Fibrin Clot Lysis Time; Fibrinolysis; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor | 2019 |
Variable gender-dependent platelet responses to combined antiplatelet therapy in patients with stable coronary-artery disease.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Sex Characteristics | 2018 |
EBUS-TBNA on Patients Receiving Antiplatelet Therapy: Are We Throwing Caution to the Wind?
Topics: Aged; Biopsy, Fine-Needle; Bronchoscopy; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Hemorrhage; Humans; Image-Guided Biopsy; Incidence; Lung Neoplasms; Lymph Nodes; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prospective Studies; Withholding Treatment | 2019 |
Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Cardiac Surgical Procedures; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome | 2019 |
intravenous cangrelor (Kengrexal°) and coronary angioplasty: No advantage over first-line clopidogrel.
Topics: Adenosine Monophosphate; Administration, Intravenous; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome | 2016 |
Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Female; Health Care Costs; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Pharmacogenetics; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Retrospective Studies | 2019 |
Platelet to red cell distribution width ratio for predicting clopidogrel efficacy in patients undergoing percutaneous coronary interventions: insights from the ONSIDE-TEST study.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Erythrocyte Indices; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Random Allocation; ROC Curve; Treatment Outcome | 2019 |
Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention.
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug Resistance; Europe; Female; Genetic Association Studies; Genetic Predisposition to Disease; Hemorrhage; Homozygote; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Soluble Guanylyl Cyclase; Stents; Time Factors; Treatment Outcome | 2019 |
[Differential expression of lncRNA in patients with coronary artery disease plus clopidogrel resistance].
Topics: Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; RNA, Long Noncoding | 2019 |
Letter by Long et al Regarding Article, "Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease".
Topics: Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Steel; Ticagrelor | 2019 |
Pharmacodynamic changes of platelet reactivity status in patients with chronic kidney disease after coronary artery stenting.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Flow Cytometry; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Stents; Time Factors | 2019 |
Association of PON1 gene promoter DNA methylation with the risk of Clopidogrel resistance in patients with coronary artery disease.
Topics: Aged; Aryldialkylphosphatase; Asian People; Clopidogrel; Coronary Artery Disease; CpG Islands; DNA Methylation; Drug Resistance; Dyslipidemias; Gene Expression Regulation; Humans; Middle Aged; Platelet Aggregation Inhibitors; Promoter Regions, Genetic; Regression Analysis | 2019 |
Management of aspirin intolerance in patients undergoing percutaneous coronary intervention. The role of mono-antiplatelet therapy: a retrospective, multicenter, study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stents; Treatment Outcome | 2019 |
Clinical outcomes and predictive model of platelet reactivity to clopidogrel after acute ischemic vascular events.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genotype; Glycated Hemoglobin; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Ischemia; Regression Analysis | 2019 |
Effect of Selective Serotonin Reuptake Inhibitors on Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Retrospective Cohort Study.
Topics: Aged; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Stroke; Treatment Outcome | 2019 |
Multicenter research of bleeding risk between prasugrel and clopidogrel in Japanese patients with coronary artery disease undergoing percutaneous coronary intervention.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stroke; Survival Rate; Time Factors; Treatment Outcome | 2019 |
Dual platelet antiaggregation therapy after myocardial revascularization surgery.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Graft Occlusion, Vascular; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome; Vascular Patency | 2019 |
Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Platelet Reactivity and Early Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention and Treated With Aspirin and Clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Homozygote; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Receptors, Cell Surface; Risk Assessment; Risk Factors; Stents; Time Factors; Treatment Outcome | 2019 |
The Impact of Preoperative Clopidogrel on Outcomes After Coronary Artery Bypass Grafting.
Topics: Aged; Blood Transfusion; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Coronary Artery Disease; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Patient Readmission; Platelet Aggregation Inhibitors; Postoperative Complications; Reoperation; Survival Rate; Treatment Outcome | 2019 |
Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Stents; Stroke | 2020 |
Genotyping and phenotyping CYP3A4\\CYP3A5: no association with antiplatelet effect of clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Alleles; Biomarkers, Pharmacological; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic | 2019 |
Omalizumab for the Treatment of Persistent Drug Induced Urticaria Elicited by Thienopyridines: A Case Report.
Topics: Aged; Anti-Allergic Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug Hypersensitivity; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Omalizumab; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome; Urticaria | 2020 |
Replacement of ticagrelor with clopidogrel complicated with acute in‑stent thrombosis.
Topics: Clopidogrel; Coronary Artery Disease; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Stents; Thrombosis; Ticagrelor | 2019 |
Course of platelet miRNAs after cessation of P2Y12 antagonists.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; MicroRNAs; Middle Aged; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2019 |
CYP2C19 pharmacogenetics in patients undergoing coronary stent placement: Is it time to test everyone?
Topics: Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Standard of Care; Stents; Treatment Outcome | 2019 |
Impact of platelet turnover on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Multivariate Analysis; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prognosis; Proportional Hazards Models; ST Elevation Myocardial Infarction; Stroke | 2019 |
Relationship between drug application and mortality rate in Chinese older coronary artery disease/chronic heart failure patients with and without low glomerular filtration rate.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Asian People; Aspirin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Digoxin; Drug Utilization; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nitrates | 2019 |
Evaluation of platelet reactivity during combined antiplatelet therapy in patients with stable coronary artery disease in relation to diabetes type 2 and the GPIIB/IIIA receptor gene polymorphism.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Fibrinogen; Humans; Integrin beta3; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Prospective Studies; Thromboxane B2 | 2019 |
Association Between Residual Platelet Reactivity on Clopidogrel Treatment and Severity of Coronary Atherosclerosis: Intrinsic Hypercoagulability as a Mediator.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Retrospective Studies; Thrombelastography; Thrombophilia; Ticlopidine | 2019 |
The association of P2Y
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Extracellular Vesicles; Female; Humans; Male; MicroRNAs; Middle Aged; Phosphatidylserines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine | 2013 |
Paraoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after PCI.
Topics: Aged; Aged, 80 and over; Aryldialkylphosphatase; Clopidogrel; Coronary Artery Disease; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenetics; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prospective Studies; Risk Factors; Stents; Ticlopidine | 2013 |
Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
Topics: Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prosthesis Design; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Pharmacological interactions: the next frontier?
Topics: Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyrroles; Ticlopidine | 2013 |
Invited commentary.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Humans; Male; Ticlopidine; Tranexamic Acid | 2013 |
Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Humans; Hypertension; Male; Mean Platelet Volume; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Count; Risk Factors; Stents; Ticlopidine | 2014 |
Soluble P-selectin level correlates with acetylsalicylic acid but not with clopidogrel response in patients with stable coronary artery disease after a percutaneous coronary intervention.
Topics: Aged; Anti-Inflammatory Agents; Aryl Hydrocarbon Hydroxylases; Aspirin; CD40 Ligand; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Microfilament Proteins; Middle Aged; P-Selectin; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2013 |
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients.
Topics: Aged; Aryldialkylphosphatase; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Logistic Models; Male; Middle Aged; Platelet Aggregation Inhibitors; Promoter Regions, Genetic; Ticlopidine; Treatment Outcome | 2013 |
Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Biomarkers, Pharmacological; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C9; Drug Resistance; Drug Therapy, Combination; Female; Gene Frequency; Genetic Association Studies; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2013 |
Aspirin desensitisation for Chinese patients with coronary artery disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Desensitization, Immunologic; Drug Hypersensitivity; Drug-Eluting Stents; Female; Hong Kong; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Ticlopidine; Time Factors | 2013 |
Perioperative management of a neurosurgical patient with a meningioma and recent coronary artery stent.
Topics: Aged; Aspirin; Blood Loss, Surgical; Clopidogrel; Contraindications; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Meningioma; Perioperative Care; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine | 2013 |
The impact of the environment on diseases and drugs.
Topics: Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticlopidine | 2013 |
Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading.
Topics: Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Ticlopidine | 2013 |
Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Function Tests; Polymorphism, Genetic; Proton Pump Inhibitors; Ticlopidine | 2013 |
Pharmacogenomics of anti-platelet therapy focused on peripheral blood cells of coronary arterial disease patients.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Gene Expression; Gene Expression Profiling; Humans; Insulin-Like Growth Factor I; Leukocytes, Mononuclear; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Oligonucleotide Array Sequence Analysis; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptor, IGF Type 1; Ticlopidine; Treatment Outcome | 2013 |
[Clopidogrel resistance of patients with coronary artery disease and its correlation with platelet count and mean platelet volume].
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Prospective Studies; Ticlopidine | 2013 |
The place of newer oral anticoagulants in the treatment of patients with non-valvular atrial fibrillation and coronary artery disease.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Ticlopidine | 2013 |
[Relationship between human platelet antigen-1 gene polymorphism and clopidogrel resistance in patients with coronary artery disease].
Topics: Antigens, Human Platelet; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Genetic Predisposition to Disease; Humans; Integrin beta3; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2013 |
Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Endothelium, Vascular; Female; Humans; Linear Models; Logistic Models; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2Y12; Ticlopidine | 2013 |
P2RY12 gene polymorphisms and effect of clopidogrel on platelet aggregation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Receptors, Purinergic P2Y12; Ticlopidine | 2013 |
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulation; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Disease-Free Survival; Drug Monitoring; Drug Therapy, Combination; Female; Hemorrhage; Humans; International Normalized Ratio; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Risk Factors; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome; Warfarin | 2014 |
An allele-specific PCR system for rapid detection and discrimination of the CYP2C19∗4A, ∗4B, and ∗17 alleles: implications for clopidogrel response testing.
Topics: Alleles; Aryl Hydrocarbon Hydroxylases; Base Sequence; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Genetic Association Studies; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymerase Chain Reaction; Prodrugs; Reference Standards; Sensitivity and Specificity; Sequence Analysis, DNA; Ticlopidine | 2013 |
Cilostazol--a forgotten antiplatelet agent, but does it even matter?
Topics: Cilostazol; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Tetrazoles; Ticlopidine | 2013 |
Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Sirolimus; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Impact of initial clinical presentation on clopidogrel low response.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Female; Humans; Linear Models; Logistic Models; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Clopidogrel results in favourable changes in nitric oxide metabolism in patients undergoing percutaneous coronary intervention.
Topics: Biomarkers; Clopidogrel; Coronary Artery Disease; Cyclic GMP; Humans; Nitrates; Nitric Oxide; Nitrites; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Ticlopidine; Time Factors; Treatment Outcome; Vasodilation; Wales | 2014 |
Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Incidence; Male; Metabolic Syndrome; Middle Aged; Obesity; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stents; Thiophenes; Ticlopidine; United States | 2014 |
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Drug Therapy, Combination; Drug-Eluting Stents; Female; Genotype; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Spontaneous chest wall hematoma with dual antiplatelet therapy.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Follow-Up Studies; Hematoma; Humans; Male; Platelet Aggregation Inhibitors; Thoracic Wall; Ticlopidine; Tomography, X-Ray Computed | 2014 |
Haemodialysis impairs clopidogrel but not aspirin responsiveness in patients with end-stage renal disease. Results of a pilot study.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Male; Middle Aged; Pilot Projects; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Receptors, Purinergic P2Y12; Renal Dialysis; Risk; Ticlopidine | 2014 |
Impact of cigarette smoking on P2Y12 receptor binding activity before and after clopidogrel therapy in patients with coronary artery disease.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Radioligand Assay; Receptors, Purinergic P2Y12; Smoking; Ticlopidine; Treatment Outcome | 2014 |
Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Stroke; Thienopyridines; Ticlopidine; Warfarin | 2014 |
The relationship between fractional flow reserve, platelet reactivity and platelet leukocyte complexes in stable coronary artery disease.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Female; Fractional Flow Reserve, Myocardial; Humans; Leukocytes; Male; Middle Aged; Myocardial Ischemia; Platelet Activation; Platelet Aggregation Inhibitors; Prognosis; Ticlopidine | 2013 |
Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.
Topics: Adenosine Diphosphate; Aged; Angioplasty; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Monocytes; P-Selectin; Peptide Fragments; Percutaneous Coronary Intervention; Peripheral Arterial Disease; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Stents; Ticlopidine | 2014 |
Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy.
Topics: Adult; Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; P-Selectin; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prothrombin; Receptor, PAR-1; Thiophenes; Thrombin; Ticlopidine | 2014 |
Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; Comorbidity; Coronary Artery Disease; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Phenprocoumon; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Ticlopidine; Vitamin K; Warfarin | 2014 |
Impact of chronic kidney disease on platelet reactivity and outcomes of patients receiving clopidogrel and undergoing percutaneous coronary intervention.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Electrocardiography; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prognosis; Prospective Studies; Renal Insufficiency, Chronic; Ticlopidine | 2014 |
Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.
Topics: Adult; Aged; Amino Acid Substitution; Aspirin; Clopidogrel; Coronary Artery Disease; Factor XIII; Female; Fibrin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Thrombelastography; Ticlopidine | 2014 |
Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Gene Frequency; Humans; Indians, North American; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2014 |
Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Republic of Korea; Retrospective Studies; Stroke; Tetrazoles; Ticlopidine; Treatment Outcome | 2015 |
Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Logistic Models; Male; Middle Aged; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Proportional Hazards Models; Recombinant Proteins; Risk Factors; Stents; Ticlopidine | 2014 |
Increased mean platelet volume is associated with non-responsiveness to clopidogrel.
Topics: Adenosine Diphosphate; Blood Platelets; Cells, Cultured; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Platelet Aggregation; Platelet Count; Platelet Function Tests; Ticlopidine | 2014 |
[Unexplained hypereosinophilia: too much or not enough?].
Topics: Clopidogrel; Coronary Artery Disease; Eosinophilia; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients.
Topics: Aged; Clopidogrel; Coronary Artery Disease; DNA Methylation; Drug Resistance; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Promoter Regions, Genetic; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticlopidine; Treatment Failure | 2014 |
Successful multidisciplinary treatment of hilar cholangiocarcinoma in a patient with complicated new-onset coronary artery disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Hepatectomy; Humans; Jejunostomy; Male; Neoadjuvant Therapy; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2014 |
Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus; Female; Genotype; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prospective Studies; Stents; Ticlopidine | 2014 |
Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Factor XIIIa; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombelastography; Ticlopidine | 2015 |
Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Posttreatment platelet reactivity on clopidogrel is associated with the risk of adverse events after off-pump coronary artery bypass.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Bypass, Off-Pump; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; ROC Curve; Ticlopidine | 2014 |
[Association between clopidogrel resistance and polymorphism of platelet adenosine diphosphate receptor in patients with coronary atherosclerotic disease].
Topics: Adolescent; Adult; Aged; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Mutation; Polymorphism, Genetic; Prognosis; Receptors, Purinergic P2Y12; Ticlopidine; Young Adult | 2014 |
The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.
Topics: Adult; Aged; Biomarkers; Blood Platelets; Body Mass Index; Body Size; Body Surface Area; Body Weight; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Drug Dosage Calculations; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Retrospective Studies; Ticlopidine; Treatment Outcome | 2014 |
Comparison of loading with maintenance dose of clopidogrel on platelet reactivity in Chinese with different CYP2C19 genotypes prior to percutaneous coronary intervention.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Prospective Studies; Ticlopidine | 2014 |
The chronovariability of platelet reactivity: a hurdle in the road to personalized antiplatelet therapy?
Topics: Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Platelet Aggregation; Ticlopidine | 2014 |
Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population.
Topics: Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Drug Resistance; Ethnicity; Humans; India; Pharmacogenetics; Platelet Aggregation; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction; Ticlopidine | 2014 |
Evidence of platelet sensitization to ADP following discontinuation of clopidogrel therapy in patients with stable coronary artery disease.
Topics: Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2015 |
[Clinical impact of dual antiplatelet therapy on peptic ulcer disease].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Middle Aged; Peptic Ulcer; Platelet Aggregation Inhibitors; Proportional Hazards Models; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; Ticlopidine | 2014 |
Diabetes mellitus and clopidogrel response variability.
Topics: Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Male; Platelet Aggregation; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2014 |
Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Reference Values; Risk Assessment; Ticlopidine; Treatment Outcome | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Coronary Restenosis; Coronary Stenosis; Diabetes Complications; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Postoperative Complications; Randomized Controlled Trials as Topic; Risk Factors; Ticlopidine | 2014 |
Association of Medicare Part D low-income cost subsidy program enrollment with increased fill adherence to clopidogrel after coronary stent placement.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Databases, Factual; Female; Humans; Insurance Benefits; Male; Medicare Part D; Middle Aged; Outcome Assessment, Health Care; Patient Compliance; Pharmaceutical Services; Platelet Aggregation Inhibitors; Stents; Ticlopidine; United States | 2014 |
[Does dual antiplatelet therapy increase the risk of peptic ulcer disease?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Peptic Ulcer; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aryldialkylphosphatase; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2014 |
Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients.
Topics: Aged; Aspirin; Cardiac Catheterization; Chi-Square Distribution; Clopidogrel; Cohort Studies; Coronary Angiography; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation; Platelet Function Tests; Racial Groups; Risk Assessment; Sex Factors; Thrombelastography; Thrombosis; Ticlopidine; Treatment Outcome | 2014 |
Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; MicroRNAs; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2015 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Registries; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Influence of dual antiplatelet therapy on mean platelet volume in patients with coronary artery disease undergoing percutaneous coronary intervention.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Monitoring; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Mean Platelet Volume; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Impact of C34T P2Y12 genotype on endothelial function and arterial stiffness in patients after percutaneous coronary intervention receiving clopidogrel.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Endothelium, Vascular; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine; Treatment Outcome; Vascular Stiffness | 2014 |
Impact of diabetes mellitus and metabolic syndrome on acute and chronic on-clopidogrel platelet reactivity in patients with stable coronary artery disease undergoing drug-eluting stent placement.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Monitoring; Drug-Eluting Stents; Female; France; Humans; Israel; Male; Metabolic Syndrome; Middle Aged; Odds Ratio; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prognosis; Prospective Studies; Ticlopidine | 2014 |
High platelet reactivity is associated with vascular function in patients after percutaneous coronary intervention receiving clopidogrel.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Postoperative Period; Prospective Studies; Ticlopidine | 2014 |
Dual antiplatelet therapy in patients with a long coronary artery lesion over 30 mm: Determinants and impact on prognosis.
Topics: Administration, Inhalation; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Linear Models; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Retrospective Studies; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected].
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Ticlopidine | 2015 |
Stent selection and antiplatelet therapy duration: one size does not fit all.
Topics: Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Postoperative Complications; Sirolimus; Ticlopidine | 2015 |
Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy.
Topics: Adenosine; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinogen; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Influence of Different β-Blockers on Platelet Aggregation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aspirin; Bisoprolol; Carbazoles; Carvedilol; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Metoprolol; Middle Aged; Nebivolol; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Propanolamines; Prospective Studies; Ticlopidine; Treatment Outcome | 2016 |
Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2015 |
Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug-Eluting Stents; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Metals; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Prosthesis Design; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs | 2015 |
Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease.
Topics: Aged; Alleles; Antigens, Human Platelet; Aspirin; Case-Control Studies; Clopidogrel; Cohort Studies; Comorbidity; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Resistance; Female; Genotype; Humans; India; Integrin beta3; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Risk Factors; Ticlopidine; Treatment Outcome | 2015 |
Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Everolimus; Female; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Sirolimus; Thrombosis; Ticlopidine; Tomography, Optical Coherence | 2016 |
Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting.
Topics: Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cohort Studies; Coronary Artery Disease; Databases, Factual; Diabetes Mellitus; Drug Administration Schedule; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Insulin; Long-Term Care; Male; Medicare; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Postoperative Care; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival Rate; Ticlopidine; Time Factors; Treatment Outcome; United States; Veterans Disability Claims | 2015 |
Low platelet activity predicts 30 days mortality in patients undergoing heart surgery.
Topics: Adenosine Diphosphate; Aged; Aortic Valve; Arachidonic Acid; Area Under Curve; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Erythrocyte Transfusion; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prognosis; Retrospective Studies; Risk Factors; Survival Analysis; Thrombosis; Ticlopidine; Treatment Outcome | 2016 |
Impact of Switching From Prasugrel to Clopidogrel Shortly After a Percutaneous Coronary Intervention Without a Loading Dose of Clopidogrel.
Topics: Clopidogrel; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy.
Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2015 |
Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prosthesis Design; Recurrence; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Concomitant nitrates enhance clopidogrel response during dual anti-platelet therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nitrates; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Ticlopidine; Time Factors; Treatment Outcome; Young Adult | 2016 |
Premature Clopidogrel Discontinuation After Drug-Eluting Stent Placement in a Large Urban Safety-Net Hospital.
Topics: Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Follow-Up Studies; Hospitals, Urban; Humans; Male; Middle Aged; Patient Compliance; Postoperative Period; Prognosis; Retrospective Studies; Ticlopidine; Time Factors; Withholding Treatment | 2016 |
Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population.
Topics: Adenosine; Aged; Aged, 80 and over; Asian People; Biotransformation; Chi-Square Distribution; China; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Monitoring; Female; Genotype; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Phenotype; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy.
Topics: Aged; Area Under Curve; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Cytochrome P-450 CYP2C19; Electrocardiography; Female; Genotype; Humans; Male; Middle Aged; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Thrombosis; Ticlopidine | 2016 |
Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Endovascular Procedures; Female; France; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Outpatients; Platelet Aggregation Inhibitors; Prevalence; Prognosis; Registries; Stroke; Ticlopidine | 2016 |
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hospitalization; Humans; Male; Markov Chains; Monte Carlo Method; Myocardial Infarction; Outcome and Process Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Pyridines; Registries; Stroke; Ticlopidine; Warfarin | 2016 |
Association between high on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention.
Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Risk Factors; Ticlopidine | 2016 |
Prevalence and risk factors of clopidogrel non-response among Saudi patients undergoing coronary angiography.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Female; Humans; In Vitro Techniques; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Prevalence; Risk Factors; Saudi Arabia; Ticlopidine; Treatment Failure | 2016 |
Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor.
Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Fibrinogen; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Triglycerides; Uric Acid | 2016 |
Relationship Between Platelet Reactivity and Culprit Lesion Morphology: An Assessment From the ADAPT-DES Intravascular Ultrasound Substudy.
Topics: Aged; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Drug Resistance; Drug-Eluting Stents; Female; Fibrosis; Germany; Humans; Least-Squares Analysis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography, Interventional; United States | 2016 |
Impact of C34T P2Y12 ADP receptor polymorphism and smoking status on cardiovascular outcome in coronary artery disease patients receiving clopidogrel.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Polymorphism, Genetic; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Smoking; Ticlopidine; Treatment Outcome | 2016 |
Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization.
Topics: Age Factors; Aged; Aged, 80 and over; Cardiac Catheterization; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Medicare; Myocardial Infarction; Myocardial Revascularization; Patient Discharge; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Referral and Consultation; Registries; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; United States | 2016 |
Effects of Arnica comp.-Heel® on reducing cardiovascular events in patients with stable coronary disease.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Plants, Medicinal; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Retrospective Studies; Secondary Prevention; Tablets; Ticlopidine; Treatment Outcome | 2016 |
Trends in P2Y12 Inhibitor Use in Patients Referred for Invasive Evaluation of Coronary Artery Disease in Contemporary US Practice.
Topics: Adenosine; Adult; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Percutaneous Coronary Intervention; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Referral and Consultation; Retrospective Studies; Ticagrelor; Ticlopidine; United States | 2016 |
Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Databases, Factual; Drug Resistance; Drug Therapy, Combination; Female; Homeodomain Proteins; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Transcription Factors; Treatment Outcome; Up-Regulation | 2016 |
[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Alleles; Angina Pectoris; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Genotype; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Tandem Mass Spectrometry; Ticlopidine | 2016 |
Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Female; Humans; Lactones; Male; Myocardial Infarction; Postoperative Hemorrhage; Pyridines; Survival Analysis; Ticlopidine; Treatment Outcome | 2016 |
Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Up-Regulation; Uric Acid | 2016 |
Hospital Variation in Premature Clopidogrel Discontinuation After Drug-Eluting Stent Placement in the Veterans Affairs (VA) Healthcare System.
Topics: Aftercare; Aged; Cardiology; Cause of Death; Clopidogrel; Coronary Artery Disease; Deprescriptions; Drug-Eluting Stents; Female; Hospitals; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Proportional Hazards Models; Retrospective Studies; Risk Factors; Ticlopidine; Time Factors; United States; United States Department of Veterans Affairs | 2016 |
Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Georgia; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Period; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Assessment; Ticlopidine; Time Factors | 2017 |
Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Exome; Female; Galactosyltransferases; Genotype; Humans; Male; Middle Aged; Phenotype; Pilot Projects; Platelet Aggregation Inhibitors; Ticlopidine | 2016 |
Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Ohio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome; Warfarin | 2017 |
[The incidence, clinical characteristics and risk factors of upper gastrointestinal bleeding in patients taking dual antiplatelet therapy after percutaneous coronary intervention in south China].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Coronary Artery Disease; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Peptic Ulcer; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Ticlopidine; Upper Gastrointestinal Tract | 2016 |
The first six-month clinical outcomes and risk factors associated with high on-treatment platelet reactivity of clopidogrel in patients undergoing coronary interventions.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Ticlopidine; Treatment Outcome; Turkey | 2016 |
The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Germany; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Registries; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; United States | 2016 |
Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience.
Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Hemorrhage; Clopidogrel; Coronary Artery Disease; Enoxaparin; Female; Fibrinolytic Agents; Humans; Inappropriate Prescribing; Intracranial Hemorrhages; Lebanon; Male; Middle Aged; Platelet Aggregation Inhibitors; Prescription Drug Misuse; Retrospective Studies; Risk Factors; Stroke; Ticlopidine; Warfarin; Young Adult | 2016 |
Predictors for Side Branch Failure During Provisional Strategy of Coronary Intervention for Bifurcation Lesions (from the Korean Bifurcation Registry).
Topics: Aged; Calcinosis; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Multivariate Analysis; Organ Size; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Registries; Republic of Korea; Risk Factors; Ticlopidine; Treatment Failure | 2016 |
Changes in response to clopidogrel therapy in patients after percutaneous coronary interventions as assessed by different platelet function tests.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2016 |
Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Aged; Aged, 80 and over; Biomarkers; Blood Platelets; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Odds Ratio; Platelet Activation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Vitamin D | 2016 |
Risk of bleeding after hospitalization for a serious coronary event: a retrospective cohort study with nested case-control analyses.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Confidence Intervals; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Hospitalization; Humans; Incidence; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Survival Rate; Ticlopidine; United Kingdom | 2016 |
Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Factors; ROC Curve; Ticlopidine; Treatment Outcome; Vulnerable Populations | 2017 |
The moving target of clopidogrel response variability: new tricks of the old dog?
Topics: Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2016 |
Single versus double antiplatelet therapy in patients undergoing coronary artery bypass grafting with coronary endarterectomy: mid-term results and clinical implications.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Drug Therapy, Combination; Endarterectomy; Female; Follow-Up Studies; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine; Treatment Outcome | 2017 |
High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine; Time Factors | 2016 |
Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphism in South Indian population with clopidogrel therapy.
Topics: Alleles; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; DNA; Female; Gene Frequency; Genotype; Humans; India; Male; Middle Aged; Pharmacogenetics; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ticlopidine; Treatment Outcome | 2017 |
Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.
Topics: Anticoagulants; Antidepressive Agents; Antimetabolites, Antineoplastic; Antitubercular Agents; Arylamine N-Acetyltransferase; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Depressive Disorder; Genotype; Isoniazid; Laboratories, Hospital; Methyltransferases; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Pulmonary Embolism; Ticlopidine; Tuberculosis; Vitamin K Epoxide Reductases; Warfarin | 2017 |
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Aged; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients.
Topics: Alleles; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Subfamily B; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prospective Studies; Ticlopidine | 2017 |
Predictive value of non-fasting remnant cholesterol for short-term outcome of diabetics with new-onset stable coronary artery disease.
Topics: Aged; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clopidogrel; Cohort Studies; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Fibrinogen; Follow-Up Studies; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neutrophils; Prognosis; Proportional Hazards Models; ROC Curve; Ticlopidine; Treatment Outcome | 2017 |
The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Postoperative Complications; Sequence Analysis, DNA; Stents; Thrombosis; Ticlopidine; Treatment Outcome; Turkey | 2017 |
Platelet reactivity in patients carrying the e-NOS G894T polymorphism after a loading dose of aspirin plus clopidogrel.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Nitric Oxide; Nitric Oxide Synthase Type III; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Ticlopidine | 2017 |
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
Topics: Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Propensity Score; Renal Dialysis; Retrospective Studies; Stroke; Survival Rate; Taiwan; Ticlopidine | 2017 |
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Female; Germany; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Propensity Score; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Factors; Sex Factors; Ticlopidine; Time Factors; Treatment Outcome; United States | 2017 |
Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; International Cooperation; Long Term Adverse Effects; Male; Middle Aged; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Factors; ST Elevation Myocardial Infarction; Ticlopidine | 2017 |
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Peripheral Arterial Disease; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Propensity Score; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
[Platelet Metabolism in Clopidogrel Resistant and Sensitive Patients With Ischemic Heart Disease].
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Drug Resistance; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2016 |
Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions.
Topics: Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Drug-Eluting Stents; Female; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Survival Analysis; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents.
Topics: Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Drug-Eluting Stents; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Evidence-Based Medicine; Fibrinolytic Agents; Humans; Primary Prevention; Risk Assessment; Risk Factors; Ticlopidine | 2008 |
Clopidogrel but not Aspirin prevents acute smoking-induced platelet aggregation in patients with stable coronary artery disease.
Topics: Adult; Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Smoking; Ticlopidine | 2009 |
Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease.
Topics: Aged; Aspirin; Baltimore; Biomarkers; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Treatment Outcome | 2008 |
Aspirin resistance an underestimated risk in patients with drug-eluting stents?
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug-Eluting Stents; Graft Occlusion, Vascular; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine | 2008 |
Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease.
Topics: Adenosine Diphosphate; Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Epinephrine; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2008 |
Unprotected left main coronary artery bifurcation stenosis: impact of plaque debulking prior to single sirolimus-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Feasibility Studies; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Sirolimus; Ticlopidine | 2008 |
Identifying clopidogrel resistance during chronic therapy: the case for a biochemical approach.
Topics: Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2008 |
Adrenoreceptors, platelet reactivity and clopidogrel resistance.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Humans; Norepinephrine; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Receptors, Adrenergic, alpha-2; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine; Treatment Failure | 2008 |
Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adrenergic alpha-Antagonists; Aged; Aspirin; Blood Platelets; Clopidogrel; Collagen; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Norepinephrine; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Receptors, Adrenergic, alpha-2; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine; Treatment Failure | 2008 |
Measurement of the platelet retention rate in a column of collagen-coated beads is useful for the assessment of efficacy of antiplatelet therapy.
Topics: Aged; Aspirin; Blood Platelets; Cell Separation; Clopidogrel; Collagen; Coronary Artery Disease; Female; Humans; In Vitro Techniques; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Treatment Outcome | 2009 |
The pursuit of clinically relevant measures of platelet function after antiplatelet drug therapy.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticlopidine; Treatment Failure | 2008 |
Gemcitabine-induced acute coronary syndrome: a case report.
Topics: Antimetabolites, Antineoplastic; Aspirin; Bundle-Branch Block; Clopidogrel; Coronary Artery Disease; Coronary Vasospasm; Deoxycytidine; Electrocardiography; Fatal Outcome; Female; Gemcitabine; Humans; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine | 2009 |
Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Contusions; Coronary Angiography; Coronary Artery Disease; Drug-Eluting Stents; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Observation; Patient Compliance; Platelet Aggregation Inhibitors; Severity of Illness Index; Ticlopidine | 2008 |
The treatment of clopidogrel resistance: triple antiplatelet therapy and future directions.
Topics: Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Antiplatyhelmintic Agents; Aspirin; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Female; Heparin; Humans; In Vitro Techniques; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Aggregation; Platelet Function Tests; Stents; Ticlopidine; Time Factors; von Willebrand Factor | 2009 |
Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Ischaemia versus bleeding: the art of clinical decision-making.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Decision Making; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2009 |
Evaluation of the platelet count drop method for assessment of platelet function in comparison with "gold standard" light transmission aggregometry.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Reproducibility of Results; Ticlopidine | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Female; Humans; Kaplan-Meier Estimate; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Prospective Studies; Thrombosis; Ticlopidine | 2009 |
Point-of-care platelet function analysis ready for prime time?
Topics: Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Thrombosis; Ticlopidine | 2009 |
The ischaemia/bleeding balance in PCI.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Lactones; Platelet Aggregation Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptors, Thrombin; Severity of Illness Index; Thrombin; Ticlopidine | 2009 |
Prolonged dual antiplatelet therapy improves clinical outcomes in high-risk patients implanted with sirolimus-eluting stents.
Topics: Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Immunosuppressive Agents; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Sirolimus; Ticlopidine; Treatment Outcome | 2009 |
Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg).
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Does the Holy Grail escape us again?
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2009 |
Treatment of multilesion coronary artery disease with simultaneous drug-eluting and bare-metal stent implantation: clinical follow up and angiographic mid-term results.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Databases as Topic; Drug-Eluting Stents; Drug-Related Side Effects and Adverse Reactions; Female; Heparin; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Spontaneous coronary artery dissection and severe hypothyroidism.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Eptifibatide; Fatal Outcome; Female; Humans; Hypothyroidism; Neck Pain; Peptides; Platelet Aggregation Inhibitors; Ticlopidine | 2009 |
Clopidogrel and proton pump inhibitors: gastric protection at expense of vascular benefit?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Proton Pump Inhibitors; Stents; Ticlopidine | 2009 |
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Proton Pump Inhibitors; Stents; Ticlopidine | 2009 |
Early, accurate, non-invasive predictors of left main or 3-vessel disease in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Electrocardiography; Female; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prognosis; Retrospective Studies; Sensitivity and Specificity; Ticlopidine; Troponin T | 2009 |
Use of a thrombelastograph platelet mapping assay for diagnosis of clopidogrel resistance: a case report.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Blood Platelets; Cardiac Catheterization; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Stents; Thrombelastography; Ticlopidine; Warfarin | 2009 |
Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Artery Disease; Databases as Topic; Drug Administration Schedule; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Combined carotid stenting and urgent coronary artery surgery in unstable angina patients with severe carotid stenosis.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon; Anticoagulants; Aspirin; Carotid Stenosis; Clopidogrel; Coronary Artery Bypass; Coronary Artery Bypass, Off-Pump; Coronary Artery Disease; Drug Administration Schedule; Female; Heparin; Humans; Male; Platelet Aggregation Inhibitors; Risk Assessment; Severity of Illness Index; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Administration Schedule; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Korea; Male; Metals; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prosthesis Design; Risk Assessment; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; Durapatite; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Prosthesis Design; Registries; Sirolimus; Stainless Steel; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2008 |
Searching for the ceiling: new reflections on the disposition and metabolism of clopidogrel.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Genotype; Humans; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Thrombosis; Ticlopidine | 2008 |
The excel stent: a good DES, but can we really stop clopidogrel after 6 months?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Platelet Aggregation Inhibitors; Polymers; Prosthesis Design; Risk Assessment; Sirolimus; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Simultaneous hybrid revascularization by carotid stenting and coronary artery bypass grafting: the SHARP study.
Topics: Aged; Angioplasty, Balloon, Coronary; Carotid Arteries; Carotid Artery Diseases; Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Time Factors; Tomography, X-Ray Computed | 2009 |
1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Durapatite; Female; Humans; Intensive Care Units; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymers; Prospective Studies; Sirolimus; Ticlopidine; Time Factors; Ultrasonography | 2009 |
Coronary artery disease: Platelet activity: an obstacle for successful PCI.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Patient Selection; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Assessment; Risk Factors; Stents; Thrombosis; Ticlopidine; Treatment Outcome | 2009 |
Development and validation of a risk scoring model to predict net adverse cardiovascular outcomes after primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: rationale and design of the RISK-PCI study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Longitudinal Studies; Male; Middle Aged; Models, Statistical; Models, Theoretical; Multivariate Analysis; Platelet Aggregation Inhibitors; Research Design; Risk Assessment; Risk Factors; ROC Curve; Ticlopidine; Treatment Outcome | 2009 |
The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Synergism; Female; Flow Cytometry; Humans; Imines; In Vitro Techniques; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyridines; Receptor, PAR-1; Thrombosis; Ticlopidine | 2009 |
Platelet reactivity and stent thrombosis: still some issues to solve.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug-Eluting Stents; Electrodes; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Assessment; Smoking; Thrombosis; Ticlopidine | 2009 |
Prevalence and risk factors for aspirin and clopidogrel resistance in patients with coronary artery disease or ischemic cerebrovascular disease.
Topics: Aged; Aspirin; Blood Pressure; Cerebral Arterial Diseases; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Hemoglobins; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prevalence; Risk Factors; Ticlopidine | 2009 |
Challenge. What is your diagnosis? Answer. Primary nodal diffuse large B-cell lymphoma with secondary cutaneous involvement.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Coronary Artery Disease; Diuretics; Exanthema; Humans; Hydrochlorothiazide; Lisinopril; Lymphoma, Large B-Cell, Diffuse; Male; Platelet Aggregation Inhibitors; Skin Neoplasms; Sotalol; Stents; Ticlopidine | 2009 |
The carina angle-new geometrical parameter associated with periprocedural side branch compromise and the long-term results in coronary bifurcation lesions with main vessel stenting only.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Clopidogrel; Confidence Intervals; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Drug-Eluting Stents; Everolimus; Female; Humans; Image Interpretation, Computer-Assisted; Immunosuppressive Agents; Male; Mathematics; Multivariate Analysis; Odds Ratio; Paclitaxel; Platelet Aggregation Inhibitors; Poland; Registries; Retrospective Studies; Sirolimus; Statistics as Topic; Ticlopidine; Time Factors | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair 10; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Ethnicity; Female; Genome-Wide Association Study; Genotype; Humans; Male; Middle Aged; Pharmacogenetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Ticlopidine; Treatment Outcome | 2009 |
Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2009 |
One-year follow-up of nonrandomized comparison between coronary artery bypass grafting surgery and drug-eluting stent for the treatment of unprotected left main coronary artery disease in elderly patients (aged >or=75 years).
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Confidence Intervals; Coronary Artery Bypass; Coronary Artery Disease; Drug-Eluting Stents; Female; Heparin; Humans; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Platelet Aggregation Inhibitors; Prospective Studies; Stroke Volume; Ticlopidine; Time Factors; Ventricular Function, Left | 2009 |
Side balloon stenting of the left main bifurcation: a three-year angiographic follow-up.
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Humans; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Time Factors | 2009 |
Femoral artery complications after cardiac catheterization: a study of patient profile.
Topics: Aged; Anticoagulants; Cardiac Catheterization; Clopidogrel; Coronary Artery Disease; Female; Femoral Artery; Hematoma; Hemorrhage; Hemostatic Techniques; Heparin; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Punctures; Retrospective Studies; Risk Assessment; Risk Factors; Sex Factors; Ticlopidine | 2010 |
Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Propensity Score; Proton Pump Inhibitors; Retrospective Studies; Stents; Ticlopidine; Treatment Outcome | 2010 |
Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Graft Occlusion, Vascular; Humans; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Treatment Outcome; Young Adult | 2010 |
Prevalence of unresponsiveness to aspirin and/or clopidogrel in patients with stable coronary heart disease.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Ticlopidine | 2009 |
[Basic examination before clinical examination. That is why it is worthwhile to return to the laboratory].
Topics: Aspirin; Biomarkers; Blood Coagulation; CD40 Ligand; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Punctures; Thrombin; Ticlopidine; Veins | 2009 |
Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications.
Topics: Aged; Blood Coagulation Tests; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2010 |
Clopidogrel and calcium-channel blockers: a clinically important interaction?
Topics: Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Drug Combinations; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication.
Topics: Acute Coronary Syndrome; Angina Pectoris; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Disease; Creatine Kinase, MB Form; Diabetes Mellitus; Drug Therapy, Combination; Flow Cytometry; Humans; Myocardium; Necrosis; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors; Treatment Outcome; Troponin I; Up-Regulation | 2010 |
Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients.
Topics: Aged; Alleles; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Coronary Disease; Female; Genotype; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Polymorphism, Genetic; Prospective Studies; Receptors, Purinergic P2; Social Adjustment; Ticlopidine | 2010 |
High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Death, Sudden, Cardiac; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Predictive Value of Tests; Risk Factors; Ticlopidine | 2009 |
Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Body Mass Index; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Complications; Dose-Response Relationship, Drug; Female; France; Genetic Markers; Genotype; Humans; Male; Middle Aged; Monitoring, Physiologic; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Predictive Value of Tests; Prospective Studies; Risk Factors; Ticlopidine | 2009 |
Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Electrodes; Female; Humans; Logistic Models; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; ROC Curve; Sensitivity and Specificity; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Germany; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Risk Assessment; Risk Factors; ROC Curve; Severity of Illness Index; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
There is no place like home after successful percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Evidence-Based Medicine; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Parenteral; Injections; Length of Stay; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors; Radial Artery; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance".
Topics: Aged; Blood Platelets; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Patient Compliance; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Ticlopidine | 2009 |
Aortic thromboembolism successfully treated with anticoagulation and antiplatelet therapy.
Topics: Anticoagulants; Aorta, Thoracic; Arm; Clopidogrel; Coronary Artery Disease; Echocardiography, Transesophageal; Humans; Ischemia; Male; Middle Aged; Platelet Aggregation Inhibitors; Thromboembolism; Ticlopidine; Warfarin | 2009 |
Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions.
Topics: Aged; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Genetic Variation; Humans; Intraoperative Complications; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Premedication; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine | 2009 |
Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Biotransformation; Blood Platelets; Cell Adhesion Molecules; Chromatography, Liquid; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Flow Cytometry; Humans; Linear Models; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Tandem Mass Spectrometry; Ticlopidine | 2010 |
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Female; Follow-Up Studies; Gene Frequency; Genotype; Hemorrhage; Heterozygote; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Risk Factors; Stents; Ticlopidine; Treatment Outcome | 2010 |
Antiplatelet effect of 50-mg maintenance dose of clopidogrel compared to 200 mg ticlopidine: a preliminary study.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Asian People; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Humans; Japan; Male; Middle Aged; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Highlights from Transcatheter Cardiovascular Therapeutics 2009: San Francisco, California, September 21 to 25, 2009.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiac Surgical Procedures; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Heart Valve Diseases; Humans; Myocardial Revascularization; Platelet Aggregation Inhibitors; Retreatment; Stents; Ticlopidine; Treatment Outcome | 2010 |
Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine; Treatment Outcome; Warfarin | 2010 |
Very late drug-eluting stent thrombosis in the perioperative period of endoscopic choledocholithotomy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Endoscopy, Digestive System; Gallstones; Humans; Male; Middle Aged; Perioperative Care; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2009 |
High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Severity of Illness Index; Stents; Ticlopidine; Treatment Outcome | 2010 |
In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coagulants; Collagen; Coronary Artery Disease; Factor VIIa; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Recombinant Proteins; Thrombin; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Triple therapy: the future or from the past?
Topics: Administration, Oral; Anticoagulants; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Revascularization; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prognosis; Risk Factors; Stents; Thromboembolism; Ticlopidine | 2010 |
Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Triple therapy: triple safety or triple danger?
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug Tolerance; Evidence-Based Medicine; Humans; Platelet Aggregation Inhibitors; Risk Assessment; Stents; Thromboembolism; Ticlopidine; Treatment Outcome | 2010 |
Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel.
Topics: Adenosine Diphosphate; Administration, Oral; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multivariate Analysis; Phenprocoumon; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Laser-Assisted; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Pyridines; Retrospective Studies; Risk Factors; Ticlopidine; Treatment Outcome | 2010 |
Role of ticagrelor in clopidogrel nonresponders: resistance is futile?
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "one-stop" hybrid coronary revascularization.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Prospective Studies; Ticlopidine | 2010 |
Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Prospective Studies; Risk Factors; Stroke; Thromboembolism; Ticlopidine; Treatment Outcome; Warfarin | 2010 |
Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Treatment Outcome | 2010 |
Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Disease; Creatine Kinase, MB Form; Female; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Myocardium; Necrosis; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Predictive Value of Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; Troponin I | 2010 |
Platelet inhibition with cangrelor.
Topics: Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Research Design; Ticlopidine | 2010 |
A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Databases, Factual; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2010 |
Plasma sequestration: a good therapy to prevent the deleterious effect of clopidogrel when clopidogrel is used within one to four days of coronary bypass surgery.
Topics: Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Critical Care; Erythrocyte Transfusion; Humans; Length of Stay; Plasmapheresis; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Preoperative Care; Ticlopidine; Time Factors | 2010 |
Antithrombotic management in patients undergoing coronary stent implantation requiring chronic oral anticoagulation: how to balance safety and efficacy?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardium; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2010 |
Rotablation in the drug eluting era: immediate and long-term results from a single center experience.
Topics: Aged; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Aspirin; Atherectomy, Coronary; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel.
Topics: Adenosine Diphosphate; Adult; Area Under Curve; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Synergism; Humans; Male; Middle Aged; Platelet Aggregation; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Rifampin; Ticlopidine | 2010 |
Carotid angioplasty in asymptomatic patients undergoing CABG surgery.
Topics: Aged; Angioplasty, Balloon; Anticoagulants; Carotid Stenosis; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Endarterectomy, Carotid; Feasibility Studies; Female; Heparin; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Severity of Illness Index; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography, Doppler | 2010 |
Effect of 450-mg loading dose of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Asian People; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Glucose; C-Reactive Protein; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cytokines; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoassay; Inflammation; Male; Pilot Projects; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine; Treatment Outcome | 2010 |
Efficiency of preoperative tranexamic Acid in coronary bypass surgery: an analysis correlated with preoperative clopidogrel use.
Topics: Aged; Antifibrinolytic Agents; Blood Transfusion; Clopidogrel; Confidence Intervals; Coronary Artery Bypass; Coronary Artery Disease; Female; Health Status Indicators; Humans; Length of Stay; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Patient Readmission; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Preanesthetic Medication; Prospective Studies; Regression Analysis; Risk Factors; Statistics as Topic; Ticlopidine; Tranexamic Acid; Turkey | 2010 |
Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Patient Readmission; Population Surveillance; Prognosis; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; Survival Rate; Taiwan; Ticlopidine | 2010 |
The H(2)-receptor antagonist ranitidine interferes with clopidogrel-mediated P2Y(12) inhibition in platelets.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Interactions; Female; Histamine H2 Antagonists; Humans; Male; Middle Aged; Platelet Activation; Purinergic P2Y Receptor Antagonists; Ranitidine; Receptors, Purinergic P2Y12; Ticlopidine | 2010 |
In-laboratory high-dose clopidogrel loading: do we need a mirror of diamond for "Armida's garden"?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2010 |
Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon; Aspirin; Blood Platelets; C-Reactive Protein; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Female; Humans; Inflammation; Male; Pilot Projects; Platelet Activation; Stents; Ticlopidine; Treatment Outcome | 2010 |
Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era?
Topics: Aged; Black People; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Patient Compliance; Platelet Aggregation Inhibitors; Regression Analysis; Retrospective Studies; Risk Factors; Social Class; Thrombosis; Ticlopidine; Treatment Outcome; White People | 2010 |
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2 Receptor Antagonists; Risk Factors; ROC Curve; Stents; Ticlopidine | 2010 |
The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Biological Assay; Biomarkers; Blood Platelets; Case-Control Studies; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Predictive Value of Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Sensitivity and Specificity; Ticlopidine; Young Adult | 2011 |
Use of genetics and transcriptomics in the diagnosis and treatment of coronary artery disease.
Topics: Anticoagulants; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Gene Expression Profiling; Genetic Testing; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Warfarin | 2010 |
Intracoronary shear-related up-regulation of platelet P-selectin and platelet-monocyte aggregation despite the use of aspirin and clopidogrel.
Topics: Aged; Aspirin; Blood Platelets; CD11b Antigen; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Flow Cytometry; Humans; Leukocytes; Monocytes; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Up-Regulation | 2011 |
Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Tetrazoles; Ticlopidine | 2010 |
Letter by Lozano et al regarding article, "Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent)".
Topics: Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Humans; Myocardial Infarction; Postoperative Hemorrhage; Prosthesis Implantation; Risk Factors; Survival Analysis; Ticlopidine; Withholding Treatment | 2010 |
Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Body Mass Index; California; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Logistic Models; Longitudinal Studies; Male; Middle Aged; Phenotype; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Predictive Value of Tests; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Ticlopidine | 2010 |
Acceptance of high platelet reactivity as a risk factor: now, what do we do about it?
Topics: Aryl Hydrocarbon Hydroxylases; Body Mass Index; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Genotype; Humans; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Predictive Value of Tests; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Ticlopidine | 2010 |
Interaction of clopidogrel and omeprazole.
Topics: Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2010 |
The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.
Topics: Adenosine Diphosphate; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Asian People; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Republic of Korea; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Hybrid revascularization, comprising coronary artery bypass graft with exclusive arterial conduits followed by early drug-eluting stent implantation, in multivessel coronary artery disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Chi-Square Distribution; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Artery Bypass, Off-Pump; Coronary Artery Disease; Drug-Eluting Stents; Feasibility Studies; Female; France; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2010 |
Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry.
Topics: Aged; Cerebrovascular Disorders; Clopidogrel; Contraindications; Coronary Artery Disease; Drug Interactions; Female; Humans; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Registries; Retrospective Studies; Stroke; Ticlopidine | 2011 |
Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2011 |
Measurement of platelet reactivity of patients with cardiovascular disease on-treatment with acetyl salicylic acid: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Medication Adherence; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Assessment; Risk Factors; Sex Factors; Ticlopidine; Treatment Outcome | 2011 |
An early and simple predictor of severe left main and/or three-vessel disease in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Biomarkers; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Early Diagnosis; Electrocardiography; Female; Heart Conduction System; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Ticlopidine; Treatment Outcome; Troponin T | 2011 |
Frequency and location of yellow and disrupted coronary plaques in patients as detected by angioscopy.
Topics: Acute Coronary Syndrome; Aged; Angioscopy; Aspirin; Clopidogrel; Coronary Artery Disease; Disease Progression; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Retrospective Studies; Severity of Illness Index; Ticlopidine | 2011 |
Light transmittance aggregometry induced by different concentrations of adenosine diphosphate to monitor clopidogrel therapy: a methodological study.
Topics: Adenosine Diphosphate; Angioplasty; Clopidogrel; Coronary Artery Disease; Drug Monitoring; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Point-of-Care Systems; Ticlopidine | 2011 |
Functional profile of the platelet P2Y₁₂ receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Thrombosis; Ticlopidine | 2011 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence Intervals; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Risk Reduction Behavior; Sirolimus; Ticlopidine; Time Factors | 2010 |
Invited commentary.
Topics: Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Artery Disease; Drainage; Humans; Intubation, Gastrointestinal; Minimally Invasive Surgical Procedures; Platelet Aggregation Inhibitors; Postoperative Complications; Premedication; Sternotomy; Thrombosis; Ticlopidine | 2011 |
Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chronic Disease; Clopidogrel; Cohort Studies; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kidney Diseases; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Ticlopidine; Treatment Outcome | 2011 |
Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Disease; Endothelium, Vascular; Female; Humans; Hyperemia; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Time Factors | 2011 |
[Relationships of blood stasis syndrome, CYP2C19 gene polymorphism with clopidogrel resistance and post-PCI prognosis].
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diagnosis, Differential; Drug Resistance; Female; Humans; Male; Medicine, Chinese Traditional; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prognosis; Ticlopidine | 2010 |
Clopidogrel with or without omeprazole in coronary disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cardiovascular Diseases; Chemistry, Pharmaceutical; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2011 |
Clopidogrel with or without omeprazole in coronary disease.
Topics: Clopidogrel; Coronary Artery Disease; Cost-Benefit Analysis; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2011 |
Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation.
Topics: Acute Coronary Syndrome; Aged; Blood Vessel Prosthesis Implantation; Clopidogrel; Cohort Studies; Combined Modality Therapy; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Retrospective Studies; Ticlopidine | 2011 |
[Assessing clinical efficacy of the generic clopidogrel "Egutromb" in roentgenosurgical practice].
Topics: Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Dose-Response Relationship, Drug; Drugs, Generic; Humans; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2010 |
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Lactones; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyridines; Quinazolinones; Randomized Controlled Trials as Topic; Receptor, PAR-1; Sulfonamides; Ticagrelor; Ticlopidine | 2011 |
The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Linkage Disequilibrium; Male; Middle Aged; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2011 |
Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting.
Topics: Aged; Calcium Channel Blockers; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug Synergism; Drug-Eluting Stents; Endpoint Determination; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2011 |
Impact of combination of calcium-channel blockers with clopidogrel on clinical outcomes in patients with coronary artery disease.
Topics: Aged; Calcium Channel Blockers; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Ticlopidine; Treatment Outcome | 2011 |
Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on
Topics: Aspirin; Blood Loss, Surgical; Cardiovascular Surgical Procedures; Clopidogrel; Contraindications; Coronary Artery Disease; Drug-Eluting Stents; Evidence-Based Medicine; Hemostasis, Surgical; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Precision Medicine; Ticlopidine | 2011 |
A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent.
Topics: Aged; Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Drug-Eluting Stents; Female; Genotype; Humans; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prosthesis Design; Sirolimus; Thrombectomy; Thrombosis; Ticlopidine; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Intra-individual variability of residual platelet reactivity assessed by the VerifyNow-P2Y12 assay in patients with clopidogrel resistance after percutaneous coronary intervention.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2011 |
Left main stent thrombosis complicated by eptifibatide-induced acute thrombocytopenia.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Electrocardiography; Eptifibatide; Heparin; Humans; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Count; Stents; Thrombectomy; Thrombocytopenia; Thrombosis; Ticlopidine; Treatment Outcome | 2011 |
Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Resistance; Female; Flow Cytometry; France; Heart Diseases; Humans; Kaplan-Meier Estimate; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Risk Assessment; Risk Factors; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Simultaneous drug-eluting and bare-metal stent implantation: long-term clinical outcome and findings of clinically indicated coronary angiography.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Confidence Intervals; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Platelet Aggregation Inhibitors; Prospective Studies; Statistics as Topic; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Feasibility and safety of 7-Fr radial approach for complex PCI.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Feasibility Studies; Female; Femoral Artery; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Radial Artery; Retrospective Studies; Ticlopidine; Ultrasonography, Interventional | 2011 |
High on treatment platelet reactivity and stent thrombosis.
Topics: Adult; Aged; Angioplasty; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine | 2011 |
Percutaneous coronary intervention of unprotected left main coronary artery disease as culprit lesion in patients with acute myocardial infarction.
Topics: Aged; Angioplasty; Bundle-Branch Block; Clopidogrel; Confidence Intervals; Coronary Artery Disease; Coronary Vessels; Emergency Medical Services; Female; Health Status Indicators; Hemodynamics; Hospital Mortality; Humans; Italy; Logistic Models; Male; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Prognosis; Retrospective Studies; Shock, Cardiogenic; Ticlopidine; Treatment Outcome | 2011 |
A complex case of angulated and bifurcated lesion facilitated by excimer laser coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Humans; Lasers, Excimer; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
Subacute stent thrombosis owing to complete clopidogrel resistance successfully managed with prasugrel.
Topics: Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Clopidogrel; Contraindications; Coronary Artery Disease; Drug Resistance; Drug-Eluting Stents; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticlopidine; Treatment Failure; Treatment Outcome | 2011 |
Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hospitals, High-Volume; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Registries; Risk Assessment; Risk Factors; Tacrolimus; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Ability of the INNOVANCE PFA P2Y system to detect clopidogrel-induced ADP receptor blockade in preangiocath individuals.
Topics: Adult; Angiography; Blood Coagulation; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diagnostic Equipment; Drug Monitoring; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Sensitivity and Specificity; Ticlopidine; Young Adult | 2011 |
Letter by Gasparovic et al regarding article, "Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial".
Topics: Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Artery Disease; Drug Resistance; Follow-Up Studies; Graft Occlusion, Vascular; Hemorheology; Humans; Hyperplasia; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Saphenous Vein; Ticlopidine; Tunica Intima | 2011 |
Letter by Bisdas et al regarding article, "Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial".
Topics: Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Artery Disease; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Resistance; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Hyperplasia; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Saphenous Vein; Ticlopidine; Tunica Intima | 2011 |
Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Renal Insufficiency, Chronic; Retrospective Studies; Ticlopidine | 2012 |
Stent-related cardiac events beyond three years after implantation of the sirolimus-eluting stent (from the EVASTENT Patients).
Topics: Clopidogrel; Cohort Studies; Coronary Artery Disease; Coronary Thrombosis; Diabetes Mellitus; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Matched-Pair Analysis; Middle Aged; Myocardial Revascularization; Platelet Aggregation Inhibitors; Registries; Sirolimus; Ticlopidine | 2011 |
Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Treatment Outcome | 2011 |
Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Annexin A5; Aspirin; Baltimore; Clopidogrel; Collagen; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Comparison of venous and arterial blood sampling for the assessment of platelet aggregation with whole blood impedance aggregometry.
Topics: Adenosine Diphosphate; Arachidonic Acid; Area Under Curve; Arteries; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Electric Impedance; Female; Humans; Male; Phlebotomy; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Research Design; Specimen Handling; Ticlopidine; Veins | 2011 |
[Comparison of efficacy and safety of treatment with drugs of clopidogrel in patients after coronary artery stenting].
Topics: Abdominal Pain; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug Substitution; Drugs, Generic; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Stents; Therapeutic Equivalency; Ticlopidine; Treatment Outcome | 2011 |
Optical coherence tomography findings during "evolving" stent thrombosis.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiopulmonary Resuscitation; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Coronary Vessels; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Stents; Ticlopidine; Tomography, Optical Coherence; Ultrasonography, Interventional | 2011 |
Impact of gastric acid-suppressing therapies on platelet reactivity in patients with coronary artery disease treated with clopidogrel: results of a pharmacodynamic study.
Topics: Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome | 2011 |
The effect of clopidogrel besylate and clopidogrel hydrogensulfate on platelet aggregation in patients with coronary artery disease: a retrospective study.
Topics: Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine | 2012 |
Effects of P2Y(1) receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Collagen; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y1; Receptors, Thrombin; Thrombosis; Ticlopidine | 2012 |
Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Case-Control Studies; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cytochrome P-450 CYP2C19; DNA; Female; France; Genetic Predisposition to Disease; Genotype; Humans; Integrin beta3; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prognosis; Proton Pump Inhibitors; Risk Factors; Stents; Thrombosis; Ticlopidine | 2011 |
Increased clopidogrel response is associated with ABCC3 expression: a pilot study.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Coronary Artery Disease; Gene Expression Regulation; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Pilot Projects; RNA, Messenger; Ticlopidine; Treatment Outcome | 2012 |
Coronary artery stents and antiplatelet therapy in patients with cirrhosis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Fatty Liver; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Stents; Ticlopidine | 2012 |
Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Incidence; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prevalence; Prosthesis Design; Registries; Risk Assessment; Risk Factors; Severity of Illness Index; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel.
Topics: Aged; Aged, 80 and over; Amplified Fragment Length Polymorphism Analysis; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; China; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Proportional Hazards Models; Ticlopidine | 2011 |
Clopidogrel use and early outcomes among older patients receiving a drug-eluting coronary artery stent.
Topics: Age Factors; Aged; Aged, 80 and over; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Dementia; Drug-Eluting Stents; Female; Humans; Male; Medicare Part D; Medication Adherence; Platelet Aggregation Inhibitors; Retrospective Studies; Survival Analysis; Thrombosis; Ticlopidine; United States | 2012 |
Renal function assessed using cystatin C and antiplatelet efficacy of clopidogrel assessed using the vasodilator-stimulated phosphoprotein index in patients having percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Proteins; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cystatin C; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Immunoassay; Kidney Function Tests; Male; Microfilament Proteins; Phosphoproteins; Platelet Aggregation Inhibitors; Prognosis; Stents; Ticlopidine | 2012 |
Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry.
Topics: Aged; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Interactions; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Proton Pump Inhibitors; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Austria; Blood Platelets; Cardiovascular Diseases; Cell Adhesion Molecules; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Gene Frequency; Genotype; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Microfilament Proteins; Middle Aged; Multivariate Analysis; Pharmacogenetics; Phenotype; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Predictive Value of Tests; Prospective Studies; Risk Assessment; Risk Factors; Sensitivity and Specificity; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Extension of Kaplan-Meier methods in observational studies with time-varying treatment.
Topics: Age Factors; Aged; Clopidogrel; Comorbidity; Confounding Factors, Epidemiologic; Coronary Artery Disease; Drug-Eluting Stents; Female; Health Behavior; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Sex Factors; Ticlopidine; Time Factors | 2012 |
Vasodilator-stimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: does standardisation matter?
Topics: Blood Specimen Collection; Cell Adhesion Molecules; Cell Separation; Clopidogrel; Coronary Artery Disease; Flow Cytometry; Humans; Microfilament Proteins; Observer Variation; Phosphoproteins; Phosphorylation; Platelet Activation; Platelet Function Tests; Prospective Studies; Reference Standards; Ticlopidine; Vasodilator Agents | 2012 |
Desensitization to prasugrel: cardiology's increased need for allergy consultation.
Topics: Atherectomy, Coronary; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Desensitization, Immunologic; Drug Dosage Calculations; Drug Hypersensitivity; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Referral and Consultation; Stents; Thiophenes; Ticlopidine | 2012 |
Management of a hypersensitivity reaction to thienopyridines: prasugrel-induced fever and hepatitis resolved after switching to clopidogrel.
Topics: Adult; Clopidogrel; Coronary Artery Disease; Drug Hypersensitivity; Female; Fever; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2012 |
Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; In Vitro Techniques; Ketanserin; Light; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Serotonin; Serotonin Antagonists; Stents; Ticlopidine; Treatment Outcome | 2012 |
Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cotinine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Odds Ratio; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Smoking; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinolytic Agents; Follow-Up Studies; Heparin; Humans; Injections, Subcutaneous; Male; Platelet Aggregation Inhibitors; Postoperative Complications; Preoperative Care; Prospective Studies; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; Warfarin | 2012 |
Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Asian People; Aspirin; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Drug Therapy, Combination; Enzyme Inhibitors; Female; Histamine H2 Antagonists; Humans; Male; Omeprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Ticlopidine | 2012 |
[Effect of clopidogrel combined with calcium-channel blocker on coronary artery disease in elderly patients: a propensity score-based retrospective cohort study].
Topics: Aged; Aged, 80 and over; Calcium Channel Blockers; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Therapy, Combination; Humans; Middle Aged; Propensity Score; Retrospective Studies; Ticlopidine | 2012 |
High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Drug Resistance; Female; Humans; Least-Squares Analysis; Linear Models; Male; Middle Aged; Multivariate Analysis; New York City; Plaque, Atherosclerotic; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Risk Assessment; Risk Factors; Severity of Illness Index; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Vascular Calcification | 2012 |
Blockbuster interactions: are they bad for the patient?
Topics: Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2012 |
[Comparison on the effects of clopidogrel, statins combination in treating coronary artery disease among the elderly patients: a retrospective cohort study].
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Retrospective Studies; Ticlopidine | 2012 |
Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prosthesis Design; Pyridines; Registries; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
[Omega-3--clopidogrel can help!].
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Fatty Acids, Omega-3; Female; Humans; Male; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2012 |
Fractalkine activates a signal transduction pathway similar to P2Y12 and is associated with impaired clopidogrel responsiveness.
Topics: Adenosine Diphosphate; Alprostadil; Chemokine CX3CL1; Clopidogrel; Coronary Artery Disease; Humans; Phosphatidylinositol 3-Kinases; Phosphorylation; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Ticlopidine | 2012 |
CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Genotype; Humans; Male; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation; Ticlopidine | 2012 |
Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Haplotypes; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Ticlopidine; Treatment Outcome | 2013 |
Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practice.
Topics: Aged; Analysis of Variance; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Health Status Indicators; Humans; Male; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prospective Studies; Risk Assessment; Ticlopidine; Time Factors | 2012 |
Medium to long-term clinical outcomes with everolimus-eluting stents in real-life percutaneous coronary intervention.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; New Zealand; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; Sirolimus; Survival Analysis; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Complex coronary lesions and rotational atherectomy: one hospital's experience.
Topics: Aged; Angiography; Aspirin; Atherectomy, Coronary; Cardiology; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Radiography, Interventional; Retrospective Studies; Ticlopidine; Treatment Outcome | 2012 |
Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Animals; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Humans; Imines; Platelet Activation; Platelet Aggregation Inhibitors; Pyridines; Receptors, Thrombin; Ticlopidine | 2012 |
Impact of proton pump inhibitors or famotidine on the antiplatelet actions during dual-antiplatelet therapy in Japanese patients.
Topics: Aged; Asian People; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Interactions; Famotidine; Female; Histamine H2 Antagonists; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Proton Pump Inhibitors; Ticlopidine | 2013 |
Early and late outcome associated with bleeding events in the setting of dual antiplatelet therapy following stent placement.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine | 2012 |
Less may be more: insights on dual antiplatelet therapy duration after drug-eluting stent implantation from the MATRIX registry.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Tacrolimus; Ticlopidine | 2012 |
Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Prospective Studies; Prosthesis Design; Registries; Risk Assessment; Risk Factors; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Femoral pseudoaneurysm with a communicating arteriovenous fistula: a complication after percutaneous coronary intervention.
Topics: Aneurysm, False; Angioplasty, Balloon, Coronary; Arteriovenous Fistula; Aspirin; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug Therapy, Combination; Femoral Artery; Fibrinolytic Agents; Humans; Male; Middle Aged; Ticlopidine; Treatment Outcome | 2012 |
Dual antiplatelet therapy after drug-eluting stent implantation: is it time to slacken the reins?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Drug-Eluting Stents; Female; Humans; Male; Medication Adherence; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Sirolimus; Ticlopidine; Withholding Treatment | 2012 |
Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Retrospective Studies; Risk Factors; Spain; Survival Rate; Ticlopidine; Time Factors | 2012 |
Three years ago I received a drug-coated stent and was put on aspirin and Plavix. My cardiologist recently retired, and my new cardiologist told me to stop taking Plavix. It scares me to death. I read the story you released in February about the danger
Topics: Clopidogrel; Contraindications; Coronary Artery Disease; Drug-Eluting Stents; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Withholding Treatment | 2011 |
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Female; Fibrinolytic Agents; Heart Failure; Humans; Hypertension; Male; Risk Assessment; Stroke; Ticlopidine; Treatment Outcome; Warfarin | 2012 |
Dual antiplatelet agent-induced spontaneous liver hematoma.
Topics: Aged; Aspirin; Chemical and Drug Induced Liver Injury; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hematoma; Humans; Male; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2012 |
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
Topics: Adolescent; Adult; Aged; Blood Platelets; Body Weight; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Thiophenes; Ticlopidine; Young Adult | 2012 |
Evaluating the impact of public health notification: Duke clopidogrel experience.
Topics: Access to Information; Aged; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Information Services; Drug-Eluting Stents; Evidence-Based Medicine; Female; Humans; Logistic Models; Male; Metals; Middle Aged; North Carolina; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prosthesis Design; Public Health Informatics; Registries; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response.
Topics: Carboxylic Ester Hydrolases; Clopidogrel; Coronary Artery Disease; DNA; Female; Genotype; Heterozygote; Humans; Male; Middle Aged; Pharmacogenetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Ticlopidine | 2013 |
[Expert answer. Coronary artery patients with atrial fibrillation on anticoagulation treatment may need antithrombotic treatment. What kind is there?].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Ticlopidine; Warfarin | 2012 |
A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; China; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Disease-Free Survival; Drug Therapy, Combination; Drug-Eluting Stents; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Propensity Score; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Registries; Risk Assessment; Risk Factors; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
I'm having a stent put in one of my coronary arteries soon and I wonder how long I will need to be on clopidogrel. Does it depend on the kind of stent?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Humans; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2010 |
Chest pain in a patient with coronary artery disease taking clopidogrel.
Topics: Chest Pain; Clopidogrel; Coronary Artery Disease; Esophageal Diseases; Esophagoscopy; Hematoma; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Tomography, X-Ray Computed | 2013 |
Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prognosis; Stroke; Thrombosis; Ticlopidine; Treatment Outcome | 2013 |
Triple antiplatelet therapy with cilostazol: hitting the "sweet-spot".
Topics: Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Tetrazoles; Ticlopidine | 2013 |
Decreased plasma IL-35 levels are related to the left ventricular ejection fraction in coronary artery diseases.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Cytokines; Female; Humans; Interleukins; Male; Middle Aged; Statistics, Nonparametric; Stroke Volume; Ticlopidine | 2012 |
Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention.
Topics: Aged; Blood Platelets; C-Reactive Protein; Clopidogrel; Coronary Artery Disease; Creatine Kinase, MB Form; Female; Fibrinogen; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Predictive Value of Tests; Premedication; Prospective Studies; ROC Curve; Sensitivity and Specificity; Ticlopidine; Troponin | 2013 |
Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Models, Cardiovascular; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Receptors, Purinergic P2Y12; Thrombin; Thromboembolism; Ticlopidine; Translational Research, Biomedical | 2013 |
Risk factors for upper gastrointestinal bleeding in coronary artery disease patients receiving both aspirin and clopidogrel.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Retrospective Studies; Risk Factors; Ticlopidine; Upper Gastrointestinal Tract | 2013 |
The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prodrugs; Prognosis; Ticlopidine | 2013 |
Chronic kidney disease--is it a true risk factor of reduced clopidogrel efficacy in elderly patients with stable coronary artery disease?
Topics: Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Artery Disease; Creatinine; Female; Hemoglobins; Humans; Male; Odds Ratio; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2Y12; Regression Analysis; Renal Insufficiency, Chronic; Risk Factors; Ticlopidine; Treatment Outcome | 2013 |
Characterization of aspirin allergies in patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Aspirin; California; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Hypersensitivity; Female; Humans; Male; Retrospective Studies; Ticlopidine | 2013 |
A case of in-stent thrombosis in a patient with drug eluting stents during perioperative management with glycoprotein IIb/IIIa inhibitors.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Humans; Neurosurgical Procedures; Peptides; Percutaneous Coronary Intervention; Perioperative Period; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Effect of clopidogrel on platelet aggregation and plasma concentration of fibrinogen in subjects with cerebral or coronary atherosclerotic disease.
Topics: Clopidogrel; Coronary Artery Disease; Fibrinogen; Humans; Intracranial Arteriosclerosis; Platelet Aggregation; Ticlopidine | 2002 |
Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Drug Therapy, Combination; Dual Specificity Phosphatase 2; Female; Flow Cytometry; Humans; Intercellular Adhesion Molecule-1; Leukocytes; Male; Middle Aged; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Phosphatase 2; Protein Tyrosine Phosphatases; Ticlopidine | 2003 |
[Effects of antiaggregants on concentration of plasma cytokines in patients with acute coronary syndrome].
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cytokines; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine | 2003 |
[Sudden edema and pain in the knee].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Edema; Hemorrhage; Humans; Knee Joint; Male; Pain; Platelet Aggregation Inhibitors; Radiography; Ticlopidine | 2003 |
Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Creatine Kinase; Creatine Kinase, MB Form; Drug Resistance; Female; Humans; Incidence; Isoenzymes; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Period; Sex Factors; Ticlopidine; Troponin I | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Epinephrine; Eptifibatide; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Prodrugs; Prospective Studies; Purinergic P2 Receptor Antagonists; Recurrence; Risk; Smoking; Stents; Ticlopidine; Treatment Outcome | 2004 |
The effect of clopidogrel on apoptosis--an in vivo study.
Topics: Adult; Aged; Apoptosis; Cells, Cultured; Clopidogrel; Coronary Artery Disease; DNA; DNA Fragmentation; Electrophoresis, Agar Gel; Female; Humans; Leukocyte Count; Lymphocytes; Male; Middle Aged; Ticlopidine | 2004 |
Coronary spasm in a 59-yr-old woman with hyperventilation.
Topics: Alkalosis, Respiratory; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antihypertensive Agents; Aspirin; Cardiac Catheterization; Clopidogrel; Coronary Artery Disease; Coronary Vasospasm; Diagnosis, Differential; Diltiazem; Electrocardiography; Female; Heparin; Humans; Hyperventilation; Hyponatremia; Middle Aged; Platelet Aggregation Inhibitors; Schizophrenia; Ticlopidine; Water Intoxication | 2004 |
[Antiplatelet therapy in patients with peripheral arterial disease (PAD)].
Topics: Arterial Occlusive Diseases; Aspirin; Cause of Death; Cerebral Infarction; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Ticlopidine | 2004 |
Evolution of spontaneous atherosclerotic plaque rupture with medical therapy: long-term follow-up with intravascular ultrasound.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Disease Progression; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Rupture, Spontaneous; Ticlopidine; Troponin I; Ultrasonography, Interventional | 2004 |
[Acute coronary syndrome, stroke, arterial occlusive disease. Bring the patients out of the danger zone!].
Topics: Arterial Occlusive Diseases; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Embolism, Cholesterol; Humans; Intracranial Embolism; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine | 2004 |
[Patients with arterial occlusive disease die of myocardial infarct or stroke. The dangerous sisters: arterial occlusive disease and coronary heart disease].
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Cause of Death; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Humans; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prognosis; Risk Factors; Stroke; Ticlopidine | 2004 |
Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Electrocardiography; Eptifibatide; Heparin; Humans; Male; Middle Aged; Myocardial Ischemia; Nitroglycerin; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Stents; Ticlopidine; Vasodilator Agents | 2004 |
Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting.
Topics: Aged; Atorvastatin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation Inhibitors; Preoperative Care; Prospective Studies; Pyrroles; Simvastatin; Stents; Ticlopidine | 2004 |
High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoprotein IIb; Risk Factors; Stents; Ticlopidine | 2004 |
Concordance between clopidogrel use and prescribing guidelines.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Australia; Clopidogrel; Cohort Studies; Coronary Artery Disease; Cost-Benefit Analysis; Cross-Sectional Studies; Drug Prescriptions; Drug Utilization Review; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Ticlopidine | 2004 |
Why don't we practice evidence-based medicine?
Topics: Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Evidence-Based Medicine; Health Knowledge, Attitudes, Practice; Hospitalization; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Ventricular Dysfunction, Left | 2005 |
Impact of continued hospitalization in patients pre-treated with clopidogrel prior to coronary angiography and undergoing coronary artery bypass grafting.
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Female; Hospitalization; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Survival Analysis; Ticlopidine; Treatment Outcome; Ventricular Dysfunction, Left | 2005 |
Reasons for inability of clopidogrel to inhibit platelet aggregation early after coronary artery bypass surgery.
Topics: Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2005 |
Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Desensitization, Immunologic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2005 |
Oral antiplatelet therapy.
Topics: Cerebrovascular Disorders; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Salicylates; Ticlopidine | 2005 |
Oral antiplatelet therapy.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dipyridamole; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2005 |
Raising the loading dose of clopidogrel: aiming at the proper target?
Topics: Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2005 |
Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Ticlopidine | 2004 |
Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
Topics: Acetylcysteine; Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Utilization Review; Female; Health Care Surveys; Heparin; Humans; Italy; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Pyridines; Registries; Ticlopidine | 2005 |
Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen.
Topics: Adenosine Diphosphate; Aged; Binding, Competitive; Blood Platelets; Clopidogrel; Coronary Artery Disease; Data Interpretation, Statistical; Eptifibatide; Fibrinogen; Flow Cytometry; Fluorescein-5-isothiocyanate; Humans; Iodine Radioisotopes; Male; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Thrombin; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Ask the doctors. My mother in her early 90s has been diagnosed with atherosclerosis, had a successful angioplasty a year ago for severe chest pain, takes clopidogrel and aspirin, and in general eats a low-fat diet, although she really likes melted ice cre
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Diet, Fat-Restricted; Exercise; Female; Humans; Hypolipidemic Agents; Ice Cream; Platelet Aggregation Inhibitors; Ticlopidine | 2005 |
Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Membrane Proteins; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine | 2005 |
Antiplatelet therapy and the vascular tree.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticlopidine | 2006 |
Interpretation of clopidogrel resistance.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2005 |
Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system.
Topics: Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Cost-Benefit Analysis; Delivery of Health Care; Drug Delivery Systems; Health Care Costs; Humans; Models, Economic; Myocardial Revascularization; Paclitaxel; Reoperation; Stents; Sweden; Taxus; Ticlopidine | 2006 |
Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Female; Humans; Inflammation; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Substance Withdrawal Syndrome; Thrombosis; Ticlopidine | 2006 |
[Postoperative antithrombotic treatment in diabetic patients].
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mellitus; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Postoperative Complications; Risk Factors; Thrombosis; Ticlopidine; Warfarin | 2006 |
Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril.
Topics: Adenosine Diphosphate; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Cardiovascular Diseases; Clopidogrel; Collagen; Coronary Artery Disease; Electric Impedance; Enalapril; Female; Fibrinolytic Agents; Germany; Humans; Hypertension; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ramipril; Ticlopidine; Treatment Outcome | 2006 |
Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel.
Topics: Adenine; Alleles; Anticoagulants; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Genetic Variation; Genotype; Guanine; Humans; Introns; Liver; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Ticlopidine | 2006 |
Clopidogrel desensitization.
Topics: Aged; Angioplasty; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Desensitization, Immunologic; Humans; Male; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Urticaria | 2006 |
Late in-stent thrombosis in a patient with systemic lupus erythematosus and hyperhomocysteinemia while on clopidogrel and aspirin.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Coagulation Disorders; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Female; Humans; Hyperhomocysteinemia; Lupus Erythematosus, Systemic; Middle Aged; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Time Factors | 2006 |
Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Clopidogrel; Coronary Artery Disease; Cyclooxygenase 1; Cyclooxygenase 2; Dose-Response Relationship, Drug; Drug Resistance; Female; Flow Cytometry; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Recurrence; Signal Transduction; Thrombosis; Thromboxane B2; Ticlopidine; Time Factors; Treatment Refusal | 2006 |
Prasugrel, clopidogrel, and combining Swedish apples with American oranges.
Topics: Clinical Trials, Phase II as Topic; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2006 |
[Combination of clopidogrel and aspirin was no better than aspirin alone for prevention of atherothrombotic events in stable patients. Results of CHARISMA].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Severity of Illness Index; Ticlopidine; Treatment Outcome | 2006 |
Viscosity, hemostasis and inflammation in atherosclerotic heart diseases.
Topics: Aged; Aspirin; Blood Viscosity; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Female; Glucose; Glycated Hemoglobin; Hemostasis; Humans; Inflammation; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; von Willebrand Factor | 2006 |
The CHARISMA trial and the REACH registry outcomes.
Topics: Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Humans; Incidence; Platelet Aggregation Inhibitors; Registries; Risk Factors; Ticlopidine; Treatment Outcome | 2006 |
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Delivery Systems; Female; Humans; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Stents; Ticlopidine; Treatment Outcome | 2007 |
Clinical trials update from the annual scientific session of the American College of Cardiology 2006.
Topics: Aspirin; Cardiac Catheterization; Cardiology; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Enoxaparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Societies, Medical; Stents; Thrombolytic Therapy; Ticlopidine; United States | 2006 |
Does clopidogrel each day keep stent thrombosis away?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Delivery Systems; Humans; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Stents; Thrombosis; Ticlopidine | 2007 |
Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Stents; Stroke; Ticlopidine | 2007 |
Severe neutropenia under clopidogrel treatment three weeks after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Female; Humans; Neutropenia; Platelet Aggregation Inhibitors; Severity of Illness Index; Stents; Ticlopidine; Time Factors | 2007 |
Long-term outcomes in treating left main trifurcation coronary artery disease with the Paclitaxel-eluting stent.
Topics: Aged; Catheterization; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug Delivery Systems; Female; Humans; Logistic Models; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Ticlopidine; Treatment Outcome; Tubulin Modulators | 2007 |
Clopidogrel-mediated reduction of circulating tissue factor in patients with stable coronary artery disease.
Topics: Adult; CD40 Ligand; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Solubility; Thromboplastin; Ticlopidine; Treatment Outcome | 2007 |
Determination of aspirin responsiveness by use of whole blood platelet aggregometry.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Blood Donors; Clopidogrel; Collagen; Coronary Artery Disease; Drug Resistance; Electric Impedance; Female; Humans; In Vitro Techniques; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyridines; Reference Values; Sex Factors; Thromboxane B2; Ticlopidine | 2007 |
Selective serotonin reuptake inhibitors may interfere with the antiplatelet effect of clopidogrel.
Topics: Antidepressive Agents, Second-Generation; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Depression; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Prognosis; Selective Serotonin Reuptake Inhibitors; Ticlopidine | 2007 |
Increased incidence of stent thrombosis in patients with cocaine use.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cocaine-Related Disorders; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Follow-Up Studies; Hospitals, Urban; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Research Design; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome; United States | 2007 |
Drug-eluting stents.
Topics: Canada; Clopidogrel; Coronary Artery Disease; Cost-Benefit Analysis; Drug Delivery Systems; Humans; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2007 |
Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative.
Topics: Acute Disease; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heart Conduction System; Humans; Male; Middle Aged; Patient Discharge; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Quality of Health Care; Retrospective Studies; Syndrome; Ticlopidine; Treatment Outcome; United States | 2007 |
Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Creatine Kinase, MB Form; Drug Resistance; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardium; Necrosis; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Period; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Ticlopidine; Treatment Outcome; Troponin I | 2007 |
Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Male; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Stents; Ticlopidine; Treatment Outcome | 2008 |
Confined late stent thrombosis following clopidogrel withdrawal in a patient with multi-segment sirolimus-eluting stent implants.
Topics: Abciximab; Aged; Angioplasty, Balloon; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Coronary Thrombosis; Heparin; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Male; Platelet Aggregation Inhibitors; Sirolimus; Stents; Ticlopidine | 2007 |
Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Flow Cytometry; Humans; Male; Middle Aged; Phosphorylation; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine | 2007 |
Sirolimus-eluting stent thrombosis several years after clopidogrel discontinuation.
Topics: Adult; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug Delivery Systems; Humans; Immunosuppressive Agents; Male; Platelet Aggregation Inhibitors; Sirolimus; Stents; Ticlopidine; Time Factors | 2007 |
Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease.
Topics: Adult; Aged; Caffeine; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Drug Synergism; Female; Humans; Hydrazones; Male; Middle Aged; P-Selectin; Phosphodiesterase Inhibitors; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Receptor, Adenosine A2A; Ticlopidine | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Male; Multivariate Analysis; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prognosis; Prospective Studies; Renal Insufficiency; ROC Curve; Sensitivity and Specificity; Stroke; Ticlopidine | 2007 |
Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk.
Topics: Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prognosis; Stroke; Ticlopidine | 2007 |
The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angina Pectoris; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Models, Statistical; Platelet Aggregation; Platelet Function Tests; Regression Analysis; Stents; Ticlopidine | 2008 |
The CAPRIE-like subgroups of CHARISMA: a CAPRIEciously biased analysis of an unCHARISMAtic truth.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Research Design; Ticlopidine; Treatment Outcome | 2007 |
P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Genotype; Haplotypes; Humans; Male; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine; Treatment Outcome | 2008 |
Coronary artery stenting in patients treated by clopidogrel without aspirin.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Stents; Thrombosis; Ticlopidine | 2009 |
Outcomes associated with combined antiplatelet and anticoagulant therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Dipyridamole; Drug Therapy, Combination; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Thromboembolism; Ticlopidine; Treatment Outcome; Warfarin | 2008 |
Restrictive access to clopidogrel and mortality following coronary stent implantation.
Topics: Aged; Canada; Cause of Death; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Coronary Restenosis; Drug Costs; Drug Prescriptions; Female; Follow-Up Studies; Humans; Insurance, Pharmaceutical Services; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Survival Rate; Ticlopidine; Time Factors | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clinical Protocols; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Drug Resistance; Feasibility Studies; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Ticlopidine | 2008 |
Rapid oral aspirin desensitization for patients with aspirin allergy requiring dual antiplatelet therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Hypersensitivity; Drug Therapy, Combination; Humans; Inactivation, Metabolic; Membrane Proteins; Platelet Aggregation Inhibitors; Receptors, Leukotriene; Ticlopidine | 2008 |
Clinical outcomes after multilesion percutaneous coronary intervention: comparison between exclusive and selective use of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; Female; Follow-Up Studies; Health Care Costs; Humans; Male; Middle Aged; Patient Selection; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Quebec; Retrospective Studies; Stents; Ticlopidine; Treatment Outcome | 2008 |
Drug-eluting versus bare-metal stents: when and for whom?
Topics: Angioplasty, Balloon, Coronary; Canada; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Diabetes Complications; Drug-Eluting Stents; Health Care Costs; Humans; Patient Selection; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2008 |
Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Thrombosis; Ticlopidine; Treatment Outcome | 2008 |
Unilateral idiopathic adrenal hematomas with a preoperative diagnosis of indeterminate adrenal tumors.
Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Adrenalectomy; Aged; Anemia; Aspirin; Clopidogrel; Coronary Artery Disease; Diagnosis, Differential; Female; Hematoma; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Preoperative Care; Retrospective Studies; Stents; Ticlopidine | 2008 |
Acute stent thrombosis in a patient with giant cell arteritis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Giant Cell Arteritis; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prednisone; Stents; Ticlopidine | 2008 |
Innovations in bifurcations.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Humans; Patient Selection; Platelet Aggregation Inhibitors; Prosthesis Design; Research Design; Severity of Illness Index; Stents; Ticlopidine; Treatment Outcome; Ultrasonography, Interventional | 2008 |
Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Germany; Glomerular Filtration Rate; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Renal Insufficiency; Retrospective Studies; Surveys and Questionnaires; Survival Analysis; Ticlopidine | 2008 |
Clopidogrel instead of ticlopidine after coronary stent placement: is the switch justified?
Topics: Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Postoperative Complications; Stents; Thrombosis; Ticlopidine | 2000 |
Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Equipment Design; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Prospective Studies; Registries; Stents; Ticlopidine | 2000 |
Bench to bedside: the development of rapamycin and its application to stent restenosis.
Topics: Angioplasty, Balloon, Coronary; Animals; Calcineurin Inhibitors; Carrier Proteins; Cell Cycle Proteins; Cell Division; Cell Movement; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Graft Occlusion, Vascular; Humans; Hyperplasia; Macromolecular Substances; Phosphotransferases (Alcohol Group Acceptor); Platelet Aggregation Inhibitors; Signal Transduction; Sirolimus; Stents; Tacrolimus; Tacrolimus Binding Protein 1A; Ticlopidine; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Tunica Media; Vascular Patency | 2001 |
Coronary stent deployment in situs inversus.
Topics: Aged; Aspirin; Chest Pain; Clopidogrel; Coronary Artery Disease; Dextrocardia; Electrocardiography; Humans; Male; Situs Inversus; Stents; Ticlopidine | 2001 |
Same-day transradial outpatient stenting with a 6-hr course of glycoprotein IIb/IIIa receptor blockade: a feasibility study.
Topics: Adult; Aged; Ambulatory Surgical Procedures; Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Creatine Kinase; Electrocardiography; Feasibility Studies; Female; Follow-Up Studies; Humans; Length of Stay; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Stroke Volume; Ticlopidine; Time Factors; Treatment Outcome | 2002 |
[Two platelet inhibitors after acute coronary syndrome. Many colleagues are not aware of this].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Survival Rate; Ticlopidine | 2002 |